0001628280-18-010896.txt : 20180809 0001628280-18-010896.hdr.sgml : 20180809 20180809134841 ACCESSION NUMBER: 0001628280-18-010896 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180809 DATE AS OF CHANGE: 20180809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-RAD LABORATORIES, INC. CENTRAL INDEX KEY: 0000012208 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 941381833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-07928 FILM NUMBER: 181004388 BUSINESS ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 BUSINESS PHONE: 5107247000 MAIL ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 FORMER COMPANY: FORMER CONFORMED NAME: BIO RAD LABORATORIES INC DATE OF NAME CHANGE: 19920703 10-Q 1 a10q63018.htm 10-Q JUNE 30, 2018 Document
false--12-31Q220180000012208Large Accelerated FilerBIO-RAD LABORATORIES, INC.2554900021466000246791275107674247360095100540246785455106757247354275099623P8YP7YP12YP12YP8YP0YP6YP1YP1YP1YP1YP1YP0YP1YP8YP7YP11YP11YP8YP0YP6YP1YP1YP3YP1YP1YP0YP3Y0582917582917 0000012208 2018-01-01 2018-06-30 0000012208 us-gaap:CommonClassBMember 2018-08-02 0000012208 us-gaap:CommonClassAMember 2018-08-02 0000012208 2017-12-31 0000012208 bio:TreasuryClassBMember 2018-06-30 0000012208 2018-06-30 0000012208 us-gaap:CommonClassBMember 2017-12-31 0000012208 us-gaap:CommonClassAMember 2017-12-31 0000012208 us-gaap:CommonClassBMember 2018-06-30 0000012208 bio:TreasuryClassAMember 2018-06-30 0000012208 us-gaap:CommonClassAMember 2018-06-30 0000012208 bio:TreasuryClassAMember 2017-12-31 0000012208 bio:TreasuryClassBMember 2017-12-31 0000012208 2017-01-01 2017-06-30 0000012208 2018-04-01 2018-06-30 0000012208 2017-04-01 2017-06-30 0000012208 2016-12-31 0000012208 2017-06-30 0000012208 srt:AsiaPacificMember 2018-04-01 2018-06-30 0000012208 srt:AmericasMember 2018-04-01 2018-06-30 0000012208 country:US 2017-01-01 2017-06-30 0000012208 srt:AmericasMember 2017-01-01 2017-06-30 0000012208 country:US 2017-04-01 2017-06-30 0000012208 srt:EuropeMember 2017-04-01 2017-06-30 0000012208 srt:AmericasMember 2018-01-01 2018-06-30 0000012208 srt:AsiaPacificMember 2017-01-01 2017-06-30 0000012208 srt:EuropeMember 2017-01-01 2017-06-30 0000012208 srt:EuropeMember 2018-04-01 2018-06-30 0000012208 srt:AsiaPacificMember 2018-01-01 2018-06-30 0000012208 country:US 2018-04-01 2018-06-30 0000012208 country:US 2018-01-01 2018-06-30 0000012208 srt:EuropeMember 2018-01-01 2018-06-30 0000012208 srt:AsiaPacificMember 2017-04-01 2017-06-30 0000012208 srt:AmericasMember 2017-04-01 2017-06-30 0000012208 us-gaap:NewAccountingPronouncementMember 2018-01-01 0000012208 us-gaap:NewAccountingPronouncementMember 2017-01-01 2017-06-30 0000012208 us-gaap:NewAccountingPronouncementMember 2017-06-30 0000012208 2018-01-01 0000012208 us-gaap:NewAccountingPronouncementMember 2018-04-01 2018-06-30 0000012208 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000012208 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 0000012208 us-gaap:NewAccountingPronouncementMember 2018-01-01 2018-06-30 0000012208 us-gaap:AccountingStandardsUpdate201601Member 2018-01-01 0000012208 us-gaap:NewAccountingPronouncementMember 2017-04-01 2017-06-30 0000012208 us-gaap:AccountingStandardsUpdate201601Member 2018-06-30 0000012208 us-gaap:NewAccountingPronouncementMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-01-01 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-06-30 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-06-30 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:MarketPriceOfRiskMember 2018-01-01 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:ProjectedVolatilityOfSalesMemberMember 2018-01-01 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-12-01 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoicesMember 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestoneminimumamountMember 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoiceslowMember 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-04-01 2018-06-30 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2018-01-01 2018-06-30 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2018-06-30 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2018-01-01 2018-06-30 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2018-06-30 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-06-30 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-06-30 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-06-30 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 bio:LifeScienceMember 2017-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:LifeScienceMember 2018-01-01 2018-06-30 0000012208 bio:ClinicalDiagnosticsMember 2018-06-30 0000012208 bio:ClinicalDiagnosticsMember 2018-01-01 2018-06-30 0000012208 bio:LifeScienceMember 2018-06-30 0000012208 bio:ClinicalDiagnosticsMember 2018-01-01 2018-03-31 0000012208 us-gaap:CustomerRelationshipsMember 2017-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2017-12-31 0000012208 us-gaap:LicensingAgreementsMember 2017-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2017-12-31 0000012208 us-gaap:TradeNamesMember 2017-12-31 0000012208 bio:KnowHowMember 2017-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2018-06-30 0000012208 us-gaap:DevelopedTechnologyRightsMember 2018-06-30 0000012208 bio:KnowHowMember 2018-06-30 0000012208 us-gaap:LicensingAgreementsMember 2018-06-30 0000012208 us-gaap:NoncompeteAgreementsMember 2018-06-30 0000012208 us-gaap:TradeNamesMember 2018-06-30 0000012208 srt:MaximumMember us-gaap:TradeNamesMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2018-01-01 2018-06-30 0000012208 srt:MinimumMember us-gaap:TradeNamesMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:LicensingAgreementsMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:NoncompeteAgreementsMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2017-01-01 2017-06-30 0000012208 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2017-01-01 2017-06-30 0000012208 srt:MaximumMember us-gaap:NoncompeteAgreementsMember 2017-01-01 2017-06-30 0000012208 srt:MaximumMember us-gaap:LicensingAgreementsMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:TradeNamesMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-06-30 0000012208 srt:MinimumMember us-gaap:LicensingAgreementsMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember bio:KnowHowMember 2018-01-01 2018-06-30 0000012208 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2018-01-01 2018-06-30 0000012208 srt:MinimumMember bio:KnowHowMember 2017-01-01 2017-06-30 0000012208 srt:MaximumMember bio:KnowHowMember 2018-01-01 2018-06-30 0000012208 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2017-01-01 2017-06-30 0000012208 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-06-30 0000012208 srt:MinimumMember us-gaap:TradeNamesMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:LicensingAgreementsMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember bio:KnowHowMember 2017-01-01 2017-06-30 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2017-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2018-06-30 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2017-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2018-06-30 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2010-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2018-04-01 2018-06-30 0000012208 us-gaap:LineOfCreditMember 2018-06-30 0000012208 us-gaap:StandbyLettersOfCreditMember 2018-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-04-01 2018-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-04-01 2018-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-04-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-04-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-06-30 0000012208 2017-01-01 2017-12-31 0000012208 bio:USFederalMember 2017-01-01 2017-06-30 0000012208 bio:ClinicalDiagnosticsMember 2017-04-01 2017-06-30 0000012208 bio:LifeScienceMember 2017-01-01 2017-03-31 0000012208 us-gaap:CorporateNonSegmentMember 2017-04-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2018-01-01 2018-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-04-01 2018-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-04-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2018-04-01 2018-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-06-30 0000012208 us-gaap:OperatingSegmentsMember 2018-01-01 2018-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2017-04-01 2017-06-30 0000012208 us-gaap:OperatingSegmentsMember 2017-04-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-01-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2017-01-01 2017-06-30 0000012208 us-gaap:OperatingSegmentsMember 2018-04-01 2018-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-06-30 0000012208 us-gaap:OperatingSegmentsMember 2017-01-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-04-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2018-04-01 2018-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2018-04-01 2018-06-30 0000012208 bio:LifeScienceMember 2017-01-01 2017-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2017-01-01 2017-06-30 0000012208 bio:ClinicalDiagnosticsMember 2017-01-01 2017-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2018-01-01 2018-06-30 0000012208 bio:LifeScienceMember 2017-04-01 2017-06-30 0000012208 bio:LifeScienceMember 2018-04-01 2018-06-30 0000012208 bio:ClinicalDiagnosticsMember 2018-04-01 2018-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2018-04-01 2018-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2017-04-01 2017-06-30 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2018-01-01 2018-06-30 0000012208 bio:EuropeanReorganizationMember 2018-01-01 2018-06-30 0000012208 bio:EuropeanReorganizationMember 2018-06-30 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-06-30 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2018-06-30 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2018-06-30 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-06-30 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-06-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2018-01-01 2018-06-30 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-04-01 2018-06-30 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember 2018-04-01 2018-06-30 0000012208 us-gaap:AccountsPayableAndAccruedLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-06-30 0000012208 us-gaap:FacilityClosingMember 2018-01-01 2018-06-30 0000012208 us-gaap:OtherCurrentLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-06-30 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember 2018-01-01 2018-06-30 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember 2017-12-01 2018-06-30 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2018-01-01 2018-06-30 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-04-01 2018-06-30 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-06-30 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-06-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-04-01 2018-06-30 0000012208 bio:EuropeanReorganizationMember 2016-05-01 2018-06-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-06-30 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:pure xbrli:shares


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 10-Q
(Mark One)
 
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2018
or
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from______________to __________

Commission file number 1-7928

BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware
 
94-1381833
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
1000 Alfred Nobel Drive, Hercules, California
 
94547
(Address of principal executive offices)
 
(Zip Code)
(510) 724-7000
(Registrant's telephone number, including area code)
No Change
(Former name, former address and former fiscal year, if changed since last report.)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 
Yes    x
     No     o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232,405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit files).
 
Yes    x
     No     o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.  (Check one):
Large accelerated filer
x
 
Accelerated filer
o
Non-accelerated filer
o
 
Smaller reporting company
o
 
 
 
Emerging growth company
o
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
 
Yes    o
     No     x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Title of Class
 
Shares Outstanding at August 2, 2018
Class A Common Stock, Par Value $0.0001 per share
 
24,735,427
Class B Common Stock, Par Value $0.0001 per share
 
5,099,623




BIO-RAD LABORATORIES, INC.

FORM 10-Q JUNE 30, 2018

TABLE OF CONTENTS



2


INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

Other than statements of historical fact, statements made in this report include forward-looking statements, such as statements with respect to our future financial performance, operating results, plans and objectives that involve risk and uncertainties.  Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions.  Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements.  We have based these forward-looking statements on our current expectations and projections about future events.  However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including, but not limited to, those identified under “Part II, Item 1A, Risk Factors” of this Quarterly Report on Form 10-Q. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.


3




PART I – FINANCIAL INFORMATION

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share data)
 
June 30, 2018
 
December 31, 2017
ASSETS:
 (Unaudited)
 
 
Cash and cash equivalents
$
403,006

 
$
383,824

Short-term investments
415,241

 
371,154

Restricted investments
5,560

 
5,560

Accounts receivable, less allowance for doubtful accounts of $21,466 million at 2018 and $25,549 at 2017
404,091

 
464,847

Inventories:
 
 
 
Raw materials
118,999

 
113,925

Work in process
140,917

 
142,589

Finished goods
331,517

 
338,290

Total inventories
591,433

 
594,804

Other current assets
173,003

 
156,460

Total current assets
1,992,334

 
1,976,649

Property, plant and equipment
1,289,367

 
1,305,150

Less: accumulated depreciation and amortization
(799,118
)
 
(811,654
)
Property, plant and equipment, net
490,249

 
493,496

Goodwill, net
500,022

 
506,069

Purchased intangibles, net
158,035

 
174,113

Other investments
3,170,820

 
1,027,736

Other assets
74,763

 
94,949

Total assets
$
6,386,223

 
$
4,273,012

 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY:
 
 
 
Accounts payable, accrued payroll and employee benefits
$
261,721

 
$
306,814

Current maturities of long-term debt and notes payable
1,721

 
420

Income and other taxes payable
29,585

 
39,941

Other current liabilities
149,394

 
155,521

Total current liabilities
442,421

 
502,696

Long-term debt, net of current maturities
438,776

 
434,581

Deferred income taxes
686,906

 
222,209

Other long-term liabilities
179,174

 
183,276

Total liabilities
1,747,277

 
1,342,762

 
 
 
 
Stockholders’ equity:
 
 
 
Class A common stock, shares issued 24,736,009 and 24,679,127 at 2018 and 2017, respectively; shares outstanding 24,735,427 and 24,678,545 at 2018 and 2017, respectively
2

 
2

Class B common stock, shares issued 5,100,540 and 5,107,674 at 2018 and 2017, respectively; shares outstanding 5,099,623 and 5,106,757 at 2018 and 2017, respectively
1

 
1

Additional paid-in capital
376,595

 
361,231

Class A treasury stock at cost, 582 shares at 2018 and 2017
(128
)
 
(128
)
Class B treasury stock at cost, 917 shares at 2018 and 2017
(89
)
 
(89
)
Retained earnings
4,281,275

 
1,830,439

Accumulated other comprehensive (loss)/income
(18,710
)
 
738,794

Total stockholders’ equity
4,638,946

 
2,930,250

Total liabilities and stockholders’ equity
$
6,386,223

 
$
4,273,012

The accompanying notes are an integral part of these condensed consolidated financial statements. 

4




BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Income
(In thousands, except per share data)
(Unaudited)

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
Net sales
$
575,911

 
$
504,666

 
$
1,127,430

 
$
1,004,717

Cost of goods sold
274,244

 
231,291

 
523,560

 
461,279

Gross profit
301,667

 
273,375

 
603,870

 
543,438

Selling, general and administrative expense
210,425

 
212,489

 
419,555

 
406,891

Research and development expense
47,450

 
62,587

 
96,877

 
112,039

Income (loss) from operations
43,792

 
(1,701
)
 
87,438

 
24,508

Interest expense
5,977

 
6,045

 
11,759

 
11,361

Foreign currency exchange (gains) losses, net
(15
)
 
2,516

 
1,239

 
4,305

Change in fair market value of equity securities
(286,398
)
 
—

 
(1,102,332
)
 
—

Other (income) expense, net
(15,858
)
 
(11,382
)
 
(27,003
)
 
(12,425
)
Income before income taxes
340,086

 
1,120

 
1,203,775

 
21,267

(Provision) benefit for income taxes
(72,043
)
 
3,915

 
(278,958
)
 
(3,819
)
Net income
$
268,043

 
$
5,035

 
$
924,817

 
$
17,448

 
 
 
 
 
 
 
 
Basic earnings per share:
 
 
 
 
 
 
 
Net income per basic share
$
8.99

 
$
0.17

 
$
31.03

 
$
0.59

Weighted average common shares - basic
29,814

 
29,613

 
29,801

 
29,597

 
 
 
 
 
 
 
 
Diluted earnings per share:
 
 
 
 
 
 
 
Net income per diluted share
$
8.87

 
$
0.17

 
$
30.63

 
$
0.58

Weighted average common shares - diluted
30,219

 
30,006

 
30,197

 
29,962



The accompanying notes are an integral part of these condensed consolidated financial statements. 


5


BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Comprehensive Income
(In thousands)
(Unaudited)

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
Net income
$
268,043

 
$
5,035

 
$
924,817

 
$
17,448

Other comprehensive (loss) income:
 
 
 
 
 
 
 
Foreign currency translation adjustments
(124,118
)
 
41,679

 
(77,572
)
 
60,522

Foreign other post-employment benefits adjustments, net of income taxes
1,458

 
(1,938
)
 
1,176

 
(2,053
)
Net holding (loss) gain on equity securities and net unrealized holding (loss) gain on available-for-sale investments, net of income taxes
(135
)
 
54,564

 
(1,851
)
 
134,713

Other comprehensive (loss) income, net of income taxes
(122,795
)
 
94,305

 
(78,247
)
 
193,182

Comprehensive income
$
145,248

 
$
99,340

 
$
846,570

 
$
210,630




The accompanying notes are an integral part of these condensed consolidated financial statements.


6



BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Cash Flows
(In thousands, unaudited)
 
Six Months Ended
 
June 30,
 
2018
 
2017
Cash flows from operating activities:
 
 
 
Cash received from customers
$
1,160,904

 
$
999,779

Cash paid to suppliers and employees
(1,007,565
)
 
(968,719
)
Interest paid, net
(11,277
)
 
(10,865
)
Income tax payments, net
(47,620
)
 
(19,066
)
Investment proceeds and miscellaneous receipts, net
18,354

 
13,197

Proceeds from (payments for) forward foreign exchange contracts, net
5,412

 
(8,029
)
Net cash provided by operating activities
118,208

 
6,297

Cash flows from investing activities:
 
 
 
Capital expenditures
(53,897
)
 
(64,951
)
Proceeds from dispositions of property, plant and equipment
4,100

 
21

Proceeds from divestiture of a product line
6,919

 
—

Proceeds from (payments for) acquisitions and long-term investments
266

 
(73,573
)
Payments for purchases of intangible assets
(3
)
 
(3,920
)
Payments for purchases of marketable securities and investments
(183,001
)
 
(142,993
)
Proceeds from sales of marketable securities and investments
34,548

 
39,362

Proceeds from maturities of marketable securities and investments
88,410

 
98,379

Net cash used in investing activities
(102,658
)
 
(147,675
)
Cash flows from financing activities:
 
 
 
Net payments on line-of-credit arrangements and notes payable
—

 
(36
)
Payments on long-term borrowings
(1,505
)
 
(149
)
Payments of contingent consideration
(1,270
)
 
(3,105
)
Proceeds from issuances of common stock for share-based compensation
3,274

 
3,778

Payments for purchases of treasury stock
—

 
(883
)
Net cash provided by (used in) financing activities
499

 
(395
)
Effect of foreign exchange rate changes on cash
3,053

 
7,190

Net increase (decrease) in cash, cash equivalents, and restricted cash
19,102

 
(134,583
)
Cash, cash equivalents, and restricted cash at beginning of period
384,983

 
457,171

Cash, cash equivalents, and restricted cash at end of period
$
404,085

 
$
322,588


The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets that agrees to the same amounts shown in the Condensed Consolidated Statements of Cash Flows (in thousands):

 
June 30, 2018
 
June 30, 2017
Cash and cash equivalents
$
403,006

 
$321,584
Restricted cash included in Other current assets
105

 
561

Restricted cash included in Other assets
974

 
443

Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows
$
404,085

 
$
322,588


These restricted cash items are primarily related to performance guarantees.

The accompanying notes are an integral part of these condensed consolidated financial statements.



7


BIO-RAD LABORATORIES, INC

Notes to Condensed Consolidated Financial Statements
(Unaudited)

1.BASIS OF PRESENTATION AND USE OF ESTIMATES

Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2017.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.

Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
Revenue Recognition
On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018.  Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition."

We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for the six months ended June 30, 2018 was not significant.

The Company recognizes revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or

8


services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.
Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. Accordingly, in these cases, the delivery of the equipment and the installation are separate performance obligations. The Company will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.
At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products.
Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation.
In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.
We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

Reagent Rental Agreements
Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. The Company has concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, the Company first allocates the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned.
For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the

9


arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.
Revenue allocated to the lease elements are approximately 5% of total revenue and are included as part of the Net sales in our Condensed Consolidated Statements of Income.
Contract costs:
We apply a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities.
Disaggregation of Revenue:
The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited):
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
 
 
2018
 
2017
 
2018
 
2017
Europe
 
$
197.2

 
$
163.9

 
$
396.8

 
$
348.9

Pacific Rim
 
122.0

 
107.5

 
231.4

 
202.3

United States
 
221.6

 
202.5

 
431.5

 
389.8

Other (primarily Canada and Latin America)
 
35.1

 
30.8

 
67.7

 
63.7

Total Net sales
 
$
575.9

 
$
504.7

 
$
1,127.4

 
$
1,004.7



The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 10).

Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are recognized as (or when) the Company performs under the contract which is generally over time during the term of the service contract. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $36.7 million at December 31, 2017 to $41.4 million at June 30, 2018 is primarily driven by cash payments received or due in advance of satisfying our performance obligations, offset by $22.4 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2017.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):

January 1, 2018
$
18.7

Provision for warranty
14.9

Actual warranty costs
(17.5
)
June 30, 2018
$
16.1



10



Recent Accounting Pronouncements Adopted

In February 2018, the FASB issued Accounting Standards Update No. ("ASU") 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to Retained earnings as of the beginning of the fiscal year in which the guidance is adopted. We adopted ASU 2018-03 on January 1, 2018 and made an irrevocable election to account for our investment of the ordinary shares of Sartorius AG at fair value (see ASU 2016-01 below).

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. Changes in fair value for equity securities will no longer be reported in other comprehensive income. For equity investments without readily determinable fair values, the cost method is also eliminated. We adopted ASU 2016-01 on January 1, 2018 and record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes and were valued at $0.6 million as of June 30, 2018. Changes in the basis of these equity investments are reported in current earnings. For equity securities that are affected by ASU 2016-01 and ASU 2018-03, see Note 2 to the condensed consolidated financial statements, which primarily consists of our investment in Sartorius AG.

The impact of the adoption of ASU 2016-01 and ASU 2018-03 on January 1, 2018 was through a cumulative-effect adjustment of $864.5 million to Total stockholders' equity by increasing Retained earnings of $1,543.7 million and decreasing Accumulated other comprehensive income of $679.2 million, including increasing Deferred income taxes by $232.9 million and an increase in Other investments of $1,097.4 million in our Condensed Consolidated Balance Sheet. As a result of ASU 2016-01 and ASU 2018-03 for the three and six months ended June 30, 2018, we recorded $286.4 million and $1,102.3 million, respectively, for the Change in fair market value of equity securities in the Condensed Consolidated Statement of Income that resulted in a deferred tax expense for the three and six months ended June 30, 2018 of $62.6 million and $243.8 million, respectively.

In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which changed how we present the net periodic benefit cost of our defined benefit pension and/or other postretirement plans. We adopted ASU 2017-07 on January 1, 2018 and applied the practical expedient to estimate amounts for comparative purposes utilizing the information disclosed in Note 12 to the consolidated financial statements in our Form 10-K for the year ended December 31, 2017. The interest costs are recorded in Interest expense, and the other costs are recorded in Other (income) expense, net in the Condensed Consolidated Statements of Income. For the second quarter of 2017 for interest costs and other costs, we reclassified $0.076 million, $0.538 million, and $0.036 million from Costs of goods sold (COGS), Selling, general and administrative expense (SG&A) and Research and development expense (R&D), respectively, to Interest expense of $0.275 million and Other (income) expense, net of $0.375 million. For the first six months of 2017 for interest costs and other costs, we reclassified $0.152 million, $1.076 million, and $0.072 million from COGS, SG&A and R&D, respectively, to Interest expense of $0.550 million and Other (income) expense, net of $0.750 million.

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash," which required us to cease to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 and updated the Condensed Consolidated Statements of Cash Flows to incorporate restricted cash included in Other current assets and Other assets of $1.1 million as of June 30, 2018 and $1.0 million as of June 30, 2017.

11



In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," which required immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  We adopted ASU 2016-16 on January 1, 2018 on a modified retrospective basis through a cumulative-effect adjustment by decreasing Retained earnings by $17.6 million, and decreasing Prepaid taxes by $22.8 million and increasing Deferred tax assets by $5.2 million that are both recorded in Other assets in our Condensed Consolidated Balance Sheet.

In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments" and adopted it on January 1, 2018, which did not have an impact to our statement of cash flows presentation.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASC 606"), an updated standard on revenue recognition. The new standard provides enhancements to the quality and consistency of how revenue is reported under the principle that revenue should be recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the transfer of promised goods or services. We adopted ASC 606 as of January 1, 2018 using the cumulative effect transition method as more fully described above under the caption “Revenue Recognition.”

Recent Accounting Pronouncements to be Adopted

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU 2018-11, "Targeted Improvements," which gives the option to apply the transition provisions of ASU 2016-02 at its adoption date instead of at the earliest comparative period presented in its financial statements. In addition, ASU 2018-11 provides a practical expedient that permits lessors to not separate nonlease components from the associated lease component if certain conditions are met. Also in July 2018, the FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases," which clarifies certain aspects of ASU 2016-02. We will adopt ASU 2016-02 on a modified retrospective basis on its adoption date of January 1, 2019 with practical expedients, instead of at the earliest comparative period presented in our financial statements. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.


2.FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•
Level 1: Quoted prices in active markets for identical instruments

12


•
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of June 30, 2018 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
68.4

 
$
—

 
$
68.4

Time deposits
25.7

 
10.0

 
—

 
35.7

Money market funds
30.2

 
—

 
—

 
30.2

Foreign government obligations
—

 
1.8

 
—

 
1.8

U.S. government sponsored agencies
—

 
6.0

 
—

 
6.0

Total cash equivalents (a)
55.9

 
86.2

 
—

 
142.1

Restricted investment
5.6

 
—

 
—

 
5.6

Equity securities (b)
3,196.6

 
—

 
—

 
3,196.6

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
223.6

 
—

 
223.6

U.S. government sponsored agencies
—

 
66.0

 
—

 
66.0

Foreign government obligations
—

 
2.6

 
—

 
2.6

Municipal obligations
—

 
15.6

 
—

 
15.6

Asset-backed securities
—

 
62.9

 
—

 
62.9

Total available-for-sale investments (c)
—

 
370.7

 
—

 
370.7

Forward foreign exchange contracts (d)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
3,258.1

 
$
457.5

 
$
—

 
$
3,715.6

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (e)
$
—

 
$
1.0

 
$
—

 
$
1.0

Contingent consideration (f)
—

 
—

 
13.0

 
13.0

Total financial liabilities carried at fair value
$
—

 
$
1.0

 
$
13.0

 
$
14.0


As of first quarter 2018, our equity securities are no longer reported as Available-for-sale investments due to the implementation of ASU 2016-01. Changes in fair value of equity securities are now reported on the Condensed Consolidated Statements of Income rather than Other Comprehensive Income (see Note 1).

13


Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2017 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
36.0

 
$
—

 
$
36.0

Time deposits
43.7

 
10.0

 
—

 
53.7

U.S. government sponsored agencies
—

 
11.2

 
—

 
11.2

Money market funds
3.4

 
—

 
—

 
3.4

Total cash equivalents (a)
47.1

 
57.2

 
—

 
104.3

Restricted investment
5.6

 
—

 
—

 
5.6

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
185.7

 
—

 
185.7

U.S. government sponsored agencies
—

 
67.6

 
—

 
67.6

Foreign government obligations
—

 
3.4

 
—

 
3.4

Brokered certificates of deposit
—

 
0.7

 
—

 
0.7

Municipal obligations
—

 
15.0

 
—

 
15.0

Marketable equity securities
973.4

 
—

 
—

 
973.4

Asset-backed securities
—

 
55.6

 
—

 
55.6

Total available-for-sale investments (c)
973.4

 
328.0

 
—

 
1,301.4

Forward foreign exchange contracts (d)
—

 
0.5

 
—

 
0.5

Total financial assets carried at fair value
$
1,026.1

 
$
385.7

 
$
—

 
$
1,411.8

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (e)
$
—

 
$
1.6

 
$
—

 
$
1.6

Contingent consideration (f)
—

 
—

 
16.7

 
16.7

Total financial liabilities carried at fair value
$
—

 
$
1.6

 
$
16.7

 
$
18.3


(a)
Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.

(b)
Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):
 
June 30, 2018
Short-term investments
$
44.7

Other investments
3,151.9

        Total
$
3,196.6



The unrealized gains on our equity securities still held as of June 30, 2018 are $1,102.3 million and are primarily due to our investment in Sartorius AG and is recorded in our Condensed Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Note 1).

(c)Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):

14


 
June 30, 2018
 
December 31, 2017
Short-term investments
$
370.5

 
$
371.2

Other investments
0.2

 
930.2

Total
$
370.7

 
$
1,301.4



In accordance with our adoption of ASU 2016-01 January 1, 2018, our investment in Sartorius AG preferred shares, which was reported within marketable equity securities as Available-for-sale as of December 31, 2017, is now reported as an Equity security as of June 30, 2018 (see Note 1 and footnote (b) above).

(d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.

(e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.

(f) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):

 
June 30, 2018
 
December 31, 2017
Other current liabilities
$
2.6

 
$
2.7

Other long-term liabilities
10.4

 
14.0

   Total
$
13.0

 
$
16.7



During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2018 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. In the first quarter of 2018, we paid $1.3 million per the purchase agreement. Since 2016 we have decreased the cumulative valuation of the sales milestones by $8.5 million. The contingent consideration was accrued at its estimated fair value of $13.0 million as of June 30, 2018.

The following table provides a reconciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):

January 1, 2018
$
16.7

Analytical flow cytometer platform:
 
Payment of sales milestone
(1.3
)
Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(2.4
)
June 30, 2018
$
13.0




15


The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of June 30, 2018. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
 
 
 
 
Valuation Technique
Unobservable Input
 
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
Discount rate
11.1
%
 
 
Cost of debt
4.8
%
 
 
 
 



To estimate the fair value of Level 2 debt securities as of June 30, 2018 and December 31, 2017, our primary pricing provider uses Securities Evaluations as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Securities Evaluations does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.

For commercial paper as of June 30, 2018 and December 31, 2017, pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par. In the event that an additional lot of the same commercial paper issue has been purchased within the same account, then the price of all holdings of that issue in that account will be the price of the most recent lot purchased.

Our pricing provider performs daily reasonableness testing of the Securities Evaluations prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly comparison of the Securities Evaluations prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% are investigated and resolved.

Available-for-sale investments consist of the following (in millions):

 
June 30, 2018
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
224.9

 
$
0.1

 
$
(1.4
)
 
$
223.6

Municipal obligations
15.7

 
—

 
(0.1
)
 
15.6

Asset-backed securities
63.1

 
—

 
(0.4
)
 
62.7

U.S. government sponsored agencies
67.2

 
—

 
(1.2
)
 
66.0

Foreign government obligations
2.6

 
—

 
—

 
2.6

 
373.5

 
0.1

 
(3.1
)
 
370.5

Long-term investments:
 
 
 
 
 
 
 
Asset-backed securities
0.2

 
—

 
—

 
0.2

 
0.2

 
—

 
—

 
0.2

Total
$
373.7

 
$
0.1

 
$
(3.1
)
 
$
370.7


The following is a summary of the amortized cost and estimated fair value of our debt securities at June 30, 2018 by contractual maturity date (in millions):

16


 
Amortized
Cost
 
Estimated Fair
Value
Mature in less than one year
$
156.7

 
$
156.4

Mature in one to five years
170.9

 
169.3

Mature in more than five years
46.1

 
45.0

Total
$
373.7

 
$
370.7




Available-for-sale investments consist of the following (in millions):

 
December 31, 2017
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
185.9

 
$
0.3

 
$
(0.5
)
 
$
185.7

Brokered certificates of deposit
0.7

 
—

 
—

 
0.7

Municipal obligations
15.1

 
—

 
(0.1
)
 
15.0

Asset-backed securities
55.6

 
—

 
(0.2
)
 
55.4

U.S. government sponsored agencies
68.3

 
—

 
(0.7
)
 
67.6

Foreign government obligations
3.4

 
—

 
—

 
3.4

Marketable equity securities
34.4

 
9.0

 
—

 
43.4

 
363.4

 
9.3

 
(1.5
)
 
371.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
875.5

 
—

 
930.0

Asset-backed securities
0.2

 
—

 
—

 
0.2

 
54.7

 
875.5

 
—

 
930.2

Total
$
418.1

 
$
884.8

 
$
(1.5
)
 
$
1,301.4



The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):
 
June 30, 2018
 
December 31, 2017
Fair value of investments in a loss position 12 months or more
$
36.9

 
$
43.9

Fair value of investments in a loss position less than 12 months
$
199.4

 
$
168.7

Gross unrealized losses for investments in a loss position 12 months or more
$
0.9

 
$
0.7

Gross unrealized losses for investments in a loss position less than 12 months
$
2.2

 
$
0.8



The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at June 30, 2018 or at December 31, 2017.

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As

17


a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of June 30, 2018 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange losses, net in the Condensed Consolidated Statements of Income.

The following is a summary of our forward foreign exchange contracts (in millions):
 
June 30,
 
2018
Contracts maturing in July through September 2018 to sell foreign currency:
 
Notional value
$
37.8

Unrealized loss
$
0.1

Contracts maturing in July through September 2018 to purchase foreign currency:
 
Notional value
$
327.6

Unrealized loss
$
0.5



The estimated fair value of financial instruments that are not recognized at fair value in the Condensed Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which have fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):
 
June 30, 2018
 
December 31, 2017
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
—

 
—

 
 
 
$
91.8

 
$
1,249.4

 
2
Total long-term debt, excluding leases and current maturities
$
423.4

 
$
439.4

 
2
 
$
423.1

 
$
449.8

 
2


We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over 37% of the outstanding voting shares (excluding treasury shares) of Sartorius as of June 30, 2018.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ Board of Directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius.  As of June 30, 2018, due to the adoption of
ASU 2016-01 and ASU 2018-03, we account for this investment at fair market value as determined at period end by a quoted price on an organized exchange (see Note 1).



18


3.GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1, 2018:
 
 
 
 
 
Goodwill
$
234.7

 
$
324.6

 
$
559.3

Accumulated impairment losses
(35.9
)
 
(17.3
)
 
(53.2
)
Goodwill, net
198.8

 
307.3

 
506.1

 
 
 
 
 
 
Divestiture
—

 
(1.4
)
 
(1.4
)
Currency fluctuations
(0.2
)
 
(4.5
)
 
(4.7
)
 
 
 
 
 
 
Balances as of June 30, 2018:
 
 
 
 
 
Goodwill
234.5

 
318.7

 
553.2

Accumulated impairment losses
(35.9
)
 
(17.3
)
 
(53.2
)
Goodwill, net
$
198.6

 
$
301.4

 
$
500.0



In March 2018, we wrote off $1.4 million of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line.

Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
 
June 30, 2018
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-7
 
$
89.6

 
$
(65.7
)
 
$
23.9

Know how
1-8
 
192.3

 
(158.6
)
 
33.7

Developed product technology
3-11
 
131.8

 
(74.2
)
 
57.6

Licenses
1-11
 
76.4

 
(38.5
)
 
37.9

Tradenames
3-6
 
3.9

 
(3.2
)
 
0.7

Covenants not to compete
1-8
 
7.9

 
(3.7
)
 
4.2

     Total definite-lived intangible assets
 
 
$
501.9

 
$
(343.9
)
 
$
158.0


 
December 31, 2017
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-7
 
$
92.3

 
$
(64.4
)
 
$
27.9

Know how
1-8
 
194.9

 
(157.9
)
 
37.0

Developed product technology
1-12
 
133.3

 
(70.3
)
 
63.0

Licenses
1-12
 
76.7

 
(36.0
)
 
40.7

Tradenames
1-6
 
3.9

 
(3.0
)
 
0.9

Covenants not to compete
1-8
 
7.9

 
(3.3
)
 
4.6

     Total definite-lived intangible assets
 
 
$
509.0

 
$
(334.9
)
 
$
174.1




19


Amortization expense related to purchased intangible assets is as follows (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
Amortization expense
$
7.4

 
$
8.7

 
$
14.8

 
$
15.6








4. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
Six Months Ended
 
June 30, 2018
 
June 30, 2017
Net income
$
924.8

 
$
17.4

Adjustments to reconcile net income to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
68.7

 
70.7

Share-based compensation
12.1

 
10.6

Losses on dispositions of securities
0.6

 
0.3

Changes in fair market value of equity securities
(1,102.3
)
 
—

Gain on divestiture of a product line
(5.1
)
 
—

Losses on dispositions of fixed assets
0.8

 
—

Gain on sale of land
(4.1
)
 
—

Changes in fair value of contingent consideration
(2.4
)
 
(8.7
)
Decrease (increase) in accounts receivable
52.5

 
(1.8
)
Increase in inventories
(11.7
)
 
(37.9
)
Increase in other current assets
(5.9
)
 
(14.8
)
Decrease in accounts payable and other current liabilities
(43.7
)
 
(24.2
)
Decrease in income taxes payable
(20.9
)
 
(13.2
)
Increase (decrease) in deferred income taxes
246.2

 
(3.1
)
Net increase in other long-term assets/liabilities
8.6

 
11.0

Net cash provided by operating activities
$
118.2

 
$
6.3









20




5.    LONG-TERM DEBT

The principal components of long-term debt are as follows (in millions):

 
June 30,
2018
 
December 31,
2017
4.875% Senior Notes due 2020 principal amount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(1.6
)
 
(1.9
)
4.875% Senior Notes less unamortized discount and debt issuance costs
423.4

 
423.1

Capital leases and other debt
17.1

 
11.9

 
440.5

 
435.0

Less current maturities
(1.7
)
 
(0.4
)
Long-term debt
$
438.8

 
$
434.6




Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due 2020 (4.875% Notes).  The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%.  The 4.875% Notes pay a fixed rate of interest of 4.875% per year.  We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.

Credit Agreement

In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of June 30, 2018 or December 31, 2017, however $0.5 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of June 30, 2018. The Credit Agreement matures in June 2019. If we had borrowed against our Credit Agreement, the borrowing rate would have been 3.46% at June 30, 2018.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of June 30, 2018.



21




6.    ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total accumulated other comprehensive income
Balances as of January 1, 2018*:
$
77.4

$
(22.3
)
$
4.5

$
59.6

Other comprehensive (loss) income, before reclassifications
(77.6
)
0.5

(2.1
)
(79.2
)
Amounts reclassified from Accumulated other comprehensive income
—

0.8

0.2

1.0

Income tax effects
—

(0.1
)
—

(0.1
)
Other comprehensive (loss) income, net of income taxes
(77.6
)
1.2

(1.9
)
(78.3
)
Balances as of June 30, 2018:
$
(0.2
)
$
(21.1
)
$
2.6

$
(18.7
)

 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total accumulated other comprehensive income
Balances as of January 1, 2017:
$
1.3

$
(18.6
)
$
435.0

$
417.7

Other comprehensive income (loss), before reclassifications
60.5

(2.5
)
213.2

271.2

Amounts reclassified from Accumulated other comprehensive income
—

—

—

—

Income tax effects
—

0.5

(78.5
)
(78.0
)
Other comprehensive income (loss), net of income taxes
60.5

(2.0
)
134.7

193.2

Balances as of June 30, 2017:
$
61.8

$
(20.6
)
$
569.7

$
610.9



*The beginning balance has been updated as a result of adopting ASU 2016-01. See Note 1, "Basis of Presentation and Use of Estimates" under "Recent Accounting Standards Updates."

The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows:

 
Income before taxes impact (in millions):
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
 
June 30,
 
June 30,
 
 
Components of Comprehensive income
 
2018
 
2017
 
2018
 
2017
 
Location
Amortization of foreign other post-employment benefit items
 
$
(0.5
)
 
$
0.2

 
$
(0.8
)
 
$
—

 
Other (income) expense, net
Net holding (losses) gains on equity securities and available-for-sale investments
 
$
(0.1
)
 
$
(0.2
)
 
$
(0.2
)
 
$
—

 
Other (income) expense, net

Reclassification adjustments are calculated using the specific identification method.

22




7.    EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
Basic weighted average shares outstanding
29,814

 
29,613

 
29,801

 
29,597

Effect of potentially dilutive stock options and restricted stock awards
405

 
393

 
396

 
365

Diluted weighted average common shares
30,219

 
30,006

 
30,197

 
29,962

Anti-dilutive shares
13

 
—

 
13

 
15




8.    OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
Interest and investment income
$
(16.2
)
 
$
(12.0
)
 
$
(18.3
)
 
$
(13.1
)
Net realized loss (gain) on investments
0.1

 
0.2

 
0.2

 
(0.1
)
Gain on sale of land
—

 
—

 
(4.1
)
 
—

Gain on divestiture of product line
—

 
—

 
(5.1
)
 
—

Other expense
0.2

 
0.4

 
0.3

 
0.8

Other (income) expense, net
$
(15.9
)
 
$
(11.4
)
 
$
(27.0
)
 
$
(12.4
)


Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07).

23




9.    INCOME TAXES
 
Our effective income tax rate was 21% and (350)% for the three months ended June 30, 2018 and 2017, respectively. Our effective income tax rate was 23% and 18% for the six months ended June 30, 2018 and 2017, respectively. The effective tax rate for the three and six months ended June 30, 2018 was driven primarily by the large gain on equity investments taxable at the U.S. federal statutory rate of 21%. The effective tax rate for the three and six months ended June 30, 2017 was lower than the U.S. federal statutory rate of 35% due to the impact of second quarter discrete items on low pre-tax income.

In accordance with SAB 118, our accounting for the following elements of the Tax Act was incomplete at December 31, 2017. However, we were able to make reasonable estimates of certain effects and, therefore, recorded provisional estimates as follows:

•
Our deferred tax assets and liabilities were measured at the enacted tax rate that will apply when these temporary differences are expected to be realized or settled.

•
The Tax Act imposes a Transition Tax payable over eight years. The Transition Tax is assessed on the U.S. shareholders’ share of certain foreign corporations’ accumulated untaxed foreign earnings. Earnings in the form of cash and cash equivalents are taxed at a rate of 15.5% and all other earnings are taxed at a rate of 8.0%. In December 2017, we recorded a provisional income tax expense of $55 million for Transition Tax.

Our accounting for certain other elements of the Tax Act was incomplete, and we were not able to make reasonable estimates of those effects. For example, we did not make a determination as to our accounting policy with respect to the new Global Intangible Low-Taxed Income ("GILTI"). For the period ended June 30, 2018, we did not record adjustments to our provisional amounts. We will continue our analysis of these provisional amounts during the measurement period and may adjust these estimates as further regulatory guidance becomes available.
 
We assess our ability to realize our net deferred tax assets on a quarterly basis and establish a valuation allowance if it is more-likely-than-not that some portion of the deferred tax assets will not be realized in the foreseeable future. Due to the weight of negative evidence, including our history of losses in certain jurisdictions, we believe that it is more-likely-than-not that certain foreign deferred tax assets will not be realized as of June 30, 2018. Accordingly, we have maintained a valuation allowance on such deferred tax assets.

Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

As of June 30, 2018, based on the expected outcome of certain examinations or as a result of the expiration of statute of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $3 million. Substantially all such amounts will favorably impact our effective income tax rate.
 

24



10.    SEGMENT INFORMATION

Information regarding industry segments for the three months ended June 30, 2018 and 2017 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2018
$
217.8

 
$
354.0

 
$
4.1

 
2017
$
179.4

 
$
322.1

 
$
3.2

 
 
 
 
 
 
 
Segment net profit (loss)
2018
$
12.2

 
$
27.8

 
$
—

 
2017
$
(22.9
)
 
$
18.5

 
$
0.2


Information regarding industry segments for the six months ended June 30, 2018 and 2017 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2018
$
415.6

 
$
704.8

 
$
7.0

 
2017
$
353.6

 
$
644.4

 
$
6.7

 
 
 
 
 
 
 
Segment net profit (loss)
2018
$
15.5

 
$
64.4

 
$
—

 
2017
$
(41.7
)
 
$
60.1

 
$
0.4



Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits).

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance.  Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. For the three and six months ended June 30, 2018 compared to the same periods in 2017, our Life Science segment had increased sales and gross profit, along with lower Research and Development expense. In addition, the Life Science segment gross margin included a $10.0 million one-time expense associated with the RainDance acquisition in the first quarter of 2017. During the second quarter of 2017, our Clinical Diagnostics segment had an asset purchase for an early stage device for $7.5 million that was recorded in Research and development expense. The following reconciles total segment profit to consolidated income before taxes (in millions):

25


 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
Total segment profit (loss)
$
40.0

 
$
(4.2
)
 
$
79.9

 
$
18.8

Foreign currency exchange losses, net
—

 
(2.5
)
 
(1.2
)
 
(4.3
)
Net corporate operating, interest and other expense not allocated to segments
(2.2
)
 
(3.6
)
 
(4.2
)
 
(5.6
)
Change in fair market value of equity securities
286.4

 
—

 
1,102.3

 
—

Other income (expense), net
15.9

 
11.4

 
27.0

 
12.4

Consolidated income before income taxes
$
340.1

 
$
1.1

 
$
1,203.8

 
$
21.3


Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits).


11.    LEGAL PROCEEDINGS

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017 we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

26




12.    RESTRUCTURING COSTS

Restructuring Costs for European Reorganization

In May, 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with the evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. From inception of May 2016 to June 30, 2018, total expenses were $12.9 million. We recorded $(0.1) million of adjustments in restructuring charges related to severance and other employee benefits for the three and six months ended June 30, 2018. The liability of $4.2 million as of June 30, 2018 consisted of $4.1 million recorded in Accrued payroll and employee benefits and $0.1 million recorded in Other long-term liabilities in the Condensed Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $(0.1) million and in Selling, general and administrative expense of less than $(0.1) million in the Condensed Consolidated Statements of Income for the three and six months ended June 30, 2018.

The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):
 
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1, 2018
 
$
2.2

 
$
4.1

 
$
6.3

Charged to expense
 
—

 
—

 
—

Adjustment to expense
 
—

 
(0.1
)
 
(0.1
)
Cash payments
 
(0.6
)
 
(1.3
)
 
(1.9
)
Foreign currency translation gains
 
—

 
(0.1
)
 
(0.1
)
Balance as of June 30, 2018
 
$
1.6

 
$
2.6

 
$
4.2




Restructuring Costs for Termination of a Diagnostics Research and Development Project and a Facility Closure

In December 2017, we announced the termination of a diagnostics research and development project in Europe. From inception of December 2017 to June 30, 2018, total expenses were $20.4 million. We recorded $(0.6) million and $(0.7) million of adjustments in restructuring charges related to severance and employee benefits, and exit costs for the three and six months ended June 30, 2018, respectively. The adjustments were due to a decrease in severance accrual as a result of a reduction in the number of employees being terminated than originally estimated, net of an increase in exit costs accrual as a result of proposed legal settlement. In June 2018, we announced the closure of a manufacturing facility in Germany. As a result, we recorded $1.3 million of expense in restructuring charges related to severance and employee benefits for the three and six months ended June 30, 2018. Restructuring charges for the termination of a diagnostics research and development project and the facility closure are both included in our Clinical Diagnostics segment's results of operations. The respective amounts recorded for the quarter and year to date ended June 30, 2018 were reflected in Cost of goods sold of $1.3 million and $1.3 million, in Selling, general and administrative expense of $(0.3) million and $(0.1) million, and in Research and development expense of $(0.3) million and $(0.6) million in the Condensed Consolidated Statements of Income. The liability of $11.7 million as of June 30, 2018 consisted of $7.2 million recorded in Accrued payroll and employee benefits, $3.2 million recorded in Other current liabilities, and $1.3 million recorded in Other long term liabilities in the Condensed Consolidated Balance Sheets.

The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closure restructuring reserves for severance and exit costs (in millions):


27


 
 
2018
Balance as of January 1
 
$
14.1

Charged to expense
 
1.3

Adjustment to expense
 
(0.7
)
Cash payments
 
(2.7
)
Foreign currency translation gains
 
(0.3
)
Balance as of June 30
 
$
11.7




Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This discussion should be read in conjunction with the information contained in both our Consolidated Financial Statements for the year ended December 31, 2017 and the financial statements for the three and six months ended June 30, 2018.

Overview.  We are a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products.  Our business is organized into two reportable segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized tools needed for biological research and clinical diagnostics.  

We sell more than 9,000 products and services to a diverse client base comprised of scientific research, healthcare, education and government customers worldwide. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components.  Because our customers require standardization for their experiments and test results, much of our revenues are recurring.  

We are impacted by the support of many governments for both research and healthcare. The current global economic outlook is still uncertain as the need to control government social spending by many governments limits opportunities for growth. Adding to this uncertainty was the referendum in the United Kingdom to withdraw from the European Union, and a change in the U.S. executive branch of government. Approximately 38% of our year-to-date 2018 consolidated net sales are derived from the United States and approximately 62% are derived from international locations, with Europe being our largest international region.  The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens.  When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites as well as non-U.S. suppliers, and from lower international operating expenses. We regularly discuss our changes in revenue and expense categories in terms of both changing foreign exchange rates and in terms of a currency neutral basis, if notable, to explain the impact currency has on our results.

In December 2017, we announced the termination of a diagnostics research and development project in Europe. From inception of December 2017 to June 30, 2018, total expenses were $20.4 million. We recorded $(0.6) million and $(0.7) million of adjustments in restructuring charges related to severance and employee benefits, and exit costs for the three and six months ended June 30, 2018, respectively. The adjustments were due to a decrease in severance accrual as a result of a reduction in the number of employees being terminated than originally estimated, net of an increase in exit costs accrual as a result of proposed legal settlement. In June 2018, we announced the closure of a manufacturing facility in Germany. As a result, we recorded $1.3 million of expense in restructuring charges related to severance and employee benefits for the three and six months ended June 30, 2018. Restructuring charges for the termination of a diagnostics research and development project and the facility closure

28


are both included in our Clinical Diagnostics segment's results of operations. The respective amounts recorded for the quarter and year to date ended June 30, 2018 were reflected in Cost of goods sold of $1.3 million and $1.3 million, in Selling, general and administrative expense of $(0.3) million and $(0.1) million, and in Research and development expense of $(0.3) million and $(0.6) million in the Condensed Consolidated Statements of Income. The liability of $11.7 million as of June 30, 2018 consisted of $7.2 million recorded in Accrued payroll and employee benefits, $3.2 million recorded in Other current liabilities, and $1.3 million recorded in Other long term liabilities in the Condensed Consolidated Balance Sheets.

The following shows cost of goods sold, gross profit, expense items and net income as a percentage of net sales:

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
Net sales
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
Cost of goods sold
47.6

 
45.8

 
46.4

 
45.9

Gross profit
52.4

 
54.2

 
53.6

 
54.1

Selling, general and administrative expense
36.5

 
42.1

 
37.2

 
40.5

Research and development expense
8.2

 
12.4

 
8.6

 
11.2

Net income
46.5

 
1.0

 
82.0

 
1.7



Critical Accounting Policies and Estimates

An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements.  Management believes that there have been no significant changes during the three and six months ended June 30, 2018 to the items that we disclosed as our critical accounting policies and estimates in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.  

Other than the recent accounting pronouncement adoptions referred to below and discussed in Note 1 to the condensed consolidated financial statements, there have been no substantial changes in our significant accounting policies during the three and six months ended June 30, 2018, compared with the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2017.


Three Months Ended June 30, 2018 Compared to
Three Months Ended June 30, 2017

Results of Operations -- Sales, Margins and Expenses

Net sales (sales) for the second quarter of 2018 were $575.9 million compared to $504.7 million in the second quarter of 2017, an increase of 14.1%.  Excluding the impact of foreign currency, second quarter 2018 sales increased by approximately 11.0% compared to the same period in 2017. Currency neutral sales increased in all regions. On January 1, 2018, we adopted FASB Accounting Standards Codification ("ASC") 606, “Revenue from Contracts with Customers,” using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018 (see Note 1 to the condensed consolidated financial statements). The impact to revenue as a result of applying ASC 606 for the three months ended June 30, 2018 was not significant. 


29


The Life Science segment sales for the second quarter of 2018 were $217.8 million, an increase of 21.4% compared to the same period last year.  On a currency neutral basis, sales increased 18.9% compared to the second quarter in 2017. The currency neutral sales increase was primarily driven by growth in our Droplet Digital™ PCR, process chromatography, gene expression, cell biology, protein quantitation, and food science businesses. Currency neutral sales increases occurred in North America, Europe, and Asia.

The Clinical Diagnostics segment sales for the second quarter of 2018 were $354.0 million, an increase of 9.9% compared to the same period last year.  On a currency neutral basis, sales increased 6.5% compared to the second quarter in 2017.  The currency neutral sales increase was primarily attributable to growth across blood typing, quality control, infectious diseases and immunology product lines. On a geographic view, currency neutral sales for the quarter were up across all regions. In the same period last year, segment sales was impacted by our ERP deployment in which some sales were accelerated into the first quarter of 2017 and some sales were delayed to the third quarter of 2017.

Consolidated gross margins were 52.4% for the second quarter of 2018 compared to 54.2% for the second quarter of 2017.  Life Science segment gross margins for the second quarter of 2018 increased from the prior year period by approximately 4.6 percentage points primarily due to the sales increase across most businesses as well as declining royalty costs for gene expression, and purchase accounting intangible amortization within the digital biology business. In addition, lower overall production costs and increased volume led to improved margins. Clinical Diagnostics segment gross margins for the second quarter of 2018 decreased by approximately 5.2 percentage points from the same period last year. The decrease compared to the second quarter of 2017 was primarily driven by lower margin equipment sales from immunohematology and diabetes placements, higher excess and obsolete costs, service costs, and expenses associated with the closing of a manufacturing facility in Germany.

Selling, general and administrative expenses ("SG&A") decreased to $210.4 million or 36.5% of sales for the second quarter of 2018 compared to $212.5 million or 42.1% of sales for the second quarter of 2017.  Decreases to SG&A were minimal with some cost decreases that were mostly compensation and other spending reductions.

Research and development expense (R&D) decreased to $47.5 million or 8.2% of sales in the second quarter of 2018 compared to $62.6 million or 12.4% of sales in the second quarter of 2017.  Life Science segment R&D decreased in the second quarter of 2018 compared to the prior year period primarily due to the completion of projects in 2017 as well as a reduction of the RainDance R&D development team. Clinical Diagnostics segment R&D decreased in the second quarter of 2018 from the prior year period primarily from lower spending due to the termination of a diagnostics research and development project in the fourth quarter of 2017, the closing of the GnuBIO research facilities in the third quarter of 2017, and the purchase of an early stage diagnostic device for $7.5 million in the second quarter of 2017, partially offset by redirecting R&D to new efforts.

Results of Operations – Non-operating

Interest expense for the second quarter of 2018 and 2017 was $6.0 million for both periods.

Foreign currency exchange gains and losses consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk.  Foreign currency exchange was a net gain of $0.015 million for the quarter ended June 30, 2018 compared to foreign currency exchange net losses of $2.5 million for the prior year period. Gains and losses are primarily due to the estimating process inherent in the timing of product shipments and intercompany debt payments, and the cost of hedging.

Change in fair market value of equity securities of $286.4 million for the second quarter of 2018 compared to none in the second quarter of 2017 was primarily due to the adoption of Accounting Standards Update No. ("ASU") 2016-01 (see Note 1 to the condensed consolidated financial statements) and resulted in the recognition of holding gains on our investment in Sartorius AG.


30


Other (income) expense, net for the second quarter of 2018 was $15.9 million income, compared to $11.4 million income for the second quarter of 2017. The increase was primarily due to higher dividends from our investment in Sartorius AG compared to the prior year period.

Our effective income tax rate was 21% and (350)% for the three months ended June 30, 2018 and 2017, respectively. The effective tax rate for the three months ended June 30, 2018 was driven primarily by the large gain on equity investments taxable at the U.S. federal statutory rate of 21%. The effective tax rate for the three months ended June 30, 2017 was lower than the U.S. federal statutory rate of 35% due to the impact of discrete items on low pre-tax income.

In accordance with SAB 118, our accounting for the following elements of the Tax Act was incomplete at December 31, 2017. However, we were able to make reasonable estimates of certain effects and, therefore, recorded provisional estimates as follows:

•
Our deferred tax assets and liabilities were measured at the enacted tax rate that will apply when these temporary differences are expected to be realized or settled.

•
The Tax Act imposes a Transition Tax payable over eight years. The Transition Tax is assessed on the U.S. shareholders’ share of certain foreign corporations’ accumulated untaxed foreign earnings. Earnings in the form of cash and cash equivalents are taxed at a rate of 15.5% and all other earnings are taxed at a rate of 8.0%. In December 2017, we recorded a provisional income tax expense of $55 million for Transition Tax.

Our accounting for certain other elements of the Tax Act was incomplete, and we were not able to make reasonable estimates of those effects. For example, we did not make a determination as to our accounting policy with respect to the new Global Intangible Low-Taxed Income ("GILTI"). For the period ended June 30, 2018, we did not record adjustments to our provisional amounts. We will continue our analysis of these provisional amounts during the measurement period and may adjust these estimates as further regulatory guidance becomes available.

We assess our ability to realize our net deferred tax assets on a quarterly basis and establish a valuation allowance if it is more-likely-than-not that some portion of the deferred tax assets will not be realized in the foreseeable future. Due to the weight of negative evidence, including our history of losses in certain jurisdictions, we believe that it is more-likely-than-not that certain foreign deferred tax assets will not be realized as of June 30, 2018. Accordingly, we have maintained a valuation allowance on such deferred tax assets.

Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

As of June 30, 2018, based on the expected outcome of certain examinations or as a result of the expiration of statute of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $3 million. Substantially all such amounts will positively impact our effective income tax rate.

31



Six Months Ended June 30, 2018 Compared to
Six Months Ended June 30, 2017

Results of Operations -- Sales, Margins and Expenses

Net sales (sales) for the first half of 2018 were $1.13 billion compared to $1.00 billion in the first half of 2017, an increase of 12.2%.  Excluding the impact of foreign currency, the first half of 2018 sales increased by approximately 7.8% compared to the same period in 2017. Currency neutral sales increased in all regions. On January 1, 2018, we adopted FASB Accounting Standards Codification ("ASC") 606, “Revenue from Contracts with Customers,” using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018 (see Note 1 to the condensed consolidated financial statements). The impact to revenue as a result of applying ASC 606 for the first half of 2018 was not significant. 

The Life Science segment sales for the first half of 2018 were $415.6 million, an increase of 17.5% compared to the same period last year.  On a currency neutral basis, sales increased 14.0% compared to the first half of 2017. The currency neutral sales increase was primarily in our Droplet Digital™ PCR product line and the RainDance acquisition, process chromatography that was mostly due to customer ordering patterns, and amplification systems within the gene expression business and food science. The currency neutral sales increase was primarily reflected in North America, Europe, and China within Asia Pacific.

The Clinical Diagnostics segment sales for the first half of 2018 were $704.8 million, an increase of 9.4% compared to the same period last year.  On a currency neutral basis, sales increased 4.4% compared to the first half of 2017. The currency neutral sales increase was primarily attributable to growth across all product lines, including a resolution on a licensed patent of $6.0 million. On a geographic view, currency neutral sales for the first half of 2018 were up in North America and across all Asia Pacific regions, partially offset with decreased sales in Europe.

Consolidated gross margins were 53.6% for the first half of 2018 compared to 54.1% for the first half of 2017.  Life Science segment gross margins for the first half of 2018 increased from the prior year period by approximately 5.0 percentage points primarily due to the $10.0 million one-time expense associated with the RainDance acquisition in 2017 and lower intangible amortization within digital biology, as well as declining royalty expenses within gene expression related to amplification reagents, and lower manufacturing costs for food science. This was partially offset by lower margin percentages in antibody, protein quantification, and protein purification due to product, service, and logistics costs. Clinical Diagnostics segment gross margins for the first half of 2018 decreased by approximately 3.4 percentage points from the same period last year. The decrease compared to the first half of 2017 was primarily driven by lower margin equipment sales, higher excess and obsolete costs, service costs, and expenses associated with the closing of a manufacturing facility in Germany, partially offset by resolution on a licensed patent.

SG&A increased to $419.6 million or 37.2% of sales for the first half of 2018 compared to $406.9 million or 40.5% of sales for the first half of 2017.  Increases to SG&A was primarily related to travel $2.7 million, bad debt of $2.4 million, marketing $1.4 million, software of $1.2 million mostly for amortization of our ERP system, and lower acquisition related benefits of $6.3 million (including changes to contingent consideration) compared to the first half of 2017. These expenses were partially offset by decreases to professional fees of $2.8 million and facilities of $1.3 million.

R&D decreased to $96.9 million or 8.6% of sales in the first half of 2018 compared to $112.0 million or 11.2% of sales in the first half of 2017.  Life Science segment R&D decreased in the first half of 2018 compared to the prior year period primarily due to lower milestone expenses associated with Propel, as well as a reduction of the RainDance development team. Clinical Diagnostics segment R&D decreased in the first half of 2018 from the prior year period primarily from lower spending due to the termination of a diagnostics research and development project in the fourth quarter of 2017, the closing of the GnuBIO research facilities in the third quarter of 2017, and the

32


purchase of an early stage diagnostic device for $7.5 million in the second quarter of 2017, partially offset by redirecting R&D to new efforts.

Results of Operations – Non-operating

Interest expense for the first half of 2018 was $11.8 million, compared to $11.4 million for the first half of 2017, relatively flat compared to the prior year period.

Foreign currency exchange losses, net for the first half of 2018 decreased to $1.2 million compared to $4.3 million for the prior year period. Gains and losses are primarily due to market volatility, the estimating process inherent in the timing of product shipments and intercompany debt payments, and the cost of hedging.

Change in fair market value of equity securities of $1.10 billion for the first half of 2018 compared to none for the first half of 2017 was primarily due to the adoption of Accounting Standards Update No. ("ASU") 2016-01 (see Note 1 to the condensed consolidated financial statements) and mostly consisted of holding gains on our investment in Sartorius AG.

Other (income) expense, net for the first half of 2018 was $27.0 million income, compared to $12.4 million income for the first half of 2017. Other income, net increased primarily due higher dividends from our investment in Sartorius AG compared to the prior year period, and a land sale of $4.1 million and a divestiture of a product line of $5.1 million that both occurred in the first quarter of 2018.

Our effective income tax rate was 23% and 18% for the six months ended June 30, 2018 and 2017, respectively. The effective tax rate for the six months ended June 30, 2018 was driven by the large gain on equity investments taxable at the U.S. federal statutory rate of 21%. The effective tax rate for the six months ended June 30, 2017 was lower than the U.S. federal statutory rate of 35% due to the impact of second quarter discrete items on low pre-tax income.


Liquidity and Capital Resources

Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the markets in which we trade.  Goods are manufactured in a small number of locations, and are then shipped to local distribution facilities around the world.  Our product mix is diversified, and certain products compete largely on product efficacy, while others compete on price.  Gross margins are generally sufficient to exceed normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes.  In addition to the annual positive cash flow from operating activities, additional liquidity is readily available via the sale of short-term investments and access to our $200.0 million unsecured Credit Agreement, and to a lesser extent international lines of credit.  Borrowings under the 2014 Credit Agreement are available on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of June 30, 2018, however $0.5 million was utilized for domestic standby letters of credit that reduced our borrowing availability. The Credit Agreement matures in June 2019. We are currently evaluating our options on renewing the Credit Agreement or similar arrangements. In total under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had approximately $207.8 million available for borrowing and usage as of June 30, 2018, which was reduced by approximately $4.2 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations. Management believes that this availability, together with cash flow from operations, will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and an acquisition of reasonable proportion to our existing short-term investments and access to our Credit Agreement or similar arrangements.
 

33


At June 30, 2018, we had $818.2 million in cash, cash equivalents and short-term investments, of which approximately 25% was held in our foreign subsidiaries. We believe that our holdings of cash, cash equivalents and short-term investments in the U.S. and in our foreign subsidiaries are sufficient to meet both the current and long-term needs of our global operations. The amount of funds held in the United States can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and foreign cash flows (both inflows and outflows).

Certain foreign subsidiary earnings are subject to U.S. taxation under the Tax Act, which also repeals U.S. taxation on the subsequent repatriation of those earnings.  It is generally our intention to repatriate those foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs.  While we currently estimate that the repatriation of those earnings would not trigger material costs, these estimates are provisional, and we are still evaluating the full impact of these potential repatriations in accordance with SAB 118.

Demand for our products and services could change more dramatically than in previous years based on activity, funding, reimbursement constraints and support levels from government, universities, hospitals and private industry, including diagnostic laboratories.  The need for certain sovereign nations with large annual deficits to curtail spending could lead to slower growth of, or even a decline in, our business. Sovereign nations either delaying payment for goods and services or renegotiating their debts could impact our liquidity. As of June 30, 2018 and December 31, 2017, we had accounts receivable, net of an allowance for doubtful accounts, in Spain, Italy, Greece and Portugal of $41.0 million and $41.0 million, respectively.


Cash Flows from Operations

Net cash provided by operations was $118.2 million compared to $6.3 million for the six months ended June 30, 2018 and 2017, respectively.  The increase in operating cash flows was primarily the net effect of:
•
higher cash received from customers in 2018 primarily due to higher sales activity in the fourth quarter of 2017 than the same period in 2016, which resulted in more cash collected in the first half of 2018, in addition to improving collections subsequent to the ERP implementation last year,
•
net proceeds in 2018 compared to net payments in 2017 for forward foreign exchange contracts, and
•
higher investment income received, partially offset by
•
higher cash paid to suppliers and employees, higher employee related costs for merit increases, and more development and sales milestone payments to Propel, partially offset by a $10.0 million payment for the RainDance preexisting condition in 2017, and
•
higher income tax payments in 2018 compared to 2017.


Cash Flows from Investing Activities

Net cash used in investing activities was $102.7 million compared to $147.7 million for the six months ended June 30, 2018 and 2017, respectively. Capital expenditures were lower for the six months ended June 30, 2018 compared to the same period last year, reflecting the completion in April 2017 of the third phase of the ERP system, which was a larger deployment than the ERP implementation in July 2018. During the first quarter of 2018, we received $6.9 million for a divestiture of a product line. Purchases, sales and maturities of marketable securities and investments combined had an overall decrease of $54.8 million primarily due to higher purchases, and decreases in maturities and sales.

Proceeds from acquisitions in 2018 and payments for acquisitions and long-term investments in 2017 were primarily due to the following:


34


•
in April of 2018, we acquired a raw material supplier to Bio-Rad by assuming liabilities, including a promise to extinguish the acquired company's existing bank debt and a $369,630 payment for all the company's assets in a share purchase. The acquisition will not meet the significant or material subsidiary test. The purchase price allocation is preliminary as additional time is required to complete the valuation of assets.
•
in February 2017, we acquired all the issued and outstanding stock of RainDance for approximately $72.7 million, including certain assumed liabilities. Cash payments at closing were $72.9 million.

Our investment objective is to maintain liquidity to meet anticipated operational and other corporate requirements in which capital is preserved and increased through investing in low risk, high quality securities with commensurate returns, consistent with our risk tolerance level.

We continue to review possible acquisitions to expand both our Life Science and Clinical Diagnostics segments. We routinely meet with the principals or brokers of subject companies. However, it is not certain at this time that any of these discussions involving material or significant acquisitions will advance to completion.

Capital expenditures totaled $53.9 million and $65.0 million for the six months ended June 30, 2018 and 2017, respectively.  Capital expenditures represent the addition and replacement of production machinery and research equipment, ongoing manufacturing and facility additions for expansion, regulatory, environmental and compliance. Also included in capital expenditures are investments in business systems and data communication upgrades and enhancements.  All periods include equipment placed with Clinical Diagnostics segment customers who then contract to purchase our reagents for use. As we implement the remaining smaller phases of the ERP platform, we expect a decline in capital expenditure spending patterns. The current estimated future cash outlays for the global implementation of the single instance ERP platform is projected to be $125 million, and is estimated to take the next 3 to 4 years to fully implement.

Cash Flows from Financing Activities

Net cash provided by financing activities was $0.5 million compared to net cash used in financing activities of $0.4 million for the six months ended June 30, 2018 and 2017, respectively. This increase for the six months ended June 30, 2018 was primarily due to lower payments for contingent consideration, partially offset by higher payments on long-term debt.

We have outstanding Senior Notes of $425 million, which are not due until 2020. We believe the current cash is sufficient to meet normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes.

On November 28, 2017, we announced that the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250 million of outstanding shares of our common stock. This new authorization superseded the prior authorization of up to $18.0 million of Bio-Rad's common stock. The Credit Agreement may limit our ability to repurchase our stock. During the second and third quarters of 2017, we made open market purchases of 13,200 shares of our Class A common stock. In September 2017, we used 12,740 of the repurchased shares in connection with the vesting of restricted stock units under the 2007 Incentive Award Plan in order to obtain a tax deduction in some of our foreign entities. In June 2012, we withheld 122 shares of our Class A common stock and 917 shares of our Class B common stock to satisfy tax obligations due upon the vesting of restricted stock of certain of our employees, which is considered a repurchase of our stock. We had no other repurchases of our stock as of June 30, 2018.

Recent Accounting Pronouncements Adopted and to be Adopted

See Note 1 to the condensed consolidated financial statements for recent accounting pronouncements adopted and to be adopted.


35




Item 3. Quantitative and Qualitative Disclosures about Market Risk

During the six months ended June 30, 2018, there have been no material changes from the disclosures about market risk provided in our Annual Report on Form 10-K for the year ended December 31, 2017.


Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Subject to the limitations noted above, our management, with the participation of our CEO and CFO, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the CEO and CFO have concluded that, as of such date, our disclosure controls and procedures were not effective as a result of the material weakness in our internal control over financial reporting at December 31, 2017, which we view as an integral part of our disclosure controls and procedures, discussed in further detail below.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis.

In connection with our assessment of the effectiveness of internal control over financial reporting at December 31, 2017, we identified the following control deficiencies existed at December 31, 2017:

We did not maintain a sufficient complement of personnel in certain European countries with appropriate training and expertise in accounting and reporting in the new ERP system following the system conversion and European reorganization including the implementation of reporting lines, appropriate authorities and responsibilities within and between our accounting and reporting function, information technology and the business operations in these European countries.

We did not conduct continuous risk assessment over changes in our European business operations, IT systems and personnel to identify and assess necessary changes in internal control over financial reporting.

As a result, we did not design effective control activities over the accounting for financial statement amounts, including inventory and revenue, reported by entities impacted by the European reorganization, including management review controls with sufficient precision to identify and investigate potential outliers.

36


    
These control deficiencies resulted in immaterial misstatements to inventory, revenue, and cost of goods sold, certain of which were corrected in the consolidated financial statements as of December 31, 2017, prior to issuance.

Management is enhancing its control environment in the entities impacted by the ERP system conversion and European reorganization by (i) increasing resources with sufficient accounting and reporting expertise within our reorganized business and using our new ERP system, (ii) implementing and monitoring reporting lines and appropriate authorities and responsibilities within the accounting and reporting function, information technology and the business operations and (iii) providing training to our control owners to effectively perform controls in the new environment including training on reconciliation review controls and certain ERP system enhancements.

Management is also enhancing its risk assessment process to continuously assess the potential impact on internal control over financial reporting of changes to business operations, including changes relating to similar ERP systems conversions and reorganizations that may occur in the future.

Management is also in the process of designing additional control activities over financial statement amounts reported by entities impacted by the European reorganization.

These remediation efforts continued during the three and six months ended June 30, 2018 and are expected to be completed during the year ending December 31, 2018.

However, we cannot assure you that these efforts will be effective in timely remediating the material weakness or that additional deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement new or improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could result in additional significant deficiencies or material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations, which in turn could cause the trading price of our common stock to decline.

Changes to Internal Control Over Financial Reporting

Other than the changes discussed above, we identified no changes in internal control over financial reporting that occurred during our quarter ended June 30, 2018, that have materially affected, or that are reasonable likely to materially affect, our internal control over financial reporting.


PART II – OTHER INFORMATION

Item 1. Legal Proceedings

See Note 11, “Legal Proceedings” in the Notes to Condensed Consolidated Financial Statements of Part I, Item 1 of this Quarterly Report on Form 10-Q.


37



Item 1A. Risk Factors

Our settlement with government agencies in connection with violations by us of the U.S. Foreign Corrupt Practices Act could have a material adverse effect on our business, results of operations and financial condition.

As previously disclosed, we entered into a non-prosecution agreement (NPA) with the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) and consented to the entry of an Order by the SEC (SEC Order), effective November 3, 2014, which actions resolved both the DOJ and the SEC investigations into our violations of the U.S. Foreign Corrupt Practices Act (FCPA). Under the terms of the NPA and the SEC Order, we agreed to pay a financial penalty and certain amounts in disgorgement and interest as well as to compliance, reporting and cooperation obligations to be performed for two years. On October 28, 2016, the DOJ and SEC informed Bio-Rad that they did not intend to extend the NPA after it expired November 2, 2016.

Whether by virtue of disclosure of the NPA and the SEC Order or otherwise, we may be subject to investigations by foreign governments or further claims by third parties arising from conduct subject to the investigation or our other international operations. Many of our customers in our significant international operations are government agencies or state-owned or state-controlled universities, hospitals and laboratories. The disclosure of the NPA and the SEC Order and any further violations of the FCPA could harm our reputation with these customers, which could materially adversely affect our business, results of operations and financial condition. Any further violations of the FCPA also could result in more punitive actions by the SEC and DOJ, which also could materially adversely affect our business, results of operations and financial condition.

Our international operations expose us to additional costs and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial condition.

We have significant international operations. We have direct distribution channels in over 35 countries outside the United States, and during the first six months of 2018 our foreign subsidiaries generated 62% of our net sales. Compliance with complex foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, data privacy requirements (including the requirements for compliance with the EU General Data Protection Regulation, which went into effect May 25, 2018), labor relations laws, tax laws, anti-competition regulations, import and trade restrictions, tariffs, quotas and other trade barriers, export requirements, U.S. laws such as the FCPA and other U.S. federal laws and regulations established by the office of Foreign Asset Control, foreign laws such as the UK Bribery Act 2010 or other foreign laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers.

Given the high level of complexity of these laws, there is a risk that we may inadvertently breach some provisions, for example, through fraudulent or negligent behavior of individual employees, our failure to comply with certain formal documentation requirements, or otherwise. Our success depends, in part, on our ability to anticipate these risks and manage these challenges through policies, procedures and internal controls. However, we have a dispersed international sales organization, and we use distributors and agents in many of our international operations. This structure makes it more difficult for us to ensure that our international selling operations comply with our global policies and procedures.

Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Violations of laws and regulations also could result in prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, or our business, results of operations and financial condition. See also our risk factors regarding government regulations and regarding global economic conditions below.


38


The industries and market segments in which we operate are highly competitive, and we may not be able to compete effectively.

The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have merged, and some of our competitors have greater financial resources than we do and are less leveraged than we are, making them better equipped to license technologies and intellectual property from third parties or to fund research and development, manufacturing and marketing efforts. Moreover, competitive and regulatory conditions in many markets in which we operate restrict our ability to fully recover, through price increases, higher costs of acquired goods and services resulting from inflation and other drivers of cost increases. Many public tenders have become more competitive due to governments lengthening the commitments of their public tenders to multiple years, which reduce the number of tenders in which we can participate annually. Because the value of these multiple-year tenders is so high, our competitors have been more aggressive with their pricing. Our failure to compete effectively and/or pricing pressures resulting from competition could adversely affect our business, results of operations and financial condition.

We may not be able to grow our business because of our failure to develop new or improved products.

Our future growth depends in part on our ability to continue to improve our product offerings and develop and introduce new product lines and extensions that integrate technological advances. In particular, we may not be able to keep up with changes in the clinical diagnostics industry, such as the trend toward molecular diagnostics or point-of-care tests. If we are unable to integrate technological advances into our product offerings or to design, develop, manufacture and market new product lines and extensions successfully and in a timely manner, our business, results of operations and financial condition will be adversely affected. We have experienced product launch delays in the past, and may do so in the future. We cannot assure you that our product and process development efforts will be successful or that new products we introduce will achieve market acceptance. Failure to launch successful new products or improvements to existing products may cause our products to become obsolete, which could harm our business, results of operations and financial condition.

We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our results of operations and financial condition.

As stated above, a significant portion of our operations and sales are outside of the United States. When we make purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar negatively impacts our consolidated net sales expressed in U.S. dollars. Conversely, when the U.S. dollar weakens, our expenses at our international sites increase. In addition, the volatility of other currencies may negatively impact our operations outside of the United States and increase our costs to hedge against currency fluctuations. We cannot assure you that future shifts in currency exchange rates will not have a material adverse effect on our results of operations and financial condition.

We may experience difficulties implementing our new global enterprise resource planning system.

We are engaged in a multi-year implementation of a new global enterprise resource planning system (ERP). The ERP is designed to efficiently maintain our books and records and provide information important to the operation of our business to our management team. The ERP will continue to require significant investment of human and financial resources. In implementing the ERP, we may experience significant delays, increased costs and other difficulties. Any significant disruption or deficiency in the design and implementation of the ERP could adversely affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. For example, we experienced system implementation issues in our Clinical Diagnostics segment during our first deployment that impacted invoicing and caused an increase in accounts receivable. In our second deployment, we experienced delays in manufacturing and logistics, which adversely impacted our sales. In our third deployment in Western Europe in April 2017 we experienced system implementation issues impacting the timing of payment of vendor invoices and resulting in delays in product

39


availability and shipments. We also experienced lower productivity levels related to the April 2017 go-live of the ERP in Western Europe, which adversely impacted our sales during the second and third quarters of 2017. The third deployment was complex, and additional and significant issues may arise. We expect to implement the remaining smaller phases of the ERP platform over approximately the next 3 to 4 years. In addition, our efforts to centralize various business processes and functions within our organization in connection with our ERP implementation may continue to disrupt our operations and negatively impact our business, results of operations and financial condition.

Recent and planned changes to our organizational structure and executive management team could negatively impact our business.

We made significant changes to our organizational structure over the past four years. In 2014 and 2015, we functionalized our manufacturing and selling organizations globally and separated them from our marketing and research and development organizations. Specifically, we combined our international selling organization with our North American selling divisions into one global selling group and consolidated our manufacturing, procurement and logistics operations into one global supply chain group. We also created new management positions to head each of these groups. In addition, we appointed new executives to head each of our Life Science and Clinical Diagnostics segments. We also restructured our Life Science segment based on functional groups rather than product line divisions. In 2016, we began implementing the reorganization of the structure of our European organization, and we have continued implementing the reorganization of our European organization in 2017 and 2018. These changes may have unintended consequences, such as distraction of our management and employees, business disruption, attrition of our workforce, inability to attract or retain key employees, and reduced employee morale or productivity.

Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.

Maintaining effective disclosure controls and procedures and internal controls over financial reporting are necessary for us to produce reliable financial statements.  During the third quarter of 2017, we identified two items that were recorded in the three-month period ended September 30, 2017 that should have been recorded in the three-month period ended June 30, 2017.  Though there was no impact on the financial statements for the nine-month period ended September 30, 2017, we concluded that our disclosure controls and procedures were ineffective as of September 30, 2017 and that this deficiency constituted a material weakness.  Our management believes that our enhanced post-ERP system conversion management review control activities and augmented user acceptance testing of system changes, which were designed to remediate the material weakness over financial reporting disclosed as of September 30, 2017, were sufficiently implemented as of December 31, 2017.

In connection with our assessment of the effectiveness of internal control over financial reporting as of December 31, 2017, we determined that we did not maintain a sufficient complement of personnel in certain European countries with appropriate training and expertise in accounting and reporting in the new ERP system following the system conversion and European reorganization that the Company undertook in April 2017, including the implementation of reporting lines, appropriate authorities and responsibilities within and between our accounting and reporting function, information technology and the business operations in these European countries. We did not conduct continuous risk assessment over changes in our European business operations, IT systems and personnel to identify and assess necessary changes in internal control over financial reporting. As a result, we did not design effective control activities over the accounting for financial statement amounts, including inventory and revenue, reported by entities impacted by the European reorganization, including management review controls with sufficient precision to identify and investigate potential outliers. These control deficiencies resulted in immaterial misstatements to inventory, revenue and cost of goods sold, certain of which were corrected in the consolidated financial statements as of December 31, 2017, prior to issuance.


40


Because the deficiencies create a reasonable possibility of material misstatement in the annual or interim consolidated financial statements that will not be prevented or detected on a timely basis, they represent a material weakness in internal control over financial reporting and accordingly, our management concluded that our internal control over financial reporting was not effective as of December 31, 2017.  KPMG, LLP, an independent registered public accounting firm, audited the consolidated financial statements included in the 2017 Annual Report on Form 10-K and, as part of the audit, issued an adverse opinion on the effectiveness of the Company’s internal control over financial reporting as of December 31, 2017. Our management, with the participation of our CEO and CFO, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the period covered by this Quarterly Report on Form 10-Q and concluded that, as of such date, our disclosure controls and procedures were not effective as a result of the material weakness in our internal control over financial reporting at December 31, 2017, which we view as an integral part of our disclosure controls and procedures.

In response to this evaluation and assessment, our management is enhancing its control environment in the entities impacted by the ERP system conversion and European reorganization by (i) increasing resources with sufficient accounting and reporting expertise within our reorganized business and using our new ERP system, (ii) implementing and monitoring reporting lines and appropriate authorities and responsibilities within the accounting and reporting function, information technology and the business operations, and (iii) providing training to our control owners to effectively perform controls in the new environment including training on reconciliation review controls and certain ERP system enhancements. Our management is also enhancing its risk assessment process to continuously assess the potential impact on internal control over financial reporting of changes to business operations, including changes relating to similar ERP system conversions and reorganizations that may occur in the future. In addition, our management is in the process of designing enhanced control activities over financial statement amounts reported by entities impacted by the European reorganization. These remediation efforts, which began in the fourth quarter of 2017 and continued during the six-month period ended June 30, 2018, are expected to be completed during the year ending December 31, 2018. However, we cannot assure you that these efforts will be effective in timely remediating the material weakness or that additional deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future.

Material weaknesses have adversely affected us in the past and could affect us in the future, and the results of our periodic management evaluations and annual auditor attestation reports regarding the effectiveness of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002.  Any failure to maintain or implement new or improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could result in additional significant deficiencies or material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations.  This could cause us to lose public confidence, and could cause the trading price of our common stock to decline.  For further information regarding our controls and procedures, see Part I, Item 4 of this Quarterly Report on Form 10-Q.

Breaches of our information systems could have material adverse effect on our business and results of operations.

Through our sales and eCommerce channels, we collect and store confidential information that customers provide to, among other things, purchase products or services, enroll in promotional programs and register on our Web site. We also acquire and retain information about suppliers and employees in the normal course of business. We also create and maintain proprietary information that is critical to our business, such as our product designs and manufacturing processes. Despite recent initiatives to improve our technology systems, such as our enterprise resource planning implementation and the centralization of our global information technology organization, we could experience a significant data security breach. Computer hackers may attempt to penetrate our or our vendors’ information systems and, if successful, misappropriate confidential customer, supplier, employee or other business information, such as our intellectual property. Third parties could also gain control of our systems and use them for criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting new customers, be exposed to claims from customers, financial institutions, payment card associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a

41


result of a data privacy breach, or suffer other adverse consequences. Our operations and ability to process sales orders, particularly through our eCommerce channels, could also be disrupted. Any significant breakdown, intrusion, interruption, corruption, or destruction of our systems, as well as any data breaches, could have a material adverse effect on our business and results of operations. See also our risk factors regarding our ERP implementation above and our information technology systems below.

Risks relating to intellectual property rights may negatively impact our business.

We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure agreements to protect our intellectual property rights and products. However, we cannot assure you that our intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that meaningful protection or adequate remedies will be available to us. For instance, unauthorized third parties have attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as proprietary, or have developed equivalent technologies independently, and may do so in the future. Additionally, third parties have asserted patent, copyright and other intellectual property rights to technologies that are important to us, and may do so in the future. If we are unable to license or otherwise access protected technology used in our products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and marketing such products. From time to time, we also must enforce our patents or other intellectual property rights or defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could incur substantial costs, be forced to redesign our products, or be required to pay damages to an infringed party. Any of the foregoing matters could adversely impact our business, results of operations and financial condition.

Global economic conditions could adversely affect our operations.

In recent years, we have been faced with very challenging global economic conditions. A deterioration in the global economic environment may result in decreased demand for our products, increased competition, downward pressure on the prices for our products and longer sales cycles. A weakening of macroeconomic conditions may also adversely affect our suppliers, which could result in interruptions in supply in the future. We have also experienced delays in collecting receivables in certain countries in Western Europe, and we may experience similar delays in these and other countries or regions experiencing liquidity problems. As of June 30, 2018, we had accounts receivable, net of allowance for doubtful accounts, in Spain, Italy, Greece and Portugal of $41.0 million. In addition, a slowing of growth in the Chinese economy and in emerging markets, especially those oil-producing countries that would be affected by a decline in oil prices, could adversely affect our business, results of operations or financial condition. We also are monitoring developments following the United Kingdom's decision to leave the European Union to determine if there will be any potential impact on our business. Additionally, the United States and other countries recently have imposed tariffs on certain goods. While tariffs imposed by other countries on U.S. goods have not yet had a significant impact on our business, further escalation of tariffs or other trade barriers could adversely impact our profitability and/or our competitiveness. See also our risk factors regarding our international operations above and regarding government regulations below.

Reductions in government funding and the capital spending programs of our customers could have a material adverse effect on our business, results of operations or financial condition.

Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and pharmaceutical, biotechnology and chemical companies.  The capital spending programs of these institutions and companies have a significant effect on the demand for our products.  Such programs are based on a wide variety of factors, including the resources available to make such purchases, the availability of funding from grants by governments or government agencies, the spending priorities for various types of equipment and the policies regarding capital expenditures during industry downturns or recessionary periods.  If government funding to our customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to us, our business, results of operations or financial condition could be materially and adversely affected.
 

42



Changes in the healthcare industry could have an adverse effect on our business, results of operations and financial condition.

There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs. These changes include:

•
The trend towards managed care, together with healthcare reform of the delivery system in the United States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other participants in the healthcare industry to reduce selling prices.  Consolidation among healthcare providers and consolidation among other participants in the healthcare industry has resulted in fewer, more powerful groups, whose purchasing power gives them cost containment leverage.  In particular, there has been a consolidation of laboratories and a consolidation of blood transfusion centers. These industry trends and competitive forces place constraints on the levels of overall pricing, and thus could have a material adverse effect on our gross margins for products we sell in clinical diagnostic markets.

•
Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of reimbursement available for clinical tests from third party payors. In the United States payment for many diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in establishing their reimbursement rates. Clinicians may decide not to order clinical diagnostic tests if third party payments are inadequate, and we cannot predict whether third party payors will offer adequate reimbursement for tests utilizing our products to make them commercially attractive. Legislation, such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of 2012, has reduced the payments for clinical laboratory services paid under the CLFS. In addition, the Protecting Access to Medicare Act of 2014 (PAMA) has made significant changes to the way Medicare will pay for clinical laboratory services, which has further reduced reimbursement rates.

•
The PPACA has also imposed a 2.3% excise tax on the sales of certain medical devices in the U.S., which we are required to pay on most of our United States Clinical Diagnostic sales. However, the Consolidated Appropriations Act, 2016 (Pub. L. 114-113), signed into law on December 18, 2015, included a two year moratorium on the medical device excise tax. On January 22, 2018, the moratorium on the medical device excise tax was further extended until January 1, 2020.

To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures such as those contained in the PPACA and the PAMA, or in future legislation, by limiting the number of clinical tests being performed or the amount of reimbursement available for such tests, our business, results of operations and financial condition could be adversely affected.  If these changes in the healthcare markets in the United States and Europe continue, we could be forced to alter our approach in selling, marketing, distributing and servicing our products.

We are subject to substantial government regulation, and any changes in regulation or violations of regulations by us could adversely affect our business, prospects, results of operations or financial condition.

Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject to U.S. federal, state and local, and foreign regulation, including by the FDA in the United States and its foreign counterparts.  The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements including, for example, recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If

43


the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of production, withdrawal of approvals or clearances already granted, and criminal prosecution.

The FDA can also require us to repair, replace or refund the cost of devices that we manufactured or distributed.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our ability to modify our currently approved or cleared products on a timely basis. Changes in the FDA’s review of certain clinical diagnostic products referred to as laboratory developed tests, which are tests developed by a single laboratory for use only in that laboratory, could affect some of our customers who use our Life Science instruments for laboratory developed tests. In the past, the FDA has chosen to not enforce applicable regulations and has not reviewed such tests for approval. However, the FDA has issued draft guidance that it may begin enforcing its medical device requirements, including premarket submission requirements, to such tests. Any delay in, or failure to receive or maintain, clearance or approval for our products could prevent us from generating revenue from these products and adversely affect our business operations and financial results. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using our products.

Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale and use of our products. Such agencies may also impose new requirements that may require us to modify or re-register products already on the market or otherwise impact our ability to market our products in those countries. For example, in April 2017 the European Parliament voted to enact final regulations that include broad changes regarding in vitro diagnostic devices and medical devices, which will require us to modify or re-register some products and will result in additional costs. In addition, Russia has enacted more stringent medical product registration and labeling regulations, China has enacted stricter labeling requirements, and we expect other countries, such as Brazil and India, to impose more regulations that impact our product registrations. Due to these evolving and diverse requirements, we face uncertain product approval timelines, additional time and effort to comply, as well as the potential for reduced sales and/or fines for noncompliance. Increasing protectionism in such countries also impedes our ability to compete with local companies. For example, we may not be able to participate in certain public tenders in Russia because of increasing measures to restrict access to such tenders for companies without local manufacturing capabilities. Such regulations could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our international operations and regarding global economic conditions above.

We are also subject to government regulation of the use and handling of a number of materials and controlled substances.  The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of 1970. Failure to comply with present or future laws and regulations could result in substantial liability to us, suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us to make significant capital expenditures or incur other significant expenses.

We cannot assure you that we will be able to integrate acquired companies, products or technologies into our company successfully, or we may not be able to realize the anticipated benefits from the acquisitions.

As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies, products and technologies. In order to be successful in these activities, we must, among other things:
•
assimilate the operations and personnel of acquired companies;
•
retain acquired business customers;
•
minimize potential disruption to our ongoing business;
•
retain key technical and management personnel;
•
integrate acquired companies into our strategic and financial plans;

44


•
accurately assess the value of target companies, products and technologies;
•
comply with new regulatory requirements;
•
harmonize standards, controls, procedures and policies;
•
minimize the impact to our relationships with our employees and customers; and
•
assess, document and remediate any deficiencies in disclosure controls and procedures and internal control over financial reporting.

The benefits of any acquisition may prove to be less than anticipated and may not outweigh the costs reported in our financial statements.  Completing any potential future acquisitions could cause significant diversion of our management’s time and resources.  If we acquire new companies, products or technologies, we may be required to assume contingent liabilities or record impairment charges for goodwill and other intangible assets over time. We cannot assure you that we will successfully overcome these risks or any other problems we encounter in connection with any acquisitions, and any such acquisitions could adversely affect our business, results of operations and financial condition.

Product quality and liability issues could harm our reputation and negatively impact our business, results of operations and financial condition.

We must adequately address quality issues associated with our products, including defects in our engineering, design and manufacturing processes, as well as defects in third-party components included in our products. Our instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially those affecting reagents or third-party components, is difficult. We may incur significant costs and expend substantial time in researching and remediating such issues. Quality issues could also delay our launching or manufacturing of new products. In addition, quality issues, unapproved uses of our products, or inadequate disclosure of risks related to our products, could result in product recalls or product liability or other claims being brought against us. These issues could harm our reputation, impair our relationship with existing customers and harm our ability to attract new customers, which could negatively impact our business, results of operations and financial condition.

Lack of key personnel could hurt our business.

Our products are very technical in nature. In general, only highly qualified and well-trained scientists have the necessary skills to develop, market and sell our products, and many of our manufacturing positions require very specialized knowledge and skills.  In addition, the global nature of our business also requires that we have sophisticated and experienced staff to comply with increasingly complex international laws and regulations. We face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout our industry. In particular, the job market in Northern California, where many of our employees are located, is very competitive. If we do not offer competitive compensation and benefits, we may fail to retain or attract a sufficient number of qualified personnel, which could impair our ability to properly run our business.

In some cases we rely on temporary personnel or consultants, and we may do so in the future. Such temporary personnel or consultants may lack the knowledge and/or specific skills necessary for our business, require time to train without benefiting us through extended employment and increase our costs. In addition, as noted above, our strategic initiatives, such as our internal restructuring and ERP implementation, may be burdensome and disruptive and lead to employee dissatisfaction and attrition.

A reduction or interruption in the supply of components and raw materials could adversely affect our manufacturing operations and related product sales.

The manufacture of many of our products requires the timely delivery of sufficient amounts of quality components and materials. We manufacture our products in numerous manufacturing facilities around the world. We acquire our components and materials from many suppliers in various countries. We work closely with our suppliers to ensure the continuity of supply but we cannot guarantee these efforts will always be successful. Further, while we

45


seek to diversify our sources of components and materials, in certain instances we acquire components and materials from a sole supplier. In addition, due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials. If our supply is reduced or interrupted or of poor quality, and we are unable to develop alternative sources for such supply, our ability to manufacture our products in a timely or cost-effective manner could be adversely affected, which would adversely affect our ability to sell our products.

If our information technology systems are disrupted, or if we fail to successfully implement, manage and integrate our information technology and reporting systems, our business, results of operations and financial condition could be harmed.

Our information technology (IT) systems are an integral part of our business, and a serious disruption of our IT systems could have a material adverse effect on our business, results of operations and financial condition. We depend on our IT systems to process orders, manage inventory and collect accounts receivable.  Our IT systems also allow us to efficiently purchase products from our suppliers and ship products to our customers on a timely basis, maintain cost-effective operations and provide customer service.  We may experience disruption of our IT systems due to redundancy issues with our network servers. We cannot assure you that our contingency plans will allow us to operate at our current level of efficiency.

Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and analytical processes.  We expect that we will need to continue to improve and further integrate our IT systems, reporting systems and operating procedures by training and educating our employees with respect to these improvements and integrations on an ongoing basis in order to effectively run our business.  We may suffer interruptions in service, loss of data or reduced functionality when we upgrade or change systems. If we fail to successfully manage and integrate our IT systems, reporting systems and operating procedures, it could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our ERP implementation and data security above and events beyond our control below.

Natural disasters, terrorist attacks, acts of war or other events beyond our control may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our business, results of operations and financial condition.

We have significant manufacturing and distribution facilities, including in the western United States, France, Switzerland, Germany and Singapore.  In particular, the western United States has experienced a number of earthquakes, wildfires, floods, landslides and other natural disasters in recent years.  These occurrences could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. In addition, strikes or other labor unrest at any of our sites or surrounding areas could cause disruption to our business.

Acts of terrorism, bioterrorism, violence or war could also affect the markets in which we operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as in Southeast Asia, the Middle East and Eastern Europe. Any of these events could adversely affect our business, results of operations and financial condition.

We may have higher than anticipated tax liabilities.

We are subject to income taxes in the United States and many foreign jurisdictions. We report our results of operations based on our determination of the amount of taxes owed in various tax jurisdictions in which we operate. The determination of our worldwide provision for income taxes and other tax liabilities requires estimation, judgment and calculations where the ultimate tax determination may not be certain. Our determination of tax liability is always subject to review or examination by tax authorities in various tax jurisdictions. Tax authorities have disagreed with our judgment in the past and may disagree with positions we take in the future resulting in assessments of additional taxes. Any adverse outcome of such review or examination could have a negative impact on our operating results and financial condition.

46



Economic and political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes more difficult. For example, in recent years, the tax authorities in Europe have disagreed with our tax positions related to hybrid debt, research and development credits, transfer pricing and indirect taxes, among others. We regularly assess the likelihood of the outcome resulting from these examinations to determine the adequacy of our provision for income taxes. Although we believe our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals.

The results from various tax examinations, audits and litigation may differ from the liabilities recorded in our financial statements and could materially and adversely affect our financial results and cash flows in the period or periods for which that determination is made.

Changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect our financial position and results of operations.

On December 22, 2017, the U.S. enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act made a number of substantial changes, including, among other changes, the imposition of a one-time mandatory deemed repatriation tax on previously unrepatriated earnings accumulated offshore since 1986, establishment of a global minimum income tax and base erosion tax provisions related to offshore activities and affiliated party payments, and reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of deferred taxes to reflect their value at a lower tax rate of 21%. These changes to U.S. tax laws will significantly impact how U.S. multinational corporations are taxed on foreign earnings.

To determine the transition tax, the Tax Act requires complex computations not previously provided in U.S. tax law, including calculating and supporting with primary evidence U.S. tax attributes such as accumulated foreign earnings and profits, foreign taxes paid, and other tax components involved in foreign tax credit calculations since 1986. The application of accounting guidance for such items is currently uncertain, and compliance with the Tax Act and the accounting for such provisions require collection of information not previously required, regularly produced or within our control. As a result, provisional tax amounts were recorded in 2017 based on our reasonable estimate and we will need additional information to complete our assessment. As additional regulatory guidance is issued by the applicable taxing authorities, as accounting treatment is clarified, as we perform additional analysis required by the Tax Act, and as we refine estimates in calculating its effect, our final analysis, which will be recorded in the period completed, may be materially different from our current provisional amounts, which could materially affect our tax obligations and effective tax rate.

The Tax Act includes new U.S. tax base erosion provisions, the base-erosion and anti-abuse tax (BEAT) provisions and the global intangible low-taxed income (GILTI) provisions. The BEAT provisions in the Tax Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum tax if greater than regular tax. The GILTI provisions require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. We have included estimates for these provisions in our estimated effective tax rate for 2018. We may adjust these estimates as further regulatory guidance becomes available.

Our global operations subject us to income and other taxes in the U.S. and in numerous foreign jurisdictions, each with different tax schemes and tax rates. In addition to the changes in tax laws, the interpretation of tax laws and tax rates in these jurisdictions, the jurisdictional mix of our earnings in countries with differing statutory tax rates can have a significant impact on our effective tax rate from period to period.

The liability for the transition tax, changes to the provisional tax amounts, GILTI, BEAT and other ongoing effects of the Tax Act, including the effect of our investment in Sartorius AG, and the jurisdictional mix of our earnings could materially affect our financial results and cash flow.


47


In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development’s project on “Base Erosion and Profit Shifting” (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in particular country.

Our reported financial results may be materially affected by changes in accounting principles generally accepted in the United States.
Generally accepted accounting principles in the United States, or U.S. GAAP, are subject to interpretation by the Financial Accounting Standards Board, or FASB, the U.S. Securities and Exchange Commission, or SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, and could affect the reporting of transactions completed before the announcement of a change.
For example, in January 2016, the FASB issued Accounting Standards Update No. (ASU) 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting), such as our investment in Sartorius AG, will be measured at fair value through earnings. The impact of adoption of ASU 2016-01 in the first quarter of 2018 materially impacted our Condensed Consolidated Statement of Income due to our investment in Sartorius AG. In future periods, changes in the market value of our investment in Sartorius AG may materially impact our Consolidated Statement of Income.

We may incur losses in future periods due to write-downs in the value of financial instruments.
We have positions in a variety of financial instruments including asset backed securities and other similar instruments. Financial markets are volatile and the markets for these securities can be illiquid.  The value of these securities will continue to be impacted by external market factors including default rates, changes in the value of the underlying property, such as residential or commercial real estate, rating agency actions, the prices at which observable market transactions occur and the financial strength of various entities, such as financial guarantors who provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell these instruments without significant losses due to current debtor financial conditions or other market considerations.

We also have positions in equity securities, including our investment in Sartorius AG. Financial markets are volatile and the markets for these equity securities can be illiquid as well. A decline in the market value of our investment in Sartorius AG or in the market value of the other equity securities that we own could result in significant losses due to write-downs in the value of the equity securities. In addition, if we need to convert these positions to cash, we may not be able to sell these equity securities without significant losses.

Environmental, health and safety regulations and enforcement proceedings may negatively impact our business, results of operations and financial condition.

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes.  In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liability and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate.  The environmental laws and regulations also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations.


48


We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and possible new statutory enactments, and these expenditures may be significant.  We have incurred, and may in the future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other releases of hazardous substances into the environment at sites where we have operated, or at off-site locations where we have sent hazardous substances for disposal.  We cannot assure you, however, that such matters or any future obligations to comply with environmental or health and safety laws and regulations will not adversely affect our business, results of operations or financial condition.

Our debt may restrict our future operations.

We have substantial debt and have the ability to incur additional debt. As of June 30, 2018, we had approximately $440.5 million of outstanding indebtedness. In addition, we have a revolving credit facility that provides for up to $200.0 million, $0.5 million of which has been utilized for domestic standby letters of credit. Our incurrence of substantial amounts of debt may have important consequences.  For instance, it could:

•
make it more difficult for us to satisfy our financial obligations, including those relating to our outstanding debt;
•
require us to dedicate a substantial portion of our cash flow from operations to the payment of interest and principal due under our debt, which will reduce funds available for other business purposes;
•
increase our vulnerability to general adverse economic and industry conditions;
•
limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate;
•
place us at a competitive disadvantage compared with some of our competitors that have less debt; and
•
limit our ability to obtain additional financing required to fund working capital and capital expenditures and for other general corporate purposes.

Our existing credit facility and the terms of our other debt instruments, including agreements we may enter in the future, contain or will contain covenants imposing significant restrictions on our business.  These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise.  These covenants place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets through merger or purchase; create liens; make investments; enter into transactions with affiliates; sell assets; in the case of some of our subsidiaries, guarantee debt; and declare or pay dividends, redeem stock or make other distributions to stockholders. Our existing credit facility also requires that we comply with certain financial ratios, including a maximum consolidated leverage ratio test and a minimum consolidated interest coverage ratio test.

Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions.  The breach of any of these restrictions could result in a default.  An event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from them to be due and payable, together with accrued and unpaid interest. In addition, acceleration of our other indebtedness may cause us to be unable to make interest payments on our outstanding notes and repay the principal amount of our outstanding notes or may cause the future subsidiary guarantors, if any, to be unable to make payments under the guarantees.

We are subject to healthcare fraud and abuse laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.

We are subject to healthcare fraud and abuse regulation and enforcement by both the U.S. federal government and the U.S. states and foreign governments in which we conduct our business. These healthcare laws and regulations include, for example:

•
the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce

49


either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs;

•
U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;

•
the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals;

•
the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and

•
state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers.

These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or more of these requirements. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, results of operations and financial condition.

Regulations related to “conflict minerals” could adversely impact our business.
As part of the Dodd-Frank Wall Street Reform and Consumer Protection Act, the SEC adopted disclosure requirements regarding the use of certain minerals, known as conflict minerals, which are mined from the Democratic Republic of Congo (DRC) and adjoining countries, as well as procedures regarding a manufacturer's efforts to identify the sourcing of such minerals and metals produced from those minerals. In March and April 2017, the European Parliament and the European Council formally approved a conflict minerals regulation, and the requirements will become effective starting in January 2021. We have incurred, and will continue to incur, additional costs in order to comply with the SEC’s disclosure requirements. In addition, we might incur further costs due to possible changes to our products, processes, or sources of supply as a consequence of our due diligence activities. As our supply chain is complex, we may not be able to sufficiently verify the origins of the specified minerals used in our products through our due diligence procedures, which may harm our reputation. In addition, we may encounter challenges to satisfy those customers who require that all of the components of our products be certified as “DRC conflict free”, which could place us at a competitive disadvantage if we do not do so. We filed our report for the calendar year 2017 with the SEC on May 4, 2018.

50



Risks related to our common stock
 
A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.
We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions, holders of Class A and Class B Common Stock vote as a single class.  When voting as a single class, each share of Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote. In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining directors.

As a result of the Schwartz family's ownership of our Class A and Class B Common Stock, they are able to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us, including the determination of business opportunities that may be suitable for our company.  The Schwartz family may exercise its control over us according to interests that are different from other investors’ or debtors’ interests. In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a change in control of our company.


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.


Item 4. Mine Safety Disclosures

Not applicable.


Item 5. Other Information

None.


51




Item 6. Exhibits

(a)  Exhibits

The following documents are filed as part of this report:

Exhibit
No.
 
 
 
31.1
 
 
31.2
 
 
32.1
 
 
32.2
 
 
101.INS
The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
 
 
101.SCH
XBRL Taxonomy Extension Schema Document
 
 
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
 
 
101.LAB
XBRL Taxonomy Extension Labels Linkbase Document
 
 
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
 
 


52



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereto duly authorized.

BIO-RAD LABORATORIES, INC.
(Registrant)
 
 
 
 
Date:
August 9, 2018
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board,
 
 
 
President and Chief Executive Officer
 
 
 
 
Date:
August 9, 2018
 
/s/ Christine A. Tsingos
 
 
 
Christine A. Tsingos, Executive Vice President,
 
 
 
Chief Financial Officer

53
 EX-31.1 2 ex31163018.htm EXHIBIT 31.1 CEO SECTION 302 CERTIFICATION Exhibit


Exhibit 31.1

Certification of Chief Executive Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Norman Schwartz, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Bio-Rad Laboratories, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:
August 9, 2018
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board,
 
 
 
President and Chief Executive Officer



 EX-31.2 3 ex31263018.htm EXHIBIT 31.2 CFO SECTION 302 CERTIFICATION Exhibit


Exhibit 31.2

Certification of Chief Financial Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Christine A. Tsingos, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Bio-Rad Laboratories, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:
August 9, 2018
 
/s/ Christine A.Tsingos
 
 
 
Christine A. Tsingos
 
 
 
Executive Vice President,
 
 
 
Chief Financial Officer


 EX-32.1 4 ex32163018.htm EXHIBIT 32.1 CEO SECTION 906 CERTIFICATION Exhibit


Exhibit 32.1




Certification of Periodic Report


I, Norman Schwartz, Chief Executive Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)
the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:
August 9, 2018
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board,
 
 
 
President and Chief Executive Officer


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.


 EX-32.2 5 ex32263018.htm EXHIBIT 32.2 CFO SECTION 906 CERTIFICATION Exhibit


Exhibit 32.2




Certification of Periodic Report


I, Christine A. Tsingos, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)
the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:
August 9, 2018
 
/s/ Christine A. Tsingos
 
 
 
Christine A. Tsingos
 
 
 
Executive Vice President,
 
 
 
Chief Financial Officer


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.



 EX-101.SCH 6 bio-20180630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2115100 - Disclosure - 10. Segment Information link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - 10. Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - 10. Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - 10. Segment Profit Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - 11. Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - 11. Legal Proceedings 11. Contingent Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - 12. Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - 12. Restructuring Costs (Notes) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - 12. Restructuring Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - 1. Basis of Presentation and Use of Estimates Schedule of Revenue from External Customers Geographic (Tables) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - 1. Organization, Consolidation and Presentation of Financial Statements link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - 2. Amortized Cost and Fair Value of Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - 2. Available-for-Sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - 2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) link:presentationLink link:calculationLink link:definitionLink 2403408 - Disclosure - 2. Fair Value Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - 2. Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - 2. Fair Value Measurements 2. Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - 2. Fair Value Measurements Fair Value Level Table (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - 2. Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - 2. Foreign Exchange Forward Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - 3. Intangible Assets, Goodwill and Other link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - 3. Intangible Assets, Goodwill and Other (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - 3. Intangible Assets, Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - 3. Intangible Assets, Goodwill and Other (Tables) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - 4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure (Tables) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - 4. Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - 4. Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - 4. Supplemental Cash Flow Information (Notes) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - 5. Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - 5. Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - 5. Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Notes) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - 7. Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - 7. Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - 7. Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - 8. Other Income and Expenses link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - 8. Other Income and Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - 8. Other Income and Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - 9. Income Taxes link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - 9. Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets Parenthetical link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bio-20180630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 bio-20180630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 bio-20180630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Segment Reporting [Abstract] Net sales Schedule of Segment Reporting Information, by Segment [Table Text Block] Reconciliation of segment profit to consolidated income before taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Restructuring Costs [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] European Reorganization [Member] European Reorganization [Member] European Reorganization [Member] Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Domain] Other Comprehensive Income Location [Domain] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring and Related Costs [Table Text Block] Restructuring and Related Costs [Table Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Life Science [Member] Life Science [Member] Life Sciences [Member] Clinical Diagnostics [Member] Clinical Diagnostics [Member] Clinical Diagnostics [Member] Foreign Currency Gain (Loss) [Member] Foreign Currency Gain (Loss) [Member] Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Operating Segments [Member] Corporate, Non-Segment [Member] Corporate, Non-Segment [Member] Segment Reconciling Items [Member] Segment Reconciling Items [Member] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Research and Development Asset Acquired Other than Through Business Combination, Written-off Research and Development Asset Acquired Other than Through Business Combination, Written-off Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Unrealized Gain on Securities Unrealized Gain on Securities Supplemental Cash Flow Elements [Abstract] Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Depreciation and Amortization Depreciation, Depletion and Amortization Share-based Compensation Share-based Compensation Loss on Sale of Securities, Net Debt and Equity Securities, Gain (Loss) Changes in fair market value of equity securities Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss Gain on divestiture of a product line Noncash or Part Noncash Divestiture, Amount of Consideration Received Loss on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment Gain on sale of land Gain (Loss) on Disposition of Assets Changes in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Decrease (increase) in accounts receivable Increase (Decrease) in Accounts Receivable Increase in inventories Increase (Decrease) in Inventories Increase in other current assets Increase (Decrease) in Other Current Assets Decrease in accounts payable and other current liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Decrease in Income Taxes Payable Increase (Decrease) in Income Taxes Payable Increase (Decrease) in Deferred Income Taxes Increase (Decrease) in Deferred Income Taxes Net increase in other long-term assets/liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] All Other Segments [Member] Other Segments [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Net sales Revenue from Contract with Customer, Excluding Assessed Tax Document and Entity Information (Parenthetical) [Abstract] Document and Entity Information (Parenthetical) [Abstract] Statement [Table] Statement [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Class A [Member] Common Class A [Member] Common Class B [Member] Common Class B [Member] Statement [Line Items] Statement [Line Items] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Fair Value Disclosures [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Measurement Basis [Axis] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Carrying (Reported) Amount, Fair Value Disclosure [Member] Reported Value Measurement [Member] Estimate of Fair Value, Fair Value Disclosure [Member] Estimate of Fair Value Measurement [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Other Investments Other Investments Total long-term debt, excluding capital leases and current maturities Long-term Debt, Fair Value Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Unsecured Debt [Member] Capital Lease Obligations [Member] Line of Credit [Member] Standby Letters of Credit [Member] Standby Letters of Credit [Member] Debt Instrument [Axis] Debt Instrument, Name [Domain] Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% [Member] Capital Leases and Other Debt [Member] Capital Leases and Other Debt [Member] Capital Leases and Other Debt [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Unsecured Debt Unsecured Debt Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Redemption Price, Percentage Debt Instrument, Redemption Price, Percentage Long-term debt Long-term Debt Long-term Debt and Capital Lease Obligations, Including Current Maturities Long-term Debt and Capital Lease Obligations, Including Current Maturities Debt and Capital Lease Obligations Debt and Capital Lease Obligations Less Current Maturities Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Long-term debt, net of current maturities Long-term Debt and Capital Lease Obligations Face amount of debt sold Debt Instrument, Face Amount Line of credit maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Outstanding borrowings Long-term Line of Credit Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Interest Rate at Period End Legal Proceedings [Abstract] -- None. No documentation exists for this element. -- Loss Contingency, Damages Awarded, Value Loss Contingency, Damages Awarded, Value Litigation Settlement Interest Litigation Settlement Interest Loss Contingency, Damages Paid, Value Loss Contingency, Damages Paid, Value Other Income and Expenses [Abstract] Statement, Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Interest and investment income Investment Income, Interest and Dividend Net realized loss (gain) on investments Realized Investment Gains (Losses) Gain on divestiture of a product line Gain (Loss) on Disposition of Other Assets Other Nonoperating Expense Other Nonoperating Expense Nonoperating Income (Expense) Nonoperating Income (Expense) Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Balance Sheet Related Disclosures [Abstract] Treasury Class A [Member] Treasury Class-A [Member] Treasury Class A [Member] Treasury Class B [Member] Treasury Class B [Member] Treasury Class B [Member] Common Stock, Shares, Issued Common Stock, Shares, Issued Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Treasury Stock, Shares Treasury Stock, Shares Allowance for Doubtful Accounts Receivable, Current Allowance for Doubtful Accounts Receivable, Current Statement of Financial Position [Abstract] Common Class A [Member] Common Class B [Member] ASSETS: Assets [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments Short-term Investments Restricted investments Restricted Investments, Current Accounts receivable, net Accounts Receivable, Net, Current Inventories: Inventory, Net [Abstract] Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Total inventories Inventory, Net Prepaid expenses Prepaid Expense, Current Other current assets Other Assets, Current Total current assets Assets, Current Property, plant and equipment, at cost Property, Plant and Equipment, Gross Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Property, Plant and Equipment, Net Goodwill, net Goodwill Purchased intangibles, net Intangible Assets, Net (Excluding Goodwill) Other investments Long-term Investments Other assets Other Assets Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY: Liabilities and Equity [Abstract] Accounts payable, accrued payroll and employee benefits Accounts Payable and Accrued Liabilities, Current Accounts payable Accounts Payable, Current Accrued payroll and employee benefits Employee-related Liabilities, Current Current maturities of long-term debt and notes payable Notes and Loans Payable, Current Income and other taxes payable Taxes Payable, Current Accrued royalties Accrued Royalties, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Deferred revenue Deferred Revenue, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury Stock, Value Treasury Stock, Value Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Warranty accrual, beginning of period Standard and Extended Product Warranty Accrual Provision for warranty Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Actual warranty costs Standard and Extended Product Warranty Accrual, Decrease for Payments Warranty accrual, end of period New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Europe [Member] Europe [Member] Asia Pacific [Member] Asia Pacific [Member] UNITED STATES UNITED STATES Americas [Member] Americas [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2016-01 [Member] Accounting Standards Update 2016-01 [Member] Adjustments for New Accounting Pronouncement [Member] Adjustments for New Accounting Pronouncement [Member] Accounting Standards Update 2016-16 [Member] Accounting Standards Update 2016-16 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Investments Investments Deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Cost of goods sold Cost of Goods and Services Sold Deferred Revenue Deferred Revenue Revenue, Net Deferred Revenue, Revenue Recognized Restricted Cash and Cash Equivalents, Current Restricted Cash and Cash Equivalents, Current Retained earnings Prepaid taxes Prepaid Expense Other, Noncurrent Deferred Income Tax Assets, Net Deferred Income Tax Assets, Net Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Operating Leases, Income Statement, Lease Revenue Operating Leases, Income Statement, Lease Revenue Additional paid-in-capital Deferred Tax Assets, Gross Deferred Tax Assets, Gross Selling, general and administrative expense Selling, General and Administrative Expense Research and Development Expense Research and Development Expense Interest expense Interest Expense Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) Restricted Cash Restricted Cash Prepaid Taxes Prepaid Taxes Deferred Tax Assets, Net, Noncurrent Deferred Tax Assets, Net, Noncurrent Earnings Per Share [Abstract] Basic weighted average shares outstanding Weighted Average Number of Shares Outstanding, Basic Effect of potentially dilutive stock options and restricted stock awards Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Diluted weighted average common shares Weighted Average Number of Shares Outstanding, Diluted Anti-dilutive shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Restructuring and Related Activities Disclosure [Text Block] Restructuring and Related Activities Disclosure [Text Block] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Cash received from customers Proceeds from Customers Cash paid to suppliers and employees Payments to Suppliers and Employees Interest paid, net Interest Paid, Excluding Capitalized Interest, Operating Activities Income tax payments, net Income Taxes Paid, Net Investment proceeds and miscellaneous receipts, net Proceeds from Other Operating Activities Proceeds from (payments for) forward foreign exchange contracts, net Payments for (proceeds from) derivative instruments, operating activities Payments for (proceeds from) derivative instruments, operating activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Capital expenditures Payments to Acquire Property, Plant, and Equipment Proceeds from dispositions of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from divestiture of a product line Proceeds from Sale of Productive Assets Proceeds from (payments for) acquisitions Payments for (Proceeds from) Other Investing Activities Payments for acquisitions and long-term investments Payments to Acquire Assets, Investing Activities Payments for purchases of intangible assets Payments to Acquire Productive Assets Payments for purchases of marketable securities and investments Payments to Acquire Investments Proceeds from Sale of Debt Securities, Available-for-sale Proceeds from Sale of Debt Securities, Available-for-sale Proceeds from sales of marketable securities and investments Proceeds from Sale of Available-for-sale Securities Proceeds from maturities of marketable securities and investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net payments on line-of-credit arrangements and notes payable Proceeds from (Repayments of) Lines of Credit Payments on long-term borrowings Repayments of Long-term Debt Payments of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Proceeds from issuance of common stock for shared-based compensation Proceeds from Issuance of Common Stock Payments for purchases of treasury stock Payments for Repurchase of Common Stock Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Effect of foreign exchange rate changes on cash Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Beginning Cash, Cash Equivalents, and Restricted Cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Restricted Cash, Current Restricted Cash, Current Restricted Cash, Noncurrent Restricted Cash, Noncurrent Ending Cash, Cash Equivalents, and Restricted Cash Income Statement [Abstract] Gross profit Gross Profit Segment profit (loss) Operating Income (Loss) Foreign exchange (gains) losses, net Foreign Currency Transaction Gain (Loss), before Tax Unrealized Gain on Securities Nonoperating Income (Expense) Income before income taxes (Provision) benefit for income taxes Income Tax Expense (Benefit) Net income attributable to Bio-Rad Basic earnings per share: Earnings Per Share, Basic [Abstract] Net income per share basic attributable to Bio-Rad Earnings Per Share, Basic Weighted average common shares - basic Diluted earnings per share: Earnings Per Share, Diluted [Abstract] Net income per share diluted attributable to Bio-Rad Earnings Per Share, Diluted Weighted average common shares - diluted Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure Goodwill and Intangible Assets Disclosure [Text Block] Derivative [Table] Derivative [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Notional value Derivative, Notional Amount Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Termination of a Diagnostics Research and Development Project [Member] Termination of a Diagnostics Research and Development Project [Member] Termination of a Diagnostics Research and Development Project [Member] Facility Closing [Member] Facility Closing [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accounts Payable and Accrued Liabilities [Member] Accounts Payable and Accrued Liabilities [Member] Other Current Liabilities [Member] Other Current Liabilities [Member] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Segments [Axis] Segments [Domain] Cost of Goods, Total [Member] Cost of Goods, Total [Member] Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Research and Development Expense [Member] Research and Development Expense [Member] Restructuring Reserve Restructuring Reserve Restructuring Charges Restructuring Charges Restructuring Reserve, Current Restructuring Reserve, Current Restructuring Reserve, Noncurrent Restructuring Reserve, Noncurrent Restructuring Reserve, Accrual Adjustment Restructuring Reserve, Accrual Adjustment Payments for Restructuring Payments for Restructuring Restructuring Reserve, Foreign Currency Translation (Gain) Loss Restructuring Reserve, Foreign Currency Translation Gain (Loss) Investment Holding [Axis] Investment Holding [Axis] Investment Holding [Domain] Investment Holding [Domain] Sartorius AG [Member] Sartorius AG [Member] Sartorius AG [Member] Statutory Rate [Axis] Statutory Rate [Axis] Statutory Rate [Axis] Statutory Rate [Domain] Statutory Rate [Domain] Statutory Rate [Domain] U.S. Federal [Member] U.S. Federal [Member] U.S. Federal [Member] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit) Statutory Rates Statutory Rates Statutory Rates Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Debt Securities, Available-for-sale [Table Text Block] Debt Securities, Available-for-sale [Table Text Block] Schedule of financial assets and liabilities carried at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of available-for-sale investments Available-for-sale Securities [Table Text Block] Summary of fair value of gross unrealized losses for investments with unrealized losses Schedule of Unrealized Loss on Investments [Table Text Block] Discussion of current derivative risk management Schedule of Derivative Instruments [Table Text Block] Summary of amortized cost and estimated fair value of debt securities by contractual maturity date Investments Classified by Contractual Maturity Date [Table Text Block] Estimated fair value of financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Goodwill [Line Items] Goodwill [Line Items] Goodwill Goodwill, Gross Accumulated impairment loss Goodwill, Impaired, Accumulated Impairment Loss Goodwill, net Goodwill, Written off Related to Sale of Business Unit Goodwill, Written off Related to Sale of Business Unit Currency fluctuations Goodwill, Foreign Currency Translation Gain (Loss) Changes to goodwill by segment Schedule of Goodwill [Table Text Block] Schedule of identifiable purchased intangible assets with definite lives Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Finite-lived Intangible Assets Amortization Expense [Table Text Block] Finite-lived Intangible Assets Amortization Expense [Table Text Block] Schedule of other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Long-term Debt Long-term Debt [Text Block] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Acquired Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Customer Relationships [Member] Customer Relationships [Member] Know how [Member] Know How [Member] Know how [Member] Developed Technology Rights [Member] Developed Technology Rights [Member] Licensing Agreements [Member] Licensing Agreements [Member] Trade Names [Member] Trade Names [Member] Noncompete Agreements [Member] Noncompete Agreements [Member] Other Intangible Assets [Member] Other Intangible Assets [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Net [Abstract] Average Remaining Life (years) Finite-Lived Intangible Assets, Remaining Amortization Period Purchase Price Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Carrying Amount Finite-Lived Intangible Assets, Net Amortization [Abstract] Amortization expense Amortization of Intangible Assets Mature in less than one year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost Mature in one to five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost Mature in more than five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost Total Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Mature in less than one year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value Mature in one to five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value Mature in more than five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value Estimated Fair Value Debt Securities, Available-for-sale Statement, Scenario [Axis] Price Change Debt Security Price Change Debt Security Price Change Debt Security Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Cost Method Investment, Percentage Owned Investment ownership percentage Investment ownership percentage Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform Short-term Investments [Member] Short-term Investments [Member] Other Investments [Member] Other Investments [Member] Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Brokered certificates of deposit [Member] Interest-bearing Deposits [Member] Marketable Equity Securities [Member] Equity Securities [Member] Municipal Obligations (Member) Municipal Bonds [Member] Foreign Government Obligations [Member] Debt Security, Government, Non-US [Member] Corporate Debt Securities [Member] Corporate Debt Securities [Member] US Government Sponsored Agencies [Member] US Treasury and Government [Member] Asset-backed Securities [Member] Asset-backed Securities [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] US Treasury Securities [Member] US Treasury Securities [Member] Commercial Paper [Member] Commercial Paper [Member] Time Deposits [Member] Bank Time Deposits [Member] Money Market Funds [Member] Money Market Funds [Member] Cash Equivalents [Member] Cash Equivalents [Member] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Unrealized Gain on Securities Equity Securities, FV-NI, Unrealized Gain Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalents, Fair Value Disclosure Restricted Investments, at Fair Value Restricted Investments, at Fair Value Available-for-sale Securities Available-for-sale Securities Equity Securities Equity Securities, FV-NI Debt Securities, Available-for-sale Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure Foreign Currency Contract, Asset, Fair Value Disclosure Assets, Fair Value Disclosure Assets, Fair Value Disclosure Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure Foreign Currency Contracts, Liability, Fair Value Disclosure Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Liabilities, Fair Value Disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Other Income and Other Expense Disclosure Other Income and Other Expense Disclosure [Text Block] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Other Long-term Investments [Member] Other Long-term Investments [Member] Municipal obligations [Member] Available-for-sale Securities [Member] Available-for-sale Securities [Member] Debt Securities [Member] Debt Securities [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Amortized Cost Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Estimated Fair Value Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Segment Information Segment Reporting Disclosure [Text Block] Scenario, Forecast [Member] Scenario, Forecast [Member] Contingent Consideration by Type [Domain] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Market Price of Risk [Member] Market Price of Risk [Member] Market Price of Risk [Member] Projected Volatility of Growth Rate [Member] Projected Volatility of Sales [Member] [Member] Projected Volatility of Sales [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] Discount Rate Discount Rate Discount Rate Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Contingent consideration milestone payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Business Acquisition, Contingent Consideration, Potential Percentage Payout Business Acquisition, Contingent Consideration, Potential Percentage Payout business acquisition contingent consideration percentage payout Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Statement of Comprehensive Income [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Net unrealized holding gains (losses) on available-for-sale investments net of tax expense Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Total other comprehensive income (loss) net of tax Other Comprehensive Income (Loss), Net of Tax Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Cash Flow, Supplemental Disclosures [Text Block] Cash Flow, Supplemental Disclosures [Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Earnings Per Share Earnings Per Share [Text Block] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Translation Adjustment [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accumulated Defined Benefit Plans Adjustment [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Accumulated Net Unrealized Investment Gain (Loss) [Member] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Parent [Member] AOCI Attributable to Parent [Member] Reclassification Out of Accumulated Other Comprehensive Income [Axis] Reclassification Out of Accumulated Other Comprehensive Income [Domain] Reclassification Out Of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Beginning balance, Accumulated other comprehensive income Other Comprehensive Income (Loss), before Reclassifications, before Tax Other Comprehensive Income (Loss), before Reclassifications, before Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Ending balance, Accumulated other comprehensive income Other (income) expense, net Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Long-term Debt Instruments [Table Text Block] New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Revenue from Contract with Customer [Policy Text Block] Revenue from Contract with Customer [Policy Text Block] Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares Schedule of Weighted Average Number of Shares [Table Text Block] Loss Contingency, Information about Litigation Matters [Abstract] Legal Proceedings. Legal Matters and Contingencies [Text Block] Schedule of Revenue by Geographic [Abstract] Schedule of Revenue by Geographic [Abstract] Subsegments [Axis] Subsegments [Axis] Subsegments [Domain] Subsegments [Domain] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Domain] Subsegments Consolidation Items [Domain] Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Schedule of Product Warranty Liability [Table Text Block] Schedule of Product Warranty Liability [Table Text Block] EX-101.PRE 10 bio-20180630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 a10q63018_htm.xml IDEA: XBRL DOCUMENT 0000012208 2018-01-01 2018-06-30 0000012208 bio:TreasuryClassAMember 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-06-30 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-06-30 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000012208 us-gaap:CommonClassAMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:MarketPriceOfRiskMember 2018-01-01 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:ProjectedVolatilityOfSalesMemberMember 2018-01-01 2018-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 bio:TreasuryClassAMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 bio:TreasuryClassBMember 2017-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-12-01 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoicesMember 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestoneminimumamountMember 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoiceslowMember 2018-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-04-01 2018-06-30 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2018-01-01 2018-06-30 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2018-06-30 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2018-01-01 2018-06-30 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2018-06-30 0000012208 2017-01-01 2017-06-30 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-06-30 0000012208 2018-04-01 2018-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 2017-04-01 2017-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-06-30 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-06-30 0000012208 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-06-30 0000012208 2017-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-06-30 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-06-30 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 srt:AsiaPacificMember 2018-04-01 2018-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000012208 bio:LifeScienceMember 2017-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:LifeScienceMember 2018-01-01 2018-06-30 0000012208 bio:ClinicalDiagnosticsMember 2018-06-30 0000012208 bio:ClinicalDiagnosticsMember 2018-01-01 2018-06-30 0000012208 bio:LifeScienceMember 2018-06-30 0000012208 bio:ClinicalDiagnosticsMember 2018-01-01 2018-03-31 0000012208 us-gaap:CustomerRelationshipsMember 2017-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2017-12-31 0000012208 us-gaap:CommonClassBMember 2018-08-02 0000012208 srt:AmericasMember 2018-04-01 2018-06-30 0000012208 us-gaap:LicensingAgreementsMember 2017-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2017-12-31 0000012208 us-gaap:TradeNamesMember 2017-12-31 0000012208 bio:KnowHowMember 2017-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2018-06-30 0000012208 us-gaap:DevelopedTechnologyRightsMember 2018-06-30 0000012208 bio:KnowHowMember 2018-06-30 0000012208 us-gaap:LicensingAgreementsMember 2018-06-30 0000012208 us-gaap:NoncompeteAgreementsMember 2018-06-30 0000012208 us-gaap:TradeNamesMember 2018-06-30 0000012208 country:US 2017-01-01 2017-06-30 0000012208 srt:MaximumMember us-gaap:TradeNamesMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2018-01-01 2018-06-30 0000012208 srt:MinimumMember us-gaap:TradeNamesMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:LicensingAgreementsMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:NoncompeteAgreementsMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2017-01-01 2017-06-30 0000012208 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2017-01-01 2017-06-30 0000012208 srt:MaximumMember us-gaap:NoncompeteAgreementsMember 2017-01-01 2017-06-30 0000012208 srt:AmericasMember 2017-01-01 2017-06-30 0000012208 srt:MaximumMember us-gaap:LicensingAgreementsMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:TradeNamesMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-06-30 0000012208 srt:MinimumMember us-gaap:LicensingAgreementsMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember bio:KnowHowMember 2018-01-01 2018-06-30 0000012208 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2018-01-01 2018-06-30 0000012208 srt:MinimumMember bio:KnowHowMember 2017-01-01 2017-06-30 0000012208 srt:MaximumMember bio:KnowHowMember 2018-01-01 2018-06-30 0000012208 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2017-01-01 2017-06-30 0000012208 country:US 2017-04-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2017-01-01 2017-06-30 0000012208 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-06-30 0000012208 srt:MinimumMember us-gaap:TradeNamesMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2017-01-01 2017-06-30 0000012208 srt:MinimumMember us-gaap:LicensingAgreementsMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-06-30 0000012208 srt:MaximumMember bio:KnowHowMember 2017-01-01 2017-06-30 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2017-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2018-06-30 0000012208 srt:EuropeMember 2017-04-01 2017-06-30 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2017-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2018-06-30 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2010-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2018-04-01 2018-06-30 0000012208 us-gaap:LineOfCreditMember 2018-06-30 0000012208 us-gaap:StandbyLettersOfCreditMember 2018-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000012208 srt:AmericasMember 2018-01-01 2018-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-06-30 0000012208 srt:AsiaPacificMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000012208 srt:EuropeMember 2017-01-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-04-01 2018-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-04-01 2018-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-04-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-04-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-06-30 0000012208 2017-01-01 2017-12-31 0000012208 bio:USFederalMember 2017-01-01 2017-06-30 0000012208 srt:EuropeMember 2018-04-01 2018-06-30 0000012208 bio:ClinicalDiagnosticsMember 2017-04-01 2017-06-30 0000012208 bio:LifeScienceMember 2017-01-01 2017-03-31 0000012208 us-gaap:CorporateNonSegmentMember 2017-04-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2018-01-01 2018-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-04-01 2018-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-04-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2018-04-01 2018-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-06-30 0000012208 us-gaap:OperatingSegmentsMember 2018-01-01 2018-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-06-30 0000012208 srt:AsiaPacificMember 2018-01-01 2018-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2017-04-01 2017-06-30 0000012208 us-gaap:OperatingSegmentsMember 2017-04-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-01-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2017-01-01 2017-06-30 0000012208 us-gaap:OperatingSegmentsMember 2018-04-01 2018-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-06-30 0000012208 us-gaap:OperatingSegmentsMember 2017-01-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-04-01 2017-06-30 0000012208 us-gaap:CommonClassAMember 2018-08-02 0000012208 country:US 2018-04-01 2018-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2018-04-01 2018-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2018-04-01 2018-06-30 0000012208 bio:LifeScienceMember 2017-01-01 2017-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2017-01-01 2017-06-30 0000012208 bio:ClinicalDiagnosticsMember 2017-01-01 2017-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2018-01-01 2018-06-30 0000012208 bio:LifeScienceMember 2017-04-01 2017-06-30 0000012208 bio:LifeScienceMember 2018-04-01 2018-06-30 0000012208 bio:ClinicalDiagnosticsMember 2018-04-01 2018-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2018-04-01 2018-06-30 0000012208 country:US 2018-01-01 2018-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2017-04-01 2017-06-30 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2018-01-01 2018-06-30 0000012208 bio:EuropeanReorganizationMember 2018-01-01 2018-06-30 0000012208 bio:EuropeanReorganizationMember 2018-06-30 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-06-30 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2018-06-30 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2018-06-30 0000012208 srt:EuropeMember 2018-01-01 2018-06-30 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-06-30 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-06-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2018-01-01 2018-06-30 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-04-01 2018-06-30 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember 2018-04-01 2018-06-30 0000012208 us-gaap:AccountsPayableAndAccruedLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-06-30 0000012208 us-gaap:FacilityClosingMember 2018-01-01 2018-06-30 0000012208 us-gaap:OtherCurrentLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-06-30 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember 2018-01-01 2018-06-30 0000012208 srt:AsiaPacificMember 2017-04-01 2017-06-30 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember 2017-12-01 2018-06-30 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2018-01-01 2018-06-30 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-04-01 2018-06-30 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-06-30 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-06-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-04-01 2018-06-30 0000012208 bio:EuropeanReorganizationMember 2016-05-01 2018-06-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-06-30 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-06-30 0000012208 srt:AmericasMember 2017-04-01 2017-06-30 0000012208 us-gaap:NewAccountingPronouncementMember 2018-01-01 0000012208 us-gaap:NewAccountingPronouncementMember 2017-01-01 2017-06-30 0000012208 us-gaap:NewAccountingPronouncementMember 2017-06-30 0000012208 2018-01-01 0000012208 us-gaap:NewAccountingPronouncementMember 2018-04-01 2018-06-30 0000012208 2017-12-31 0000012208 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000012208 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 0000012208 us-gaap:NewAccountingPronouncementMember 2018-01-01 2018-06-30 0000012208 us-gaap:AccountingStandardsUpdate201601Member 2018-01-01 0000012208 us-gaap:NewAccountingPronouncementMember 2017-04-01 2017-06-30 0000012208 us-gaap:AccountingStandardsUpdate201601Member 2018-06-30 0000012208 us-gaap:NewAccountingPronouncementMember 2018-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 bio:TreasuryClassBMember 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 2018-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CommonClassBMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:CommonClassAMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CommonClassBMember 2018-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-01-01 2018-06-30 iso4217:USD shares iso4217:USD pure shares false --12-31 Q2 2018 0000012208 Large Accelerated Filer BIO-RAD LABORATORIES, INC. 25549000 21466000 24679127 5107674 24736009 5100540 24678545 5106757 24735427 5099623 P8Y P7Y P12Y P12Y P8Y P0Y P6Y P1Y P1Y P1Y P1Y P1Y P0Y P1Y P8Y P7Y P11Y P11Y P8Y P0Y P6Y P1Y P1Y P3Y P1Y P1Y P0Y P3Y 0 582 917 582 917 10-Q 2018-06-30 24735427 5099623 403006000 383824000 415241000 371154000 5560000 5560000 404091000 464847000 118999000 113925000 140917000 142589000 331517000 338290000 591433000 594804000 173003000 156460000 1992334000 1976649000 1289367000 1305150000 799118000 811654000 490249000 493496000 500022000 506069000 158035000 174113000 3170820000 1027736000 74763000 94949000 6386223000 4273012000 261721000 306814000 1721000 420000 29585000 39941000 149394000 155521000 442421000 502696000 438776000 434581000 686906000 222209000 179174000 183276000 1747277000 1342762000 2000 2000 1000 1000 376595000 361231000 128000 128000 89000 89000 4281275000 1830439000 -18710000 738794000 4638946000 2930250000 6386223000 4273012000 575911000 504666000 1127430000 1004717000 274244000 231291000 523560000 461279000 301667000 273375000 603870000 543438000 210425000 212489000 419555000 406891000 47450000 62587000 96877000 112039000 43792000 -1701000 87438000 24508000 5977000 6045000 11759000 11361000 15000 -2516000 -1239000 -4305000 286398000 0 1102332000 0 15858000 11382000 27003000 12425000 340086000 1120000 1203775000 21267000 72043000 -3915000 278958000 3819000 268043000 5035000 924817000 17448000 8.99 0.17 31.03 0.59 29814000 29613000 29801000 29597000 8.87 0.17 30.63 0.58 30219000 30006000 30197000 29962000 268043000 5035000 924817000 17448000 -124118000 41679000 -77572000 60522000 -1458000 1938000 -1176000 2053000 -135000 54564000 -1851000 134713000 -122795000 94305000 -78247000 193182000 145248000 99340000 846570000 210630000 1160904000 999779000 1007565000 968719000 11277000 10865000 47620000 19066000 18354000 13197000 -5412000 8029000 118208000 6297000 53897000 64951000 4100000 21000 6919000 0 -266000 73573000 3000 3920000 183001000 142993000 34548000 39362000 88410000 98379000 -102658000 -147675000 0 -36000 1505000 149000 1270000 3105000 3274000 3778000 0 883000 499000 -395000 3053000 7190000 19102000 -134583000 384983000 457171000 404085000 322588000 403006000 321584000 105000 561000 974000 443000 404085000 322588000 1.<span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">BASIS OF PRESENTATION AND USE OF ESTIMATES</span><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Basis of Presentation</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Use of Estimates</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018.  Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition."</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recorded a net reduction to opening retained earnings of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for the </span><span style="font-family:inherit;font-size:11pt;">six months ended</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> was not significant.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Company recognizes revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. Accordingly, in these cases, the delivery of the equipment and the installation are separate performance obligations. The Company will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Reagent Rental Agreements </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. The Company has concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, the Company first allocates the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Revenue allocated to the lease elements are approximately </span><span style="font-family:inherit;font-size:11pt;"><span>5%</span></span><span style="font-family:inherit;font-size:11pt;"> of total revenue and are included as part of the Net sales in our Condensed Consolidated Statements of Income.</span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contract costs:</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We apply a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. </span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Disaggregation of Revenue:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited):</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.625%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>197.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>163.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>396.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>348.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>122.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>107.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>231.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>202.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>221.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>202.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>431.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>389.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>575.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>504.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,127.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,004.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 10).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are recognized as (or when) the Company performs under the contract which is generally over time during the term of the service contract. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from </span><span style="font-family:inherit;font-size:11pt;"><span>$36.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>$41.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> is primarily driven by cash payments received or due in advance of satisfying our performance obligations, offset by </span><span style="font-family:inherit;font-size:11pt;"><span>$22.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of revenue recognized that were included in our deferred revenue balance as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(17.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Recent Accounting Pronouncements Adopted</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In February 2018, the FASB issued Accounting Standards Update No. ("ASU") 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to Retained earnings as of the beginning of the fiscal year in which the guidance is adopted. We adopted ASU 2018-03 on January 1, 2018 and made an irrevocable election to account for our investment of the ordinary shares of Sartorius AG at fair value (see ASU 2016-01 below).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:11pt;">In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. Changes in fair value for equity securities will no longer be reported in other comprehensive income. </span><span style="font-family:inherit;font-size:12pt;"> </span><span style="font-family:inherit;font-size:11pt;">For equity investments without readily determinable fair values, the cost method is also eliminated. We adopted ASU 2016-01 on January 1, 2018 and record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes and were valued at </span><span style="font-family:inherit;font-size:11pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">. Changes in the basis of these equity investments are reported in current earnings. For equity securities that are affected by ASU 2016-01 and ASU 2018-03, see Note 2 to the condensed consolidated financial statements, which primarily consists of our investment in Sartorius AG. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The impact of the adoption of ASU 2016-01 and ASU 2018-03 on January 1, 2018 was through a cumulative-effect adjustment of </span><span style="font-family:inherit;font-size:11pt;"><span>$864.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> to Total stockholders' equity by increasing Retained earnings of </span><span style="font-family:inherit;font-size:11pt;"><span>$1,543.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and decreasing Accumulated other comprehensive income of </span><span style="font-family:inherit;font-size:11pt;"><span>$679.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, including increasing Deferred income taxes by </span><span style="font-family:inherit;font-size:11pt;"><span>$232.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> and an increase in Other investments of </span><span style="font-family:inherit;font-size:11pt;"><span>$1,097.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> in our Condensed Consolidated Balance Sheet. As a result of ASU 2016-01 and ASU 2018-03 for the </span><span style="font-size:11pt;">three and six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">, we recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$286.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1,102.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, for the Change in fair market value of equity securities in the Condensed Consolidated Statement of Income that resulted in a deferred tax expense for the </span><span style="font-size:11pt;">three and six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> of </span><span style="font-family:inherit;font-size:11pt;"><span>$62.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$243.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which changed how we present the net periodic benefit cost of our defined benefit pension and/or other postretirement plans. We adopted ASU 2017-07 on January 1, 2018 and applied the practical expedient to estimate amounts for comparative purposes utilizing the information disclosed in Note 12 to the consolidated financial statements in our Form 10-K for the year ended December 31, 2017. The interest costs are recorded in Interest expense, and the other costs are recorded in Other (income) expense, net in the Condensed Consolidated Statements of Income. For the </span><span style="font-size:11pt;">second</span><span style="font-family:inherit;font-size:11pt;"> quarter of 2017 for interest costs and other costs, we reclassified </span><span style="font-family:inherit;font-size:11pt;"><span>$0.076 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.538 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.036 million</span></span><span style="font-family:inherit;font-size:11pt;"> from Costs of goods sold (COGS), Selling, general and administrative expense (SG&amp;A) and Research and development expense (R&amp;D), respectively, to Interest expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.275 million</span></span><span style="font-family:inherit;font-size:11pt;"> and Other (income) expense, net of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.375 million</span></span><span style="font-family:inherit;font-size:11pt;">. For the </span><span style="font-size:11pt;">first six months</span><span style="font-family:inherit;font-size:11pt;"> of 2017 for interest costs and other costs, we reclassified </span><span style="font-family:inherit;font-size:11pt;"><span>$0.152 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$1.076 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.072 million</span></span><span style="font-family:inherit;font-size:11pt;"> from COGS, SG&amp;A and R&amp;D, respectively, to Interest expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.550 million</span></span><span style="font-family:inherit;font-size:11pt;"> and Other (income) expense, net of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.750 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November 2016, the FASB issued ASU 2016-18, "Restricted Cash," which required us to cease to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 and updated the Condensed Consolidated Statements of Cash Flows to incorporate restricted cash included in Other current assets and Other assets of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," which required immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  We adopted ASU 2016-16 on January 1, 2018 on a modified retrospective basis through a cumulative-effect adjustment by decreasing Retained earnings by </span><span style="font-family:inherit;font-size:11pt;"><span>$17.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, and decreasing Prepaid taxes by </span><span style="font-family:inherit;font-size:11pt;"><span>$22.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and increasing Deferred tax assets by </span><span style="font-family:inherit;font-size:11pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> that are both recorded in Other assets in our Condensed Consolidated Balance Sheet. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments" and adopted it on January 1, 2018, which did not have an impact to our statement of cash flows presentation.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASC 606"), an updated standard on revenue recognition. The new standard provides enhancements to the quality and consistency of how revenue is reported under the principle that revenue should be recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the transfer of promised goods or services. We adopted ASC 606 as of January 1, 2018 using the cumulative effect transition method as more fully described above under the caption “Revenue Recognition.” </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Recent Accounting Pronouncements to be Adopted</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU 2018-11, "Targeted Improvements," which gives the option to apply the transition provisions of ASU 2016-02 at its adoption date instead of at the earliest comparative period presented in its financial statements. In addition, ASU 2018-11 provides a practical expedient that permits lessors to not separate nonlease components from the associated lease component if certain conditions are met. Also in July 2018, the FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases," which clarifies certain aspects of ASU 2016-02. We will adopt ASU 2016-02 on a modified retrospective basis on its adoption date of January 1, 2019 with practical expedients, instead of at the earliest comparative period presented in our financial statements. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities. Revenue Recognition<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018.  Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition."</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recorded a net reduction to opening retained earnings of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for the </span><span style="font-family:inherit;font-size:11pt;">six months ended</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> was not significant.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Company recognizes revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. Accordingly, in these cases, the delivery of the equipment and the installation are separate performance obligations. The Company will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Reagent Rental Agreements </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. The Company has concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, the Company first allocates the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Revenue allocated to the lease elements are approximately </span><span style="font-family:inherit;font-size:11pt;"><span>5%</span></span><span style="font-family:inherit;font-size:11pt;"> of total revenue and are included as part of the Net sales in our Condensed Consolidated Statements of Income.</span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contract costs:</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We apply a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. </span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Disaggregation of Revenue:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited):</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.625%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>197.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>163.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>396.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>348.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>122.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>107.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>231.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>202.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>221.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>202.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>431.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>389.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>575.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>504.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,127.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,004.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 10).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are recognized as (or when) the Company performs under the contract which is generally over time during the term of the service contract. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from </span><span style="font-family:inherit;font-size:11pt;"><span>$36.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>$41.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> is primarily driven by cash payments received or due in advance of satisfying our performance obligations, offset by </span><span style="font-family:inherit;font-size:11pt;"><span>$22.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of revenue recognized that were included in our deferred revenue balance as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(17.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Recent Accounting Pronouncements Adopted</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In February 2018, the FASB issued Accounting Standards Update No. ("ASU") 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to Retained earnings as of the beginning of the fiscal year in which the guidance is adopted. We adopted ASU 2018-03 on January 1, 2018 and made an irrevocable election to account for our investment of the ordinary shares of Sartorius AG at fair value (see ASU 2016-01 below).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:11pt;">In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. Changes in fair value for equity securities will no longer be reported in other comprehensive income. </span><span style="font-family:inherit;font-size:12pt;"> </span><span style="font-family:inherit;font-size:11pt;">For equity investments without readily determinable fair values, the cost method is also eliminated. We adopted ASU 2016-01 on January 1, 2018 and record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes and were valued at </span><span style="font-family:inherit;font-size:11pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">. Changes in the basis of these equity investments are reported in current earnings. For equity securities that are affected by ASU 2016-01 and ASU 2018-03, see Note 2 to the condensed consolidated financial statements, which primarily consists of our investment in Sartorius AG. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The impact of the adoption of ASU 2016-01 and ASU 2018-03 on January 1, 2018 was through a cumulative-effect adjustment of </span><span style="font-family:inherit;font-size:11pt;"><span>$864.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> to Total stockholders' equity by increasing Retained earnings of </span><span style="font-family:inherit;font-size:11pt;"><span>$1,543.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and decreasing Accumulated other comprehensive income of </span><span style="font-family:inherit;font-size:11pt;"><span>$679.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, including increasing Deferred income taxes by </span><span style="font-family:inherit;font-size:11pt;"><span>$232.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> and an increase in Other investments of </span><span style="font-family:inherit;font-size:11pt;"><span>$1,097.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> in our Condensed Consolidated Balance Sheet. As a result of ASU 2016-01 and ASU 2018-03 for the </span><span style="font-size:11pt;">three and six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">, we recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$286.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1,102.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, for the Change in fair market value of equity securities in the Condensed Consolidated Statement of Income that resulted in a deferred tax expense for the </span><span style="font-size:11pt;">three and six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> of </span><span style="font-family:inherit;font-size:11pt;"><span>$62.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$243.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which changed how we present the net periodic benefit cost of our defined benefit pension and/or other postretirement plans. We adopted ASU 2017-07 on January 1, 2018 and applied the practical expedient to estimate amounts for comparative purposes utilizing the information disclosed in Note 12 to the consolidated financial statements in our Form 10-K for the year ended December 31, 2017. The interest costs are recorded in Interest expense, and the other costs are recorded in Other (income) expense, net in the Condensed Consolidated Statements of Income. For the </span><span style="font-size:11pt;">second</span><span style="font-family:inherit;font-size:11pt;"> quarter of 2017 for interest costs and other costs, we reclassified </span><span style="font-family:inherit;font-size:11pt;"><span>$0.076 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.538 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.036 million</span></span><span style="font-family:inherit;font-size:11pt;"> from Costs of goods sold (COGS), Selling, general and administrative expense (SG&amp;A) and Research and development expense (R&amp;D), respectively, to Interest expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.275 million</span></span><span style="font-family:inherit;font-size:11pt;"> and Other (income) expense, net of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.375 million</span></span><span style="font-family:inherit;font-size:11pt;">. For the </span><span style="font-size:11pt;">first six months</span><span style="font-family:inherit;font-size:11pt;"> of 2017 for interest costs and other costs, we reclassified </span><span style="font-family:inherit;font-size:11pt;"><span>$0.152 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$1.076 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.072 million</span></span><span style="font-family:inherit;font-size:11pt;"> from COGS, SG&amp;A and R&amp;D, respectively, to Interest expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.550 million</span></span><span style="font-family:inherit;font-size:11pt;"> and Other (income) expense, net of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.750 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November 2016, the FASB issued ASU 2016-18, "Restricted Cash," which required us to cease to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 and updated the Condensed Consolidated Statements of Cash Flows to incorporate restricted cash included in Other current assets and Other assets of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," which required immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  We adopted ASU 2016-16 on January 1, 2018 on a modified retrospective basis through a cumulative-effect adjustment by decreasing Retained earnings by </span><span style="font-family:inherit;font-size:11pt;"><span>$17.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, and decreasing Prepaid taxes by </span><span style="font-family:inherit;font-size:11pt;"><span>$22.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and increasing Deferred tax assets by </span><span style="font-family:inherit;font-size:11pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> that are both recorded in Other assets in our Condensed Consolidated Balance Sheet. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments" and adopted it on January 1, 2018, which did not have an impact to our statement of cash flows presentation.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASC 606"), an updated standard on revenue recognition. The new standard provides enhancements to the quality and consistency of how revenue is reported under the principle that revenue should be recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the transfer of promised goods or services. We adopted ASC 606 as of January 1, 2018 using the cumulative effect transition method as more fully described above under the caption “Revenue Recognition.” </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Recent Accounting Pronouncements to be Adopted</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU 2018-11, "Targeted Improvements," which gives the option to apply the transition provisions of ASU 2016-02 at its adoption date instead of at the earliest comparative period presented in its financial statements. In addition, ASU 2018-11 provides a practical expedient that permits lessors to not separate nonlease components from the associated lease component if certain conditions are met. Also in July 2018, the FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases," which clarifies certain aspects of ASU 2016-02. We will adopt ASU 2016-02 on a modified retrospective basis on its adoption date of January 1, 2019 with practical expedients, instead of at the earliest comparative period presented in our financial statements. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities. Revenue Recognition<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018.  Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition."</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recorded a net reduction to opening retained earnings of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for the </span><span style="font-family:inherit;font-size:11pt;">six months ended</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> was not significant.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Company recognizes revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. Accordingly, in these cases, the delivery of the equipment and the installation are separate performance obligations. The Company will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Reagent Rental Agreements </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. The Company has concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, the Company first allocates the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Revenue allocated to the lease elements are approximately </span><span style="font-family:inherit;font-size:11pt;"><span>5%</span></span><span style="font-family:inherit;font-size:11pt;"> of total revenue and are included as part of the Net sales in our Condensed Consolidated Statements of Income.</span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contract costs:</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We apply a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. </span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Disaggregation of Revenue:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited):</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.625%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>197.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>163.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>396.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>348.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>122.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>107.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>231.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>202.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>221.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>202.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>431.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>389.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>575.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>504.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,127.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,004.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 10).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are recognized as (or when) the Company performs under the contract which is generally over time during the term of the service contract. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from </span><span style="font-family:inherit;font-size:11pt;"><span>$36.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>$41.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> is primarily driven by cash payments received or due in advance of satisfying our performance obligations, offset by </span><span style="font-family:inherit;font-size:11pt;"><span>$22.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of revenue recognized that were included in our deferred revenue balance as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(17.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> 100000 0.05 The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.625%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>197.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>163.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>396.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>348.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>122.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>107.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>231.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>202.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>221.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>202.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;background-color:#ccffcc;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>431.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>389.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #ffffff;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>575.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>504.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,127.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,004.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 197200000 163900000 396800000 348900000 122000000.0 107500000 231400000 202300000 221600000 202500000 431500000 389800000 35100000 30800000 67700000 63700000 575900000 504700000 1127400000 1004700000 36700000 41400000 22400000 Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(17.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 18700000 14900000 17500000 16100000 600000 864500000 1543700000 679200000 232900000 1097400000 286400000 1102300000 62600000 243800000 -76000.000 -538000 -36000.000 275000 375000 -152000 -1076000.000 -72000.000 550000 750000 1100000 1000000.0 -17600000 -22800000 5200000 FAIR VALUE MEASUREMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1: Quoted prices in active markets for identical instruments</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>68.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>68.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents (a)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>86.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>142.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Equity securities (b)</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,196.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,196.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>223.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>223.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>66.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>66.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (c)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,258.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>457.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,715.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (e)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration (f)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of first quarter 2018, our equity securities are no longer reported as Available-for-sale investments due to the implementation of ASU 2016-01. Changes in fair value of equity securities are now reported on the Condensed Consolidated Statements of Income rather than Other Comprehensive Income (see Note 1).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>53.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents (a)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>104.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (c)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,026.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>385.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,411.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (e)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration (f)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>44.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,151.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,196.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The unrealized gains on our equity securities still held as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> are </span><span style="font-family:inherit;font-size:11pt;"><span>$1,102.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> and are primarily due to our investment in Sartorius AG and is recorded in our Condensed Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Note 1).</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:24px;text-indent:0px;"><span style="font-family:inherit;font-size:11pt;padding-right:24px;">(c)</span><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>371.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In accordance with our adoption of ASU 2016-01 January 1, 2018, our investment in Sartorius AG preferred shares, which was reported within marketable equity securities as Available-for-sale as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, is now reported as an Equity security as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> (see Note 1 and footnote (b) above).</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(f) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):</span></div><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from </span><span style="font-family:inherit;font-size:11pt;"><span>39%</span></span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> for the calendar years </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> through </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;">. The sales milestones could potentially range from </span><span style="font-family:inherit;font-size:11pt;"><span>$0</span></span><span style="font-family:inherit;font-size:11pt;"> to an unlimited amount. In the first quarter of 2018, we paid </span><span style="font-family:inherit;font-size:11pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> per the purchase agreement. Since 2016 we have decreased the cumulative valuation of the sales milestones by </span><span style="font-family:inherit;font-size:11pt;"><span>$8.5 million</span></span><span style="font-family:inherit;font-size:11pt;">. The contingent consideration was accrued at its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table provides a reconciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Analytical flow cytometer platform:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following table provides quantitative information about Level 3 inputs for fair value measurement of our</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">analytical flow cytometer platform</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">contingent consideration liability as of</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:27%;"/><td style="width:26%;"/><td style="width:31%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unobservable Input</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Probability-weighted income approach</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Sales milestones:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of debt</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">To estimate the fair value of Level 2 debt securities as of </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, our primary pricing provider uses Securities Evaluations as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Securities Evaluations does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For commercial paper as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par. In the event that an additional lot of the same commercial paper issue has been purchased within the same account, then the price of all holdings of that issue in that account will be the price of the most recent lot purchased.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our pricing provider performs daily reasonableness testing of the Securities Evaluations prices. Price changes of </span><span style="font-family:inherit;font-size:11pt;"><span>5%</span></span><span style="font-family:inherit;font-size:11pt;"> or greater are investigated and resolved. In addition, we perform a quarterly comparison of the Securities Evaluations prices to custodian reported prices. Price differences outside a tolerable variance of approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>1%</span></span><span style="font-family:inherit;font-size:11pt;"> are investigated and resolved.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>224.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>223.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>66.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of the amortized cost and estimated fair value of our debt securities at </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> by contractual maturity date (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in less than one year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in one to five years</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>170.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>169.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in more than five years</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>46.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>45.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>68.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>363.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>371.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>875.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>875.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>418.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>884.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>199.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>168.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> or at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange losses, net in the Condensed Consolidated Statements of Income. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of our forward foreign exchange contracts (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in July through September 2018 to sell foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in July through September 2018 to purchase foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>327.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of financial instruments that are not recognized at fair value in the Condensed Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which have fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair Value Hierarchy Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair Value Hierarchy Level</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>91.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,249.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total long-term debt, excluding leases and current maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>439.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>449.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>37%</span></span><span style="font-family:inherit;font-size:11pt;"> of the outstanding voting shares (excluding treasury shares) of Sartorius as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ Board of Directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius.  As of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">, due to the adoption of </span></div>ASU 2016-01 and ASU 2018-03, we account for this investment at fair market value as determined at period end by a quoted price on an organized exchange (see Note 1). <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>68.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>68.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents (a)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>86.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>142.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Equity securities (b)</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,196.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,196.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>223.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>223.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>66.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>66.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (c)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,258.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>457.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,715.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (e)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration (f)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of first quarter 2018, our equity securities are no longer reported as Available-for-sale investments due to the implementation of ASU 2016-01. Changes in fair value of equity securities are now reported on the Condensed Consolidated Statements of Income rather than Other Comprehensive Income (see Note 1).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>53.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents (a)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>104.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (c)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,026.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>385.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,411.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (e)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration (f)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>44.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,151.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,196.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The unrealized gains on our equity securities still held as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> are </span><span style="font-family:inherit;font-size:11pt;"><span>$1,102.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> and are primarily due to our investment in Sartorius AG and is recorded in our Condensed Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Note 1).</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:24px;text-indent:0px;"><span style="font-family:inherit;font-size:11pt;padding-right:24px;">(c)</span><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>371.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In accordance with our adoption of ASU 2016-01 January 1, 2018, our investment in Sartorius AG preferred shares, which was reported within marketable equity securities as Available-for-sale as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, is now reported as an Equity security as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> (see Note 1 and footnote (b) above).</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(f) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):</span></div><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0 68400000 0 68400000 25700000 10000000.0 0 35700000 30200000 0 0 30200000 0 1800000 0 1800000 0 6000000.0 0 6000000.0 55900000 86200000 0 142100000 5600000 0 0 5600000 3196600000 0 0 3196600000 0 223600000 0 223600000 0 66000000.0 0 66000000.0 0 2600000 0 2600000 0 15600000 0 15600000 0 62900000 0 62900000 0 370700000 0 370700000 0 600000 0 600000 3258100000 457500000 0 3715600000 0 1000000.0 0 1000000.0 0 0 13000000.0 13000000.0 0 1000000.0 13000000.0 14000000.0 0 36000000.0 0 36000000.0 43700000 10000000.0 0 53700000 0 11200000 0 11200000 3400000 0 0 3400000 47100000 57200000 0 104300000 5600000 0 0 5600000 0 185700000 0 185700000 0 67600000 0 67600000 0 3400000 0 3400000 0 700000 0 700000 0 15000000.0 0 15000000.0 973400000 0 0 973400000 0 55600000 0 55600000 973400000 328000000.0 0 1301400000 0 500000 0 500000 1026100000 385700000 0 1411800000 0 1600000 0 1600000 0 0 16700000 16700000 0 1600000 16700000 18300000 44700000 3151900000 3196600000 1102300000 370500000 371200000 200000 930200000 370700000 1301400000 2600000 2700000 10400000 14000000.0 13000000.0 16700000 0.39 0.20 0 1300000 8500000 13000000.0 The following table provides a reconciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Analytical flow cytometer platform:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 16700000 1300000 2400000 13000000.0 <span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following table provides quantitative information about Level 3 inputs for fair value measurement of our</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">analytical flow cytometer platform</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">contingent consideration liability as of</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.</span><span style="font-family:inherit;font-size:11pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:27%;"/><td style="width:26%;"/><td style="width:31%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unobservable Input</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Probability-weighted income approach</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Sales milestones:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of debt</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 0.111 0.048 0.05 0.01 Available-for-sale investments consist of the following (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>224.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>223.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>66.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of the amortized cost and estimated fair value of our debt securities at </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> by contractual maturity date (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in less than one year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in one to five years</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>170.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>169.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in more than five years</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>46.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>45.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>370.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 224900000 100000 1400000 223600000 15700000 0 100000 15600000 63100000 0 400000 62700000 67200000 0 1200000 66000000.0 2600000 0 0 2600000 373500000 100000 3100000 370500000 200000 0 0 200000 200000 0 0 200000 373700000 100000 3100000 370700000 156700000 156400000 170900000 169300000 46100000 45000000.0 373700000 370700000 Available-for-sale investments consist of the following (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>68.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>363.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>371.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>875.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>875.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>418.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>884.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 185900000 300000 500000 185700000 700000 0 0 700000 15100000 0 100000 15000000.0 55600000 0 200000 55400000 68300000 0 700000 67600000 3400000 0 0 3400000 34400000 9000000.0 0 43400000 363400000 9300000 1500000 371200000 54500000 875500000 0 930000000.0 200000 0 0 200000 54700000 875500000 0 930200000 418100000 884800000 1500000 1301400000 The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>199.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>168.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 36900000 43900000 199400000 168700000 900000 700000 2200000 800000 The following is a summary of our forward foreign exchange contracts (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in July through September 2018 to sell foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in July through September 2018 to purchase foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>327.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 37800000 100000 327600000 500000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair Value Hierarchy Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair Value Hierarchy Level</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>91.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,249.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total long-term debt, excluding leases and current maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>439.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>449.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr></table></div> 91800000 1249400000 423400000 439400000 423100000 449800000 0.37 GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to goodwill by segment were as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balances as of January 1, 2018:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>324.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>559.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated impairment losses</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(35.9</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(17.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(53.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>198.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>307.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Divestiture</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Currency fluctuations</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.7</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balances as of June 30, 2018:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>234.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>318.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>553.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated impairment losses</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(35.9</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(17.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(53.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>198.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>500.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In March 2018, we wrote off </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>89.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(65.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>192.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(158.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-11</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>131.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(74.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-11</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(38.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>501.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(343.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>158.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>92.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(64.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>194.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(157.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>133.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(70.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-12</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(36.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>509.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(334.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>174.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization expense related to purchased intangible assets is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> Changes to goodwill by segment were as follows (in millions):<div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balances as of January 1, 2018:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>324.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>559.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated impairment losses</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(35.9</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(17.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(53.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>198.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>307.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Divestiture</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Currency fluctuations</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.7</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balances as of June 30, 2018:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>234.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>318.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>553.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated impairment losses</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(35.9</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(17.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(53.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>198.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>500.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In March 2018, we wrote off </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div> 234700000 324600000 559300000 35900000 17300000 53200000 198800000 307300000 506100000 0 1400000 1400000 -200000 -4500000 -4700000 234500000 318700000 553200000 35900000 17300000 53200000 198600000 301400000 500000000.0 1400000 Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):<div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>89.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(65.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>192.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(158.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-11</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>131.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(74.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-11</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(38.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>501.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(343.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>158.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>92.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(64.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>194.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(157.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>133.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(70.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-12</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(36.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>509.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(334.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>174.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 89600000 65700000 23900000 192300000 158600000 33700000 131800000 74200000 57600000 76400000 38500000 37900000 3900000 3200000 700000 7900000 3700000 4200000 501900000 343900000 158000000.0 92300000 64400000 27900000 194900000 157900000 37000000.0 133300000 70300000 63000000.0 76700000 36000000.0 40700000 3900000 3000000.0 900000 7900000 3300000 4600000 509000000.0 334900000 174100000 Amortization expense related to purchased intangible assets is as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 7400000 8700000 14800000 15600000 SUPPLEMENTAL CASH FLOW INFORMATION<div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation of net income to net cash provided by operating activities is as follows (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" style="padding-left:0px;padding-right:0px;padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>924.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>68.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>70.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses on dispositions of securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair market value of equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1,102.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on divestiture of a product line</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses on dispositions of fixed assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on sale of land</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease (increase) in accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(37.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in accounts payable and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(43.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(24.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in income taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>246.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net increase in other long-term assets/liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>118.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The reconciliation of net income to net cash provided by operating activities is as follows (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" style="padding-left:0px;padding-right:0px;padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>924.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>68.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>70.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses on dispositions of securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair market value of equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1,102.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on divestiture of a product line</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses on dispositions of fixed assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on sale of land</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease (increase) in accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(37.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in accounts payable and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(43.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(24.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in income taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>246.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net increase in other long-term assets/liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>118.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 924800000 17400000 68700000 70700000 12100000 10600000 -600000 -300000 1102300000 0 5100000 0 -800000 0 4100000 0 -2400000 -8700000 -52500000 1800000 11700000 37900000 5900000 14800000 -43700000 -24200000 -20900000 -13200000 -246200000 3100000 -8600000 -11000000.0 118200000 6300000 LONG-TERM DEBT<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The principal components of long-term debt are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes due 2020 principal amount</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.9</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.4</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>440.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less current maturities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>438.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Senior Notes due 2020</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2010, Bio-Rad sold </span><span style="font-family:inherit;font-size:11pt;"><span>$425.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> principal amount of Senior Notes due 2020 (</span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes).  The sale yielded net cash proceeds of </span><span style="font-family:inherit;font-size:11pt;"><span>$422.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> at an effective rate of </span><span style="font-family:inherit;font-size:11pt;"><span>4.946%</span></span><span style="font-family:inherit;font-size:11pt;">.  The </span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes pay a fixed rate of interest of </span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> per year.  We have the option to redeem any or all of the </span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes at any time at a redemption price of </span><span style="font-family:inherit;font-size:11pt;"><span>100%</span></span><span style="font-family:inherit;font-size:11pt;"> of the principal amount (plus a specified make-whole premium as defined in the indenture governing the </span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the </span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the </span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Credit Agreement</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In June 2014, Bio-Rad entered into a </span><span style="font-family:inherit;font-size:11pt;color:#000000;font-style:normal;text-decoration:none;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> or </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, however </span><span style="font-family:inherit;font-size:11pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> was utilized for domestic standby letters of credit that reduced our borrowing availability as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">. The Credit Agreement matures in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 2019</span><span style="font-family:inherit;font-size:11pt;">. If we had borrowed against our Credit Agreement, the borrowing rate would have been </span><span style="font-family:inherit;font-size:11pt;"><span>3.46%</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2018</span>. The principal components of long-term debt are as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes due 2020 principal amount</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.9</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.4</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>440.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less current maturities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>438.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 425000000.0 425000000.0 1600000 1900000 423400000 423100000 17100000 11900000 440500000 435000000.0 1700000 400000 438800000 434600000 425000000.0 0.04875 422600000 0.04946 0.04875 0.04875 0.04875 1 0.04875 0.04875 0.04875 200000000.0 500000 0.0346 .    <span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</span><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions): </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2018*:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(79.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of June 30, 2018:</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2017:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of June 30, 2017:</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>569.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>610.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">*The beginning balance has been updated as a result of adopting ASU 2016-01. See Note 1, "Basis of Presentation and Use of Estimates" under "Recent Accounting Standards Updates."</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:42%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before taxes impact (in millions):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Location</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of foreign other post-employment benefit items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net holding (losses) gains on equity securities and available-for-sale investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Reclassification adjustments are calculated using the specific identification method. Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions): <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2018*:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(79.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of June 30, 2018:</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2017:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of June 30, 2017:</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>569.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>610.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 77400000 -22300000 4500000 59600000 -77600000 500000 -2100000 -79200000 0 -800000 -200000 -1000000.0 0 100000 0 100000 -77600000 1200000 -1900000 -78300000 -200000 -21100000 2600000 -18700000 1300000 -18600000 435000000.0 417700000 60500000 -2500000 213200000 271200000 0 0 0 0 0 -500000 78500000 78000000.0 60500000 -2000000.0 134700000 193200000 61800000 -20600000 569700000 610900000 The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows:<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:42%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before taxes impact (in millions):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Location</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of foreign other post-employment benefit items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net holding (losses) gains on equity securities and available-for-sale investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Reclassification adjustments are calculated using the specific identification method. 500000 -200000 800000 0 -100000 -200000 -200000 0 .    EARNINGS PER SHARE<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,814</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,613</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,801</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,597</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-18px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options and restricted stock awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>405</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>396</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,962</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive shares</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,814</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,613</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,801</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,597</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-18px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options and restricted stock awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>405</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>396</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,962</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive shares</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 29814000 29613000 29801000 29597000 405000 393000 396000 365000 30219000 30006000 30197000 29962000 13000 0 13000 15000 .    OTHER INCOME AND EXPENSE, NET<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net includes the following components (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Interest and investment income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(16.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(18.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net realized loss (gain) on investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on sale of land</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on divestiture of product line</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07). Other (income) expense, net includes the following components (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Interest and investment income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(16.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(18.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net realized loss (gain) on investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on sale of land</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on divestiture of product line</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div> 16200000 12000000.0 18300000 13100000 -100000 -200000 -200000 100000 0 0 4100000 0 0 0 5100000 0 200000 400000 300000 800000 15900000 11400000 27000000.0 12400000 .    INCOME TAXES<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our effective income tax rate was </span><span style="font-family:inherit;font-size:11pt;"><span>21%</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>(350)%</span></span><span style="font-family:inherit;font-size:11pt;"> for the </span><span style="font-size:11pt;">three months ended</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively. Our effective income tax rate was </span><span style="font-family:inherit;font-size:11pt;"><span>23%</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>18%</span></span><span style="font-family:inherit;font-size:11pt;"> for the </span><span style="font-size:11pt;">six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively. The effective tax rate for the </span><span style="font-size:11pt;">three and six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> was driven primarily by the large gain on equity investments taxable at the U.S. federal statutory rate of </span><span style="font-family:inherit;font-size:11pt;"><span>21%</span></span><span style="font-family:inherit;font-size:11pt;">. The effective tax rate for the </span><span style="font-size:11pt;">three and six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> was lower than the U.S. federal statutory rate of </span><span style="font-family:inherit;font-size:11pt;"><span>35%</span></span><span style="font-family:inherit;font-size:11pt;"> due to the impact of second quarter discrete items on low pre-tax income. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In accordance with SAB 118, our accounting for the following elements of the Tax Act was incomplete at December 31, 2017. However, we were able to make reasonable estimates of certain effects and, therefore, recorded provisional estimates as follows: </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our deferred tax assets and liabilities were measured at the enacted tax rate that will apply when these temporary differences are expected to be realized or settled. </span></div></td></tr></table><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Tax Act imposes a Transition Tax payable over eight years. The Transition Tax is assessed on the U.S. shareholders’ share of certain foreign corporations’ accumulated untaxed foreign earnings. Earnings in the form of cash and cash equivalents are taxed at a rate of 15.5% and all other earnings are taxed at a rate of 8.0%. In December 2017, we recorded a provisional income tax expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$55 million</span></span><span style="font-family:inherit;font-size:11pt;"> for Transition Tax. </span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our accounting for certain other elements of the Tax Act was incomplete, and we were not able to make reasonable estimates of those effects. For example, we did not make a determination as to our accounting policy with respect to the new Global Intangible Low-Taxed Income ("GILTI"). For the period ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">, we did not record adjustments to our provisional amounts. We will continue our analysis of these provisional amounts during the measurement period and may adjust these estimates as further regulatory guidance becomes available.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We assess our ability to realize our net deferred tax assets on a quarterly basis and establish a valuation allowance if it is more-likely-than-not that some portion of the deferred tax assets will not be realized in the foreseeable future. Due to the weight of negative evidence, including our history of losses in certain jurisdictions, we believe that it is more-likely-than-not that certain foreign deferred tax assets will not be realized as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">. Accordingly, we have maintained a valuation allowance on such deferred tax assets. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">, based on the expected outcome of certain examinations or as a result of the expiration of statute of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to </span><span style="font-family:inherit;font-size:11pt;"><span>$3 million</span></span>. Substantially all such amounts will favorably impact our effective income tax rate. 0.21 -3.50 0.23 0.18 0.21 0.35 55000000 3000000 EGMENT INFORMATION<div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments for the three months ended </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> is as follows (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>217.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>354.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>322.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net profit (loss) </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(22.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments for the six months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> is as follows (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>415.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>704.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>353.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>644.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net profit (loss) </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>64.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(41.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>60.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance.  Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. For the three and six months ended June 30, 2018 compared to the same periods in 2017, our Life Science segment had increased sales and gross profit, along with lower Research and Development expense. In addition, the Life Science segment gross margin included a </span><span style="font-family:inherit;font-size:11pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> one-time expense associated with the RainDance acquisition in the first quarter of 2017. During the second quarter of 2017, our Clinical Diagnostics segment had an asset purchase for an early stage device for </span><span style="font-family:inherit;font-size:11pt;"><span>$7.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> that was recorded in Research and development expense. The following reconciles total segment profit to consolidated income before taxes (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment profit (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>79.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency exchange losses, net</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating, interest and other expense not allocated to segments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Change in fair market value of equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>286.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,102.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Consolidated income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>340.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,203.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits). Information regarding industry segments for the three months ended <span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> is as follows (in millions):</span><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>217.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>354.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>322.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net profit (loss) </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(22.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments for the six months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> is as follows (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>415.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>704.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>353.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>644.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net profit (loss) </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>64.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(41.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>60.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits). 217800000 354000000.0 4100000 179400000 322100000 3200000 12200000 27800000 0 -22900000 18500000 200000 415600000 704800000 7000000.0 353600000 644400000 6700000 15500000 64400000 0 -41700000 60100000 400000 10000000.0 7500000 The following reconciles total segment profit to consolidated income before taxes (in millions):<div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment profit (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>79.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency exchange losses, net</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating, interest and other expense not allocated to segments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Change in fair market value of equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>286.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,102.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Consolidated income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>340.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,203.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits). 40000000.0 -4200000 79900000 18800000 0 -2500000 -1200000 -4300000 -2200000 -3600000 -4200000 -5600000 286400000 0 1102300000 0 15900000 11400000 27000000.0 12400000 340100000 1100000 1203800000 21300000 11.    LEGAL PROCEEDINGS<div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded </span><span style="font-family:inherit;font-size:11pt;"><span>$10.92 million</span></span><span style="font-family:inherit;font-size:11pt;">, plus prejudgment interest of </span><span style="font-family:inherit;font-size:11pt;"><span>$141,608</span></span><span style="font-family:inherit;font-size:11pt;">, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017 we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. 10920000 141608 12.    RESTRUCTURING COSTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restructuring Costs for European Reorganization</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In May, 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with the evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. From inception of May 2016 to June 30, 2018, total expenses were </span><span style="font-family:inherit;font-size:11pt;"><span>$12.9 million</span></span><span style="font-family:inherit;font-size:11pt;">. We recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;"> of adjustments in restructuring charges related to severance and other employee benefits for the </span><span style="font-size:11pt;">three and six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">. The liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> consisted of </span><span style="font-family:inherit;font-size:11pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Accrued payroll and employee benefits and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Other long-term liabilities in the Condensed Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;"> and in Selling, general and administrative expense of less than </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;"> in the Condensed Consolidated Statements of Income for the </span><span style="font-size:11pt;">three and six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): </span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:40%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1, 2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation gains</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restructuring Costs for Termination of a Diagnostics Research and Development Project and a Facility Closure</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2017, we announced the termination of a diagnostics research and development project in Europe. From inception of December 2017 to June 30, 2018, total expenses were </span><span style="font-family:inherit;font-size:11pt;"><span>$20.4 million</span></span><span style="font-family:inherit;font-size:11pt;">. We recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.6) million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.7) million</span></span><span style="font-family:inherit;font-size:11pt;"> of adjustments in restructuring charges related to severance and employee benefits, and exit costs for the </span><span style="font-size:11pt;">three and six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">, respectively. The adjustments were due to a decrease in severance accrual as a result of a reduction in the number of employees being terminated than originally estimated, net of an increase in exit costs accrual as a result of proposed legal settlement. In June 2018, we announced the closure of a manufacturing facility in Germany. As a result, we recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> of expense in restructuring charges related to severance and employee benefits for the </span><span style="font-size:11pt;">three and six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;">. Restructuring charges for the termination of a diagnostics research and development project and the facility closure are both included in our Clinical Diagnostics segment's results of operations. The respective amounts recorded for the quarter and year to date ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> were reflected in Cost of goods sold of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, in Selling, general and administrative expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.3) million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;">, and in Research and development expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.3) million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.6) million</span></span><span style="font-family:inherit;font-size:11pt;"> in the Condensed Consolidated Statements of Income. The liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$11.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2018</span><span style="font-family:inherit;font-size:11pt;"> consisted of </span><span style="font-family:inherit;font-size:11pt;"><span>$7.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Accrued payroll and employee benefits, </span><span style="font-family:inherit;font-size:11pt;"><span>$3.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Other current liabilities, and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Other long term liabilities in the Condensed Consolidated Balance Sheets. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closure restructuring reserves for severance and exit costs (in millions): </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.1640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:67%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation gains</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of June 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 12900000 -100000 4200000 4100000 100000 -100000 -100000 2200000 4100000 6300000 0 0 0 0 -100000 -100000 600000 1300000 1900000 0 100000 100000 1600000 2600000 4200000 20400000 -600000 -700000 1300000 1300000 1300000 -300000 -100000 -300000 -600000 11700000 7200000 3200000 1300000 The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closure restructuring reserves for severance and exit costs (in millions): <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.1640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:67%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation gains</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of June 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div>The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:40%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1, 2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation gains</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 14100000 1300000 -700000 2700000 300000 11700000 Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2018 December 31, 2017Short-term investments$370.5 $371.2Other investments0.2 930.2Total$370.7 $1,301.4 Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets. Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2018 December 31, 2017Other current liabilities$2.6 $2.7Other long-term liabilities10.4 14.0   Total$13.0 $16.7 Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets. Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets. XML 12 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2018
Aug. 02, 2018
Entity Registrant Name BIO-RAD LABORATORIES, INC.  
Entity Central Index Key 0000012208  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Jun. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Common Class A [Member]    
Entity Common Stock, Shares Outstanding   24,735,427
Common Class B [Member]    
Entity Common Stock, Shares Outstanding   5,099,623
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
ASSETS:    
Cash and cash equivalents $ 403,006 $ 383,824
Short-term investments 415,241 371,154
Restricted investments 5,560 5,560
Accounts receivable, net 404,091 464,847
Inventories:    
Raw materials 118,999 113,925
Work in process 140,917 142,589
Finished goods 331,517 338,290
Total inventories 591,433 594,804
Other current assets 173,003 156,460
Total current assets 1,992,334 1,976,649
Property, plant and equipment, at cost 1,289,367 1,305,150
Less: accumulated depreciation and amortization (799,118) (811,654)
Property, plant and equipment, net 490,249 493,496
Goodwill, net 500,022 506,069
Purchased intangibles, net 158,035 174,113
Other investments 3,170,820 1,027,736
Other assets 74,763 94,949
Total assets 6,386,223 4,273,012
LIABILITIES AND STOCKHOLDERS' EQUITY:    
Accounts payable, accrued payroll and employee benefits 261,721 306,814
Current maturities of long-term debt and notes payable 1,721 420
Income and other taxes payable 29,585 39,941
Other current liabilities 149,394 155,521
Total current liabilities 442,421 502,696
Long-term debt, net of current maturities 438,776 434,581
Deferred income taxes 686,906 222,209
Other long-term liabilities 179,174 183,276
Total liabilities 1,747,277 1,342,762
Stockholders' equity:    
Additional paid-in capital 376,595 361,231
Retained earnings 4,281,275 1,830,439
Accumulated other comprehensive income (18,710) 738,794
Total stockholders' equity 4,638,946 2,930,250
Total liabilities and stockholders' equity 6,386,223 4,273,012
Common Class A [Member]    
Stockholders' equity:    
Common stock 2 2
Common Class B [Member]    
Stockholders' equity:    
Common stock 1 1
Treasury Class A [Member]    
Stockholders' equity:    
Treasury Stock, Value (128) (128)
Treasury Class B [Member]    
Stockholders' equity:    
Treasury Stock, Value $ (89) $ (89)
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets Parenthetical - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Allowance for Doubtful Accounts Receivable, Current $ 21,466 $ 25,549
Common Class A [Member]    
Common Stock, Shares, Issued 24,736,009 24,679,127
Common Stock, Shares, Outstanding 24,735,427 24,678,545
Common Class B [Member]    
Common Stock, Shares, Issued 5,100,540 5,107,674
Common Stock, Shares, Outstanding 5,099,623 5,106,757
Treasury Class A [Member]    
Treasury Stock, Shares 582 582
Treasury Class B [Member]    
Treasury Stock, Shares 917 917
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Net sales $ 575,911 $ 504,666 $ 1,127,430 $ 1,004,717
Cost of goods sold 274,244 231,291 523,560 461,279
Gross profit 301,667 273,375 603,870 543,438
Selling, general and administrative expense 210,425 212,489 419,555 406,891
Research and Development Expense 47,450 62,587 96,877 112,039
Segment profit (loss) 43,792 (1,701) 87,438 24,508
Interest expense 5,977 6,045 11,759 11,361
Foreign exchange (gains) losses, net (15) 2,516 1,239 4,305
Unrealized Gain on Securities (286,398) 0 (1,102,332) 0
Nonoperating Income (Expense) 15,858 11,382 27,003 12,425
Income before income taxes 340,086 1,120 1,203,775 21,267
(Provision) benefit for income taxes (72,043) 3,915 (278,958) (3,819)
Net income attributable to Bio-Rad $ 268,043 $ 5,035 $ 924,817 $ 17,448
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ 8.99 $ 0.17 $ 31.03 $ 0.59
Weighted average common shares - basic 29,814 29,613 29,801 29,597
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ 8.87 $ 0.17 $ 30.63 $ 0.58
Weighted average common shares - diluted 30,219 30,006 30,197 29,962
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Net Income (Loss) Attributable to Parent $ 268,043 $ 5,035 $ 924,817 $ 17,448
Foreign currency translation adjustments (124,118) 41,679 (77,572) 60,522
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent 1,458 (1,938) 1,176 (2,053)
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense (135) 54,564 (1,851) 134,713
Total other comprehensive income (loss) net of tax (122,795) 94,305 (78,247) 193,182
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest $ 145,248 $ 99,340 $ 846,570 $ 210,630
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Cash flows from operating activities:    
Cash received from customers $ 1,160,904 $ 999,779
Cash paid to suppliers and employees (1,007,565) (968,719)
Interest paid, net (11,277) (10,865)
Income tax payments, net (47,620) (19,066)
Investment proceeds and miscellaneous receipts, net 18,354 13,197
Proceeds from (payments for) forward foreign exchange contracts, net 5,412 (8,029)
Net cash provided by operating activities 118,208 6,297
Cash flows from investing activities:    
Capital expenditures (53,897) (64,951)
Proceeds from dispositions of property, plant and equipment 4,100 21
Proceeds from divestiture of a product line 6,919 0
Proceeds from (payments for) acquisitions 266  
Payments for acquisitions and long-term investments   (73,573)
Payments for purchases of intangible assets (3) (3,920)
Payments for purchases of marketable securities and investments (183,001) (142,993)
Proceeds from Sale of Debt Securities, Available-for-sale 34,548  
Proceeds from sales of marketable securities and investments   39,362
Proceeds from maturities of marketable securities and investments 88,410 98,379
Net cash used in investing activities (102,658) (147,675)
Cash flows from financing activities:    
Net payments on line-of-credit arrangements and notes payable 0 (36)
Payments on long-term borrowings (1,505) (149)
Payments of contingent consideration (1,270) (3,105)
Proceeds from issuance of common stock for shared-based compensation 3,274 3,778
Payments for purchases of treasury stock 0 (883)
Net cash provided by (used in) financing activities 499 (395)
Effect of foreign exchange rate changes on cash 3,053 7,190
Net increase (decrease) in cash, cash equivalents, and restricted cash 19,102 (134,583)
Beginning Cash, Cash Equivalents, and Restricted Cash 384,983 457,171
Cash and cash equivalents 403,006 321,584
Restricted Cash, Current 105 561
Restricted Cash, Noncurrent 974 443
Ending Cash, Cash Equivalents, and Restricted Cash $ 404,085 $ 322,588
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
1. Organization, Consolidation and Presentation of Financial Statements
 6 Months Ended
Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure 1.BASIS OF PRESENTATION AND USE OF ESTIMATES

Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2017.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.

Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
Revenue Recognition
On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018.  Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition."

We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for the six months ended June 30, 2018 was not significant.

The Company recognizes revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or
services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.
Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. Accordingly, in these cases, the delivery of the equipment and the installation are separate performance obligations. The Company will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.
At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products.
Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation.
In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.
We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

Reagent Rental Agreements
Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. The Company has concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, the Company first allocates the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned.
For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the
arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.
Revenue allocated to the lease elements are approximately 5% of total revenue and are included as part of the Net sales in our Condensed Consolidated Statements of Income.
Contract costs:
We apply a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities.
Disaggregation of Revenue:
The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited):
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
 
 
2018
 
2017
 
2018
 
2017
Europe
 
$
197.2

 
$
163.9

 
$
396.8

 
$
348.9

Pacific Rim
 
122.0

 
107.5

 
231.4

 
202.3

United States
 
221.6

 
202.5

 
431.5

 
389.8

Other (primarily Canada and Latin America)
 
35.1

 
30.8

 
67.7

 
63.7

Total Net sales
 
$
575.9

 
$
504.7

 
$
1,127.4

 
$
1,004.7



The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 10).

Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are recognized as (or when) the Company performs under the contract which is generally over time during the term of the service contract. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $36.7 million at December 31, 2017 to $41.4 million at June 30, 2018 is primarily driven by cash payments received or due in advance of satisfying our performance obligations, offset by $22.4 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2017.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):

January 1, 2018
$
18.7

Provision for warranty
14.9

Actual warranty costs
(17.5
)
June 30, 2018
$
16.1



Recent Accounting Pronouncements Adopted

In February 2018, the FASB issued Accounting Standards Update No. ("ASU") 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to Retained earnings as of the beginning of the fiscal year in which the guidance is adopted. We adopted ASU 2018-03 on January 1, 2018 and made an irrevocable election to account for our investment of the ordinary shares of Sartorius AG at fair value (see ASU 2016-01 below).

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. Changes in fair value for equity securities will no longer be reported in other comprehensive income. For equity investments without readily determinable fair values, the cost method is also eliminated. We adopted ASU 2016-01 on January 1, 2018 and record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes and were valued at $0.6 million as of June 30, 2018. Changes in the basis of these equity investments are reported in current earnings. For equity securities that are affected by ASU 2016-01 and ASU 2018-03, see Note 2 to the condensed consolidated financial statements, which primarily consists of our investment in Sartorius AG.

The impact of the adoption of ASU 2016-01 and ASU 2018-03 on January 1, 2018 was through a cumulative-effect adjustment of $864.5 million to Total stockholders' equity by increasing Retained earnings of $1,543.7 million and decreasing Accumulated other comprehensive income of $679.2 million, including increasing Deferred income taxes by $232.9 million and an increase in Other investments of $1,097.4 million in our Condensed Consolidated Balance Sheet. As a result of ASU 2016-01 and ASU 2018-03 for the three and six months ended June 30, 2018, we recorded $286.4 million and $1,102.3 million, respectively, for the Change in fair market value of equity securities in the Condensed Consolidated Statement of Income that resulted in a deferred tax expense for the three and six months ended June 30, 2018 of $62.6 million and $243.8 million, respectively.

In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which changed how we present the net periodic benefit cost of our defined benefit pension and/or other postretirement plans. We adopted ASU 2017-07 on January 1, 2018 and applied the practical expedient to estimate amounts for comparative purposes utilizing the information disclosed in Note 12 to the consolidated financial statements in our Form 10-K for the year ended December 31, 2017. The interest costs are recorded in Interest expense, and the other costs are recorded in Other (income) expense, net in the Condensed Consolidated Statements of Income. For the second quarter of 2017 for interest costs and other costs, we reclassified $0.076 million, $0.538 million, and $0.036 million from Costs of goods sold (COGS), Selling, general and administrative expense (SG&A) and Research and development expense (R&D), respectively, to Interest expense of $0.275 million and Other (income) expense, net of $0.375 million. For the first six months of 2017 for interest costs and other costs, we reclassified $0.152 million, $1.076 million, and $0.072 million from COGS, SG&A and R&D, respectively, to Interest expense of $0.550 million and Other (income) expense, net of $0.750 million.

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash," which required us to cease to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 and updated the Condensed Consolidated Statements of Cash Flows to incorporate restricted cash included in Other current assets and Other assets of $1.1 million as of June 30, 2018 and $1.0 million as of June 30, 2017.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," which required immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  We adopted ASU 2016-16 on January 1, 2018 on a modified retrospective basis through a cumulative-effect adjustment by decreasing Retained earnings by $17.6 million, and decreasing Prepaid taxes by $22.8 million and increasing Deferred tax assets by $5.2 million that are both recorded in Other assets in our Condensed Consolidated Balance Sheet.

In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments" and adopted it on January 1, 2018, which did not have an impact to our statement of cash flows presentation.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASC 606"), an updated standard on revenue recognition. The new standard provides enhancements to the quality and consistency of how revenue is reported under the principle that revenue should be recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the transfer of promised goods or services. We adopted ASC 606 as of January 1, 2018 using the cumulative effect transition method as more fully described above under the caption “Revenue Recognition.”

Recent Accounting Pronouncements to be Adopted

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU 2018-11, "Targeted Improvements," which gives the option to apply the transition provisions of ASU 2016-02 at its adoption date instead of at the earliest comparative period presented in its financial statements. In addition, ASU 2018-11 provides a practical expedient that permits lessors to not separate nonlease components from the associated lease component if certain conditions are met. Also in July 2018, the FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases," which clarifies certain aspects of ASU 2016-02. We will adopt ASU 2016-02 on a modified retrospective basis on its adoption date of January 1, 2019 with practical expedients, instead of at the earliest comparative period presented in our financial statements. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
2. Fair Value Measurements
 6 Months Ended
Jun. 30, 2018
Fair Value Disclosures [Abstract]  
Fair Value Measurements FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•
Level 1: Quoted prices in active markets for identical instruments
•
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of June 30, 2018 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
68.4

 
$
—

 
$
68.4

Time deposits
25.7

 
10.0

 
—

 
35.7

Money market funds
30.2

 
—

 
—

 
30.2

Foreign government obligations
—

 
1.8

 
—

 
1.8

U.S. government sponsored agencies
—

 
6.0

 
—

 
6.0

Total cash equivalents (a)
55.9

 
86.2

 
—

 
142.1

Restricted investment
5.6

 
—

 
—

 
5.6

Equity securities (b)
3,196.6

 
—

 
—

 
3,196.6

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
223.6

 
—

 
223.6

U.S. government sponsored agencies
—

 
66.0

 
—

 
66.0

Foreign government obligations
—

 
2.6

 
—

 
2.6

Municipal obligations
—

 
15.6

 
—

 
15.6

Asset-backed securities
—

 
62.9

 
—

 
62.9

Total available-for-sale investments (c)
—

 
370.7

 
—

 
370.7

Forward foreign exchange contracts (d)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
3,258.1

 
$
457.5

 
$
—

 
$
3,715.6

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (e)
$
—

 
$
1.0

 
$
—

 
$
1.0

Contingent consideration (f)
—

 
—

 
13.0

 
13.0

Total financial liabilities carried at fair value
$
—

 
$
1.0

 
$
13.0

 
$
14.0


As of first quarter 2018, our equity securities are no longer reported as Available-for-sale investments due to the implementation of ASU 2016-01. Changes in fair value of equity securities are now reported on the Condensed Consolidated Statements of Income rather than Other Comprehensive Income (see Note 1).
Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2017 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
36.0

 
$
—

 
$
36.0

Time deposits
43.7

 
10.0

 
—

 
53.7

U.S. government sponsored agencies
—

 
11.2

 
—

 
11.2

Money market funds
3.4

 
—

 
—

 
3.4

Total cash equivalents (a)
47.1

 
57.2

 
—

 
104.3

Restricted investment
5.6

 
—

 
—

 
5.6

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
185.7

 
—

 
185.7

U.S. government sponsored agencies
—

 
67.6

 
—

 
67.6

Foreign government obligations
—

 
3.4

 
—

 
3.4

Brokered certificates of deposit
—

 
0.7

 
—

 
0.7

Municipal obligations
—

 
15.0

 
—

 
15.0

Marketable equity securities
973.4

 
—

 
—

 
973.4

Asset-backed securities
—

 
55.6

 
—

 
55.6

Total available-for-sale investments (c)
973.4

 
328.0

 
—

 
1,301.4

Forward foreign exchange contracts (d)
—

 
0.5

 
—

 
0.5

Total financial assets carried at fair value
$
1,026.1

 
$
385.7

 
$
—

 
$
1,411.8

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (e)
$
—

 
$
1.6

 
$
—

 
$
1.6

Contingent consideration (f)
—

 
—

 
16.7

 
16.7

Total financial liabilities carried at fair value
$
—

 
$
1.6

 
$
16.7

 
$
18.3


(a)
Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.

(b)
Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):
 
June 30, 2018
Short-term investments
$
44.7

Other investments
3,151.9

        Total
$
3,196.6



The unrealized gains on our equity securities still held as of June 30, 2018 are $1,102.3 million and are primarily due to our investment in Sartorius AG and is recorded in our Condensed Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Note 1).

(c)Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):
 
June 30, 2018
 
December 31, 2017
Short-term investments
$
370.5

 
$
371.2

Other investments
0.2

 
930.2

Total
$
370.7

 
$
1,301.4



In accordance with our adoption of ASU 2016-01 January 1, 2018, our investment in Sartorius AG preferred shares, which was reported within marketable equity securities as Available-for-sale as of December 31, 2017, is now reported as an Equity security as of June 30, 2018 (see Note 1 and footnote (b) above).

(d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.

(e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.

(f) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):

 
June 30, 2018
 
December 31, 2017
Other current liabilities
$
2.6

 
$
2.7

Other long-term liabilities
10.4

 
14.0

   Total
$
13.0

 
$
16.7



During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2018 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. In the first quarter of 2018, we paid $1.3 million per the purchase agreement. Since 2016 we have decreased the cumulative valuation of the sales milestones by $8.5 million. The contingent consideration was accrued at its estimated fair value of $13.0 million as of June 30, 2018.

The following table provides a reconciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):

January 1, 2018
$
16.7

Analytical flow cytometer platform:
 
Payment of sales milestone
(1.3
)
Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(2.4
)
June 30, 2018
$
13.0



The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of June 30, 2018. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
 
 
 
 
Valuation Technique
Unobservable Input
 
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
Discount rate
11.1
%
 
 
Cost of debt
4.8
%
 
 
 
 



To estimate the fair value of Level 2 debt securities as of June 30, 2018 and December 31, 2017, our primary pricing provider uses Securities Evaluations as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Securities Evaluations does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.

For commercial paper as of June 30, 2018 and December 31, 2017, pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par. In the event that an additional lot of the same commercial paper issue has been purchased within the same account, then the price of all holdings of that issue in that account will be the price of the most recent lot purchased.

Our pricing provider performs daily reasonableness testing of the Securities Evaluations prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly comparison of the Securities Evaluations prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% are investigated and resolved.

Available-for-sale investments consist of the following (in millions):

 
June 30, 2018
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
224.9

 
$
0.1

 
$
(1.4
)
 
$
223.6

Municipal obligations
15.7

 
—

 
(0.1
)
 
15.6

Asset-backed securities
63.1

 
—

 
(0.4
)
 
62.7

U.S. government sponsored agencies
67.2

 
—

 
(1.2
)
 
66.0

Foreign government obligations
2.6

 
—

 
—

 
2.6

 
373.5

 
0.1

 
(3.1
)
 
370.5

Long-term investments:
 
 
 
 
 
 
 
Asset-backed securities
0.2

 
—

 
—

 
0.2

 
0.2

 
—

 
—

 
0.2

Total
$
373.7

 
$
0.1

 
$
(3.1
)
 
$
370.7


The following is a summary of the amortized cost and estimated fair value of our debt securities at June 30, 2018 by contractual maturity date (in millions):
 
Amortized
Cost
 
Estimated Fair
Value
Mature in less than one year
$
156.7

 
$
156.4

Mature in one to five years
170.9

 
169.3

Mature in more than five years
46.1

 
45.0

Total
$
373.7

 
$
370.7




Available-for-sale investments consist of the following (in millions):

 
December 31, 2017
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
185.9

 
$
0.3

 
$
(0.5
)
 
$
185.7

Brokered certificates of deposit
0.7

 
—

 
—

 
0.7

Municipal obligations
15.1

 
—

 
(0.1
)
 
15.0

Asset-backed securities
55.6

 
—

 
(0.2
)
 
55.4

U.S. government sponsored agencies
68.3

 
—

 
(0.7
)
 
67.6

Foreign government obligations
3.4

 
—

 
—

 
3.4

Marketable equity securities
34.4

 
9.0

 
—

 
43.4

 
363.4

 
9.3

 
(1.5
)
 
371.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
875.5

 
—

 
930.0

Asset-backed securities
0.2

 
—

 
—

 
0.2

 
54.7

 
875.5

 
—

 
930.2

Total
$
418.1

 
$
884.8

 
$
(1.5
)
 
$
1,301.4



The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):
 
June 30, 2018
 
December 31, 2017
Fair value of investments in a loss position 12 months or more
$
36.9

 
$
43.9

Fair value of investments in a loss position less than 12 months
$
199.4

 
$
168.7

Gross unrealized losses for investments in a loss position 12 months or more
$
0.9

 
$
0.7

Gross unrealized losses for investments in a loss position less than 12 months
$
2.2

 
$
0.8



The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at June 30, 2018 or at December 31, 2017.

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As
a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of June 30, 2018 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange losses, net in the Condensed Consolidated Statements of Income.

The following is a summary of our forward foreign exchange contracts (in millions):
 
June 30,
 
2018
Contracts maturing in July through September 2018 to sell foreign currency:
 
Notional value
$
37.8

Unrealized loss
$
0.1

Contracts maturing in July through September 2018 to purchase foreign currency:
 
Notional value
$
327.6

Unrealized loss
$
0.5



The estimated fair value of financial instruments that are not recognized at fair value in the Condensed Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which have fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):
 
June 30, 2018
 
December 31, 2017
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
—

 
—

 
 
 
$
91.8

 
$
1,249.4

 
2
Total long-term debt, excluding leases and current maturities
$
423.4

 
$
439.4

 
2
 
$
423.1

 
$
449.8

 
2


We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over 37% of the outstanding voting shares (excluding treasury shares) of Sartorius as of June 30, 2018.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ Board of Directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius.  As of June 30, 2018, due to the adoption of
ASU 2016-01 and ASU 2018-03, we account for this investment at fair market value as determined at period end by a quoted price on an organized exchange (see Note 1).
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
3. Intangible Assets, Goodwill and Other
 6 Months Ended
Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1, 2018:
 
 
 
 
 
Goodwill
$
234.7

 
$
324.6

 
$
559.3

Accumulated impairment losses
(35.9
)
 
(17.3
)
 
(53.2
)
Goodwill, net
198.8

 
307.3

 
506.1

 
 
 
 
 
 
Divestiture
—

 
(1.4
)
 
(1.4
)
Currency fluctuations
(0.2
)
 
(4.5
)
 
(4.7
)
 
 
 
 
 
 
Balances as of June 30, 2018:
 
 
 
 
 
Goodwill
234.5

 
318.7

 
553.2

Accumulated impairment losses
(35.9
)
 
(17.3
)
 
(53.2
)
Goodwill, net
$
198.6

 
$
301.4

 
$
500.0



In March 2018, we wrote off $1.4 million of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line.

Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
 
June 30, 2018
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-7
 
$
89.6

 
$
(65.7
)
 
$
23.9

Know how
1-8
 
192.3

 
(158.6
)
 
33.7

Developed product technology
3-11
 
131.8

 
(74.2
)
 
57.6

Licenses
1-11
 
76.4

 
(38.5
)
 
37.9

Tradenames
3-6
 
3.9

 
(3.2
)
 
0.7

Covenants not to compete
1-8
 
7.9

 
(3.7
)
 
4.2

     Total definite-lived intangible assets
 
 
$
501.9

 
$
(343.9
)
 
$
158.0


 
December 31, 2017
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-7
 
$
92.3

 
$
(64.4
)
 
$
27.9

Know how
1-8
 
194.9

 
(157.9
)
 
37.0

Developed product technology
1-12
 
133.3

 
(70.3
)
 
63.0

Licenses
1-12
 
76.7

 
(36.0
)
 
40.7

Tradenames
1-6
 
3.9

 
(3.0
)
 
0.9

Covenants not to compete
1-8
 
7.9

 
(3.3
)
 
4.6

     Total definite-lived intangible assets
 
 
$
509.0

 
$
(334.9
)
 
$
174.1



Amortization expense related to purchased intangible assets is as follows (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
Amortization expense
$
7.4

 
$
8.7

 
$
14.8

 
$
15.6
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
4. Supplemental Cash Flow Information (Notes)
 6 Months Ended
Jun. 30, 2018
Supplemental Cash Flow Elements [Abstract]  
Cash Flow, Supplemental Disclosures [Text Block] SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
Six Months Ended
 
June 30, 2018
 
June 30, 2017
Net income
$
924.8

 
$
17.4

Adjustments to reconcile net income to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
68.7

 
70.7

Share-based compensation
12.1

 
10.6

Losses on dispositions of securities
0.6

 
0.3

Changes in fair market value of equity securities
(1,102.3
)
 
—

Gain on divestiture of a product line
(5.1
)
 
—

Losses on dispositions of fixed assets
0.8

 
—

Gain on sale of land
(4.1
)
 
—

Changes in fair value of contingent consideration
(2.4
)
 
(8.7
)
Decrease (increase) in accounts receivable
52.5

 
(1.8
)
Increase in inventories
(11.7
)
 
(37.9
)
Increase in other current assets
(5.9
)
 
(14.8
)
Decrease in accounts payable and other current liabilities
(43.7
)
 
(24.2
)
Decrease in income taxes payable
(20.9
)
 
(13.2
)
Increase (decrease) in deferred income taxes
246.2

 
(3.1
)
Net increase in other long-term assets/liabilities
8.6

 
11.0

Net cash provided by operating activities
$
118.2

 
$
6.3
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
5. Long-Term Debt
 6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Long-term Debt LONG-TERM DEBT

The principal components of long-term debt are as follows (in millions):

 
June 30,
2018
 
December 31,
2017
4.875% Senior Notes due 2020 principal amount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(1.6
)
 
(1.9
)
4.875% Senior Notes less unamortized discount and debt issuance costs
423.4

 
423.1

Capital leases and other debt
17.1

 
11.9

 
440.5

 
435.0

Less current maturities
(1.7
)
 
(0.4
)
Long-term debt
$
438.8

 
$
434.6




Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due 2020 (4.875% Notes).  The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%.  The 4.875% Notes pay a fixed rate of interest of 4.875% per year.  We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.

Credit Agreement

In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of June 30, 2018 or December 31, 2017, however $0.5 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of June 30, 2018. The Credit Agreement matures in June 2019. If we had borrowed against our Credit Agreement, the borrowing rate would have been 3.46% at June 30, 2018.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of June 30, 2018.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Notes)
 6 Months Ended
Jun. 30, 2018
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Stockholders' Equity Note Disclosure [Text Block] .    ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total accumulated other comprehensive income
Balances as of January 1, 2018*:
$
77.4

$
(22.3
)
$
4.5

$
59.6

Other comprehensive (loss) income, before reclassifications
(77.6
)
0.5

(2.1
)
(79.2
)
Amounts reclassified from Accumulated other comprehensive income
—

0.8

0.2

1.0

Income tax effects
—

(0.1
)
—

(0.1
)
Other comprehensive (loss) income, net of income taxes
(77.6
)
1.2

(1.9
)
(78.3
)
Balances as of June 30, 2018:
$
(0.2
)
$
(21.1
)
$
2.6

$
(18.7
)

 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total accumulated other comprehensive income
Balances as of January 1, 2017:
$
1.3

$
(18.6
)
$
435.0

$
417.7

Other comprehensive income (loss), before reclassifications
60.5

(2.5
)
213.2

271.2

Amounts reclassified from Accumulated other comprehensive income
—

—

—

—

Income tax effects
—

0.5

(78.5
)
(78.0
)
Other comprehensive income (loss), net of income taxes
60.5

(2.0
)
134.7

193.2

Balances as of June 30, 2017:
$
61.8

$
(20.6
)
$
569.7

$
610.9



*The beginning balance has been updated as a result of adopting ASU 2016-01. See Note 1, "Basis of Presentation and Use of Estimates" under "Recent Accounting Standards Updates."

The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows:

 
Income before taxes impact (in millions):
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
 
June 30,
 
June 30,
 
 
Components of Comprehensive income
 
2018
 
2017
 
2018
 
2017
 
Location
Amortization of foreign other post-employment benefit items
 
$
(0.5
)
 
$
0.2

 
$
(0.8
)
 
$
—

 
Other (income) expense, net
Net holding (losses) gains on equity securities and available-for-sale investments
 
$
(0.1
)
 
$
(0.2
)
 
$
(0.2
)
 
$
—

 
Other (income) expense, net

Reclassification adjustments are calculated using the specific identification method.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
7. Earnings Per Share
 6 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
Earnings Per Share .    EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
Basic weighted average shares outstanding
29,814

 
29,613

 
29,801

 
29,597

Effect of potentially dilutive stock options and restricted stock awards
405

 
393

 
396

 
365

Diluted weighted average common shares
30,219

 
30,006

 
30,197

 
29,962

Anti-dilutive shares
13

 
—

 
13

 
15
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
8. Other Income and Expenses
 6 Months Ended
Jun. 30, 2018
Other Income and Expenses [Abstract]  
Other Income and Other Expense Disclosure .    OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
Interest and investment income
$
(16.2
)
 
$
(12.0
)
 
$
(18.3
)
 
$
(13.1
)
Net realized loss (gain) on investments
0.1

 
0.2

 
0.2

 
(0.1
)
Gain on sale of land
—

 
—

 
(4.1
)
 
—

Gain on divestiture of product line
—

 
—

 
(5.1
)
 
—

Other expense
0.2

 
0.4

 
0.3

 
0.8

Other (income) expense, net
$
(15.9
)
 
$
(11.4
)
 
$
(27.0
)
 
$
(12.4
)


Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07).
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
9. Income Taxes
 6 Months Ended
Jun. 30, 2018
Income Tax Disclosure [Abstract]  
Income Taxes .    INCOME TAXES
 
Our effective income tax rate was 21% and (350)% for the three months ended June 30, 2018 and 2017, respectively. Our effective income tax rate was 23% and 18% for the six months ended June 30, 2018 and 2017, respectively. The effective tax rate for the three and six months ended June 30, 2018 was driven primarily by the large gain on equity investments taxable at the U.S. federal statutory rate of 21%. The effective tax rate for the three and six months ended June 30, 2017 was lower than the U.S. federal statutory rate of 35% due to the impact of second quarter discrete items on low pre-tax income.

In accordance with SAB 118, our accounting for the following elements of the Tax Act was incomplete at December 31, 2017. However, we were able to make reasonable estimates of certain effects and, therefore, recorded provisional estimates as follows:

•
Our deferred tax assets and liabilities were measured at the enacted tax rate that will apply when these temporary differences are expected to be realized or settled.

•
The Tax Act imposes a Transition Tax payable over eight years. The Transition Tax is assessed on the U.S. shareholders’ share of certain foreign corporations’ accumulated untaxed foreign earnings. Earnings in the form of cash and cash equivalents are taxed at a rate of 15.5% and all other earnings are taxed at a rate of 8.0%. In December 2017, we recorded a provisional income tax expense of $55 million for Transition Tax.

Our accounting for certain other elements of the Tax Act was incomplete, and we were not able to make reasonable estimates of those effects. For example, we did not make a determination as to our accounting policy with respect to the new Global Intangible Low-Taxed Income ("GILTI"). For the period ended June 30, 2018, we did not record adjustments to our provisional amounts. We will continue our analysis of these provisional amounts during the measurement period and may adjust these estimates as further regulatory guidance becomes available.
 
We assess our ability to realize our net deferred tax assets on a quarterly basis and establish a valuation allowance if it is more-likely-than-not that some portion of the deferred tax assets will not be realized in the foreseeable future. Due to the weight of negative evidence, including our history of losses in certain jurisdictions, we believe that it is more-likely-than-not that certain foreign deferred tax assets will not be realized as of June 30, 2018. Accordingly, we have maintained a valuation allowance on such deferred tax assets.

Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

As of June 30, 2018, based on the expected outcome of certain examinations or as a result of the expiration of statute of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $3 million. Substantially all such amounts will favorably impact our effective income tax rate.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
10. Segment Information
 6 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
Segment Information EGMENT INFORMATION

Information regarding industry segments for the three months ended June 30, 2018 and 2017 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2018
$
217.8

 
$
354.0

 
$
4.1

 
2017
$
179.4

 
$
322.1

 
$
3.2

 
 
 
 
 
 
 
Segment net profit (loss)
2018
$
12.2

 
$
27.8

 
$
—

 
2017
$
(22.9
)
 
$
18.5

 
$
0.2


Information regarding industry segments for the six months ended June 30, 2018 and 2017 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2018
$
415.6

 
$
704.8

 
$
7.0

 
2017
$
353.6

 
$
644.4

 
$
6.7

 
 
 
 
 
 
 
Segment net profit (loss)
2018
$
15.5

 
$
64.4

 
$
—

 
2017
$
(41.7
)
 
$
60.1

 
$
0.4



Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits).

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance.  Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. For the three and six months ended June 30, 2018 compared to the same periods in 2017, our Life Science segment had increased sales and gross profit, along with lower Research and Development expense. In addition, the Life Science segment gross margin included a $10.0 million one-time expense associated with the RainDance acquisition in the first quarter of 2017. During the second quarter of 2017, our Clinical Diagnostics segment had an asset purchase for an early stage device for $7.5 million that was recorded in Research and development expense. The following reconciles total segment profit to consolidated income before taxes (in millions):
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
Total segment profit (loss)
$
40.0

 
$
(4.2
)
 
$
79.9

 
$
18.8

Foreign currency exchange losses, net
—

 
(2.5
)
 
(1.2
)
 
(4.3
)
Net corporate operating, interest and other expense not allocated to segments
(2.2
)
 
(3.6
)
 
(4.2
)
 
(5.6
)
Change in fair market value of equity securities
286.4

 
—

 
1,102.3

 
—

Other income (expense), net
15.9

 
11.4

 
27.0

 
12.4

Consolidated income before income taxes
$
340.1

 
$
1.1

 
$
1,203.8

 
$
21.3


Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits).
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
11. Legal Proceedings
 6 Months Ended
Jun. 30, 2018
Loss Contingency, Information about Litigation Matters [Abstract]  
Legal Proceedings. 11.    LEGAL PROCEEDINGS

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017 we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
12. Restructuring Costs (Notes)
 6 Months Ended
Jun. 30, 2018
Restructuring Costs [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] 12.    RESTRUCTURING COSTS

Restructuring Costs for European Reorganization

In May, 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with the evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. From inception of May 2016 to June 30, 2018, total expenses were $12.9 million. We recorded $(0.1) million of adjustments in restructuring charges related to severance and other employee benefits for the three and six months ended June 30, 2018. The liability of $4.2 million as of June 30, 2018 consisted of $4.1 million recorded in Accrued payroll and employee benefits and $0.1 million recorded in Other long-term liabilities in the Condensed Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $(0.1) million and in Selling, general and administrative expense of less than $(0.1) million in the Condensed Consolidated Statements of Income for the three and six months ended June 30, 2018.

The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):
 
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1, 2018
 
$
2.2

 
$
4.1

 
$
6.3

Charged to expense
 
—

 
—

 
—

Adjustment to expense
 
—

 
(0.1
)
 
(0.1
)
Cash payments
 
(0.6
)
 
(1.3
)
 
(1.9
)
Foreign currency translation gains
 
—

 
(0.1
)
 
(0.1
)
Balance as of June 30, 2018
 
$
1.6

 
$
2.6

 
$
4.2




Restructuring Costs for Termination of a Diagnostics Research and Development Project and a Facility Closure

In December 2017, we announced the termination of a diagnostics research and development project in Europe. From inception of December 2017 to June 30, 2018, total expenses were $20.4 million. We recorded $(0.6) million and $(0.7) million of adjustments in restructuring charges related to severance and employee benefits, and exit costs for the three and six months ended June 30, 2018, respectively. The adjustments were due to a decrease in severance accrual as a result of a reduction in the number of employees being terminated than originally estimated, net of an increase in exit costs accrual as a result of proposed legal settlement. In June 2018, we announced the closure of a manufacturing facility in Germany. As a result, we recorded $1.3 million of expense in restructuring charges related to severance and employee benefits for the three and six months ended June 30, 2018. Restructuring charges for the termination of a diagnostics research and development project and the facility closure are both included in our Clinical Diagnostics segment's results of operations. The respective amounts recorded for the quarter and year to date ended June 30, 2018 were reflected in Cost of goods sold of $1.3 million and $1.3 million, in Selling, general and administrative expense of $(0.3) million and $(0.1) million, and in Research and development expense of $(0.3) million and $(0.6) million in the Condensed Consolidated Statements of Income. The liability of $11.7 million as of June 30, 2018 consisted of $7.2 million recorded in Accrued payroll and employee benefits, $3.2 million recorded in Other current liabilities, and $1.3 million recorded in Other long term liabilities in the Condensed Consolidated Balance Sheets.

The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closure restructuring reserves for severance and exit costs (in millions):

 
 
2018
Balance as of January 1
 
$
14.1

Charged to expense
 
1.3

Adjustment to expense
 
(0.7
)
Cash payments
 
(2.7
)
Foreign currency translation gains
 
(0.3
)
Balance as of June 30
 
$
11.7
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies)
 6 Months Ended
Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
New Accounting Pronouncements, Policy [Policy Text Block] Revenue Recognition
On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018.  Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition."

We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for the six months ended June 30, 2018 was not significant.

The Company recognizes revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or
services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.
Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. Accordingly, in these cases, the delivery of the equipment and the installation are separate performance obligations. The Company will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.
At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products.
Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation.
In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.
We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

Reagent Rental Agreements
Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. The Company has concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, the Company first allocates the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned.
For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the
arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.
Revenue allocated to the lease elements are approximately 5% of total revenue and are included as part of the Net sales in our Condensed Consolidated Statements of Income.
Contract costs:
We apply a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities.
Disaggregation of Revenue:
The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited):
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
 
 
2018
 
2017
 
2018
 
2017
Europe
 
$
197.2

 
$
163.9

 
$
396.8

 
$
348.9

Pacific Rim
 
122.0

 
107.5

 
231.4

 
202.3

United States
 
221.6

 
202.5

 
431.5

 
389.8

Other (primarily Canada and Latin America)
 
35.1

 
30.8

 
67.7

 
63.7

Total Net sales
 
$
575.9

 
$
504.7

 
$
1,127.4

 
$
1,004.7



The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 10).

Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are recognized as (or when) the Company performs under the contract which is generally over time during the term of the service contract. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $36.7 million at December 31, 2017 to $41.4 million at June 30, 2018 is primarily driven by cash payments received or due in advance of satisfying our performance obligations, offset by $22.4 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2017.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):

January 1, 2018
$
18.7

Provision for warranty
14.9

Actual warranty costs
(17.5
)
June 30, 2018
$
16.1



Recent Accounting Pronouncements Adopted

In February 2018, the FASB issued Accounting Standards Update No. ("ASU") 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to Retained earnings as of the beginning of the fiscal year in which the guidance is adopted. We adopted ASU 2018-03 on January 1, 2018 and made an irrevocable election to account for our investment of the ordinary shares of Sartorius AG at fair value (see ASU 2016-01 below).

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. Changes in fair value for equity securities will no longer be reported in other comprehensive income. For equity investments without readily determinable fair values, the cost method is also eliminated. We adopted ASU 2016-01 on January 1, 2018 and record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes and were valued at $0.6 million as of June 30, 2018. Changes in the basis of these equity investments are reported in current earnings. For equity securities that are affected by ASU 2016-01 and ASU 2018-03, see Note 2 to the condensed consolidated financial statements, which primarily consists of our investment in Sartorius AG.

The impact of the adoption of ASU 2016-01 and ASU 2018-03 on January 1, 2018 was through a cumulative-effect adjustment of $864.5 million to Total stockholders' equity by increasing Retained earnings of $1,543.7 million and decreasing Accumulated other comprehensive income of $679.2 million, including increasing Deferred income taxes by $232.9 million and an increase in Other investments of $1,097.4 million in our Condensed Consolidated Balance Sheet. As a result of ASU 2016-01 and ASU 2018-03 for the three and six months ended June 30, 2018, we recorded $286.4 million and $1,102.3 million, respectively, for the Change in fair market value of equity securities in the Condensed Consolidated Statement of Income that resulted in a deferred tax expense for the three and six months ended June 30, 2018 of $62.6 million and $243.8 million, respectively.

In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which changed how we present the net periodic benefit cost of our defined benefit pension and/or other postretirement plans. We adopted ASU 2017-07 on January 1, 2018 and applied the practical expedient to estimate amounts for comparative purposes utilizing the information disclosed in Note 12 to the consolidated financial statements in our Form 10-K for the year ended December 31, 2017. The interest costs are recorded in Interest expense, and the other costs are recorded in Other (income) expense, net in the Condensed Consolidated Statements of Income. For the second quarter of 2017 for interest costs and other costs, we reclassified $0.076 million, $0.538 million, and $0.036 million from Costs of goods sold (COGS), Selling, general and administrative expense (SG&A) and Research and development expense (R&D), respectively, to Interest expense of $0.275 million and Other (income) expense, net of $0.375 million. For the first six months of 2017 for interest costs and other costs, we reclassified $0.152 million, $1.076 million, and $0.072 million from COGS, SG&A and R&D, respectively, to Interest expense of $0.550 million and Other (income) expense, net of $0.750 million.

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash," which required us to cease to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 and updated the Condensed Consolidated Statements of Cash Flows to incorporate restricted cash included in Other current assets and Other assets of $1.1 million as of June 30, 2018 and $1.0 million as of June 30, 2017.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," which required immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  We adopted ASU 2016-16 on January 1, 2018 on a modified retrospective basis through a cumulative-effect adjustment by decreasing Retained earnings by $17.6 million, and decreasing Prepaid taxes by $22.8 million and increasing Deferred tax assets by $5.2 million that are both recorded in Other assets in our Condensed Consolidated Balance Sheet.

In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments" and adopted it on January 1, 2018, which did not have an impact to our statement of cash flows presentation.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASC 606"), an updated standard on revenue recognition. The new standard provides enhancements to the quality and consistency of how revenue is reported under the principle that revenue should be recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the transfer of promised goods or services. We adopted ASC 606 as of January 1, 2018 using the cumulative effect transition method as more fully described above under the caption “Revenue Recognition.”

Recent Accounting Pronouncements to be Adopted

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU 2018-11, "Targeted Improvements," which gives the option to apply the transition provisions of ASU 2016-02 at its adoption date instead of at the earliest comparative period presented in its financial statements. In addition, ASU 2018-11 provides a practical expedient that permits lessors to not separate nonlease components from the associated lease component if certain conditions are met. Also in July 2018, the FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases," which clarifies certain aspects of ASU 2016-02. We will adopt ASU 2016-02 on a modified retrospective basis on its adoption date of January 1, 2019 with practical expedients, instead of at the earliest comparative period presented in our financial statements. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.
Revenue from Contract with Customer [Policy Text Block] Revenue Recognition
On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018.  Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition."

We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for the six months ended June 30, 2018 was not significant.

The Company recognizes revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or
services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.
Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. Accordingly, in these cases, the delivery of the equipment and the installation are separate performance obligations. The Company will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.
At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products.
Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation.
In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.
We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

Reagent Rental Agreements
Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. The Company has concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, the Company first allocates the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned.
For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the
arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.
Revenue allocated to the lease elements are approximately 5% of total revenue and are included as part of the Net sales in our Condensed Consolidated Statements of Income.
Contract costs:
We apply a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities.
Disaggregation of Revenue:
The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited):
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
 
 
2018
 
2017
 
2018
 
2017
Europe
 
$
197.2

 
$
163.9

 
$
396.8

 
$
348.9

Pacific Rim
 
122.0

 
107.5

 
231.4

 
202.3

United States
 
221.6

 
202.5

 
431.5

 
389.8

Other (primarily Canada and Latin America)
 
35.1

 
30.8

 
67.7

 
63.7

Total Net sales
 
$
575.9

 
$
504.7

 
$
1,127.4

 
$
1,004.7



The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 10).

Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are recognized as (or when) the Company performs under the contract which is generally over time during the term of the service contract. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $36.7 million at December 31, 2017 to $41.4 million at June 30, 2018 is primarily driven by cash payments received or due in advance of satisfying our performance obligations, offset by $22.4 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2017.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):

January 1, 2018
$
18.7

Provision for warranty
14.9

Actual warranty costs
(17.5
)
June 30, 2018
$
16.1
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
1. Basis of Presentation and Use of Estimates Schedule of Revenue from External Customers Geographic (Tables)
 6 Months Ended
Jun. 30, 2018
Segment Reporting Information [Line Items]  
Revenue from External Customers by Geographic Areas [Table Text Block] The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited):
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
 
 
2018
 
2017
 
2018
 
2017
Europe
 
$
197.2

 
$
163.9

 
$
396.8

 
$
348.9

Pacific Rim
 
122.0

 
107.5

 
231.4

 
202.3

United States
 
221.6

 
202.5

 
431.5

 
389.8

Other (primarily Canada and Latin America)
 
35.1

 
30.8

 
67.7

 
63.7

Total Net sales
 
$
575.9

 
$
504.7

 
$
1,127.4

 
$
1,004.7
Schedule of Product Warranty Liability [Table Text Block] Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):

January 1, 2018
$
18.7

Provision for warranty
14.9

Actual warranty costs
(17.5
)
June 30, 2018
$
16.1
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
2. Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2018
Fair Value Disclosures [Abstract]  
Debt Securities, Available-for-sale [Table Text Block] Available-for-sale investments consist of the following (in millions):

 
June 30, 2018
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
224.9

 
$
0.1

 
$
(1.4
)
 
$
223.6

Municipal obligations
15.7

 
—

 
(0.1
)
 
15.6

Asset-backed securities
63.1

 
—

 
(0.4
)
 
62.7

U.S. government sponsored agencies
67.2

 
—

 
(1.2
)
 
66.0

Foreign government obligations
2.6

 
—

 
—

 
2.6

 
373.5

 
0.1

 
(3.1
)
 
370.5

Long-term investments:
 
 
 
 
 
 
 
Asset-backed securities
0.2

 
—

 
—

 
0.2

 
0.2

 
—

 
—

 
0.2

Total
$
373.7

 
$
0.1

 
$
(3.1
)
 
$
370.7


The following is a summary of the amortized cost and estimated fair value of our debt securities at June 30, 2018 by contractual maturity date (in millions):
 
Amortized
Cost
 
Estimated Fair
Value
Mature in less than one year
$
156.7

 
$
156.4

Mature in one to five years
170.9

 
169.3

Mature in more than five years
46.1

 
45.0

Total
$
373.7

 
$
370.7
Schedule of financial assets and liabilities carried at fair value on a recurring basis
Financial assets and liabilities carried at fair value and measured on a recurring basis as of June 30, 2018 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
68.4

 
$
—

 
$
68.4

Time deposits
25.7

 
10.0

 
—

 
35.7

Money market funds
30.2

 
—

 
—

 
30.2

Foreign government obligations
—

 
1.8

 
—

 
1.8

U.S. government sponsored agencies
—

 
6.0

 
—

 
6.0

Total cash equivalents (a)
55.9

 
86.2

 
—

 
142.1

Restricted investment
5.6

 
—

 
—

 
5.6

Equity securities (b)
3,196.6

 
—

 
—

 
3,196.6

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
223.6

 
—

 
223.6

U.S. government sponsored agencies
—

 
66.0

 
—

 
66.0

Foreign government obligations
—

 
2.6

 
—

 
2.6

Municipal obligations
—

 
15.6

 
—

 
15.6

Asset-backed securities
—

 
62.9

 
—

 
62.9

Total available-for-sale investments (c)
—

 
370.7

 
—

 
370.7

Forward foreign exchange contracts (d)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
3,258.1

 
$
457.5

 
$
—

 
$
3,715.6

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (e)
$
—

 
$
1.0

 
$
—

 
$
1.0

Contingent consideration (f)
—

 
—

 
13.0

 
13.0

Total financial liabilities carried at fair value
$
—

 
$
1.0

 
$
13.0

 
$
14.0


As of first quarter 2018, our equity securities are no longer reported as Available-for-sale investments due to the implementation of ASU 2016-01. Changes in fair value of equity securities are now reported on the Condensed Consolidated Statements of Income rather than Other Comprehensive Income (see Note 1).
Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2017 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
36.0

 
$
—

 
$
36.0

Time deposits
43.7

 
10.0

 
—

 
53.7

U.S. government sponsored agencies
—

 
11.2

 
—

 
11.2

Money market funds
3.4

 
—

 
—

 
3.4

Total cash equivalents (a)
47.1

 
57.2

 
—

 
104.3

Restricted investment
5.6

 
—

 
—

 
5.6

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
185.7

 
—

 
185.7

U.S. government sponsored agencies
—

 
67.6

 
—

 
67.6

Foreign government obligations
—

 
3.4

 
—

 
3.4

Brokered certificates of deposit
—

 
0.7

 
—

 
0.7

Municipal obligations
—

 
15.0

 
—

 
15.0

Marketable equity securities
973.4

 
—

 
—

 
973.4

Asset-backed securities
—

 
55.6

 
—

 
55.6

Total available-for-sale investments (c)
973.4

 
328.0

 
—

 
1,301.4

Forward foreign exchange contracts (d)
—

 
0.5

 
—

 
0.5

Total financial assets carried at fair value
$
1,026.1

 
$
385.7

 
$
—

 
$
1,411.8

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (e)
$
—

 
$
1.6

 
$
—

 
$
1.6

Contingent consideration (f)
—

 
—

 
16.7

 
16.7

Total financial liabilities carried at fair value
$
—

 
$
1.6

 
$
16.7

 
$
18.3


(a)
Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.

(b)
Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):
 
June 30, 2018
Short-term investments
$
44.7

Other investments
3,151.9

        Total
$
3,196.6



The unrealized gains on our equity securities still held as of June 30, 2018 are $1,102.3 million and are primarily due to our investment in Sartorius AG and is recorded in our Condensed Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Note 1).

(c)Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):
 
June 30, 2018
 
December 31, 2017
Short-term investments
$
370.5

 
$
371.2

Other investments
0.2

 
930.2

Total
$
370.7

 
$
1,301.4



In accordance with our adoption of ASU 2016-01 January 1, 2018, our investment in Sartorius AG preferred shares, which was reported within marketable equity securities as Available-for-sale as of December 31, 2017, is now reported as an Equity security as of June 30, 2018 (see Note 1 and footnote (b) above).

(d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.

(e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.

(f) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):

 
June 30, 2018
 
December 31, 2017
Other current liabilities
$
2.6

 
$
2.7

Other long-term liabilities
10.4

 
14.0

   Total
$
13.0

 
$
16.7
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] The following table provides a reconciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):

January 1, 2018
$
16.7

Analytical flow cytometer platform:
 
Payment of sales milestone
(1.3
)
Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(2.4
)
June 30, 2018
$
13.0
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of June 30, 2018. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
 
 
 
 
Valuation Technique
Unobservable Input
 
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
Discount rate
11.1
%
 
 
Cost of debt
4.8
%
 
 
 
 
Schedule of available-for-sale investments Available-for-sale investments consist of the following (in millions):

 
December 31, 2017
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
185.9

 
$
0.3

 
$
(0.5
)
 
$
185.7

Brokered certificates of deposit
0.7

 
—

 
—

 
0.7

Municipal obligations
15.1

 
—

 
(0.1
)
 
15.0

Asset-backed securities
55.6

 
—

 
(0.2
)
 
55.4

U.S. government sponsored agencies
68.3

 
—

 
(0.7
)
 
67.6

Foreign government obligations
3.4

 
—

 
—

 
3.4

Marketable equity securities
34.4

 
9.0

 
—

 
43.4

 
363.4

 
9.3

 
(1.5
)
 
371.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
875.5

 
—

 
930.0

Asset-backed securities
0.2

 
—

 
—

 
0.2

 
54.7

 
875.5

 
—

 
930.2

Total
$
418.1

 
$
884.8

 
$
(1.5
)
 
$
1,301.4
Summary of fair value of gross unrealized losses for investments with unrealized losses The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):
 
June 30, 2018
 
December 31, 2017
Fair value of investments in a loss position 12 months or more
$
36.9

 
$
43.9

Fair value of investments in a loss position less than 12 months
$
199.4

 
$
168.7

Gross unrealized losses for investments in a loss position 12 months or more
$
0.9

 
$
0.7

Gross unrealized losses for investments in a loss position less than 12 months
$
2.2

 
$
0.8
Discussion of current derivative risk management The following is a summary of our forward foreign exchange contracts (in millions):
 
June 30,
 
2018
Contracts maturing in July through September 2018 to sell foreign currency:
 
Notional value
$
37.8

Unrealized loss
$
0.1

Contracts maturing in July through September 2018 to purchase foreign currency:
 
Notional value
$
327.6

Unrealized loss
$
0.5
Estimated fair value of financial instruments
The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):
 
June 30, 2018
 
December 31, 2017
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
—

 
—

 
 
 
$
91.8

 
$
1,249.4

 
2
Total long-term debt, excluding leases and current maturities
$
423.4

 
$
439.4

 
2
 
$
423.1

 
$
449.8

 
2
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
3. Intangible Assets, Goodwill and Other (Tables)
 6 Months Ended
Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes to goodwill by segment Changes to goodwill by segment were as follows (in millions):
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1, 2018:
 
 
 
 
 
Goodwill
$
234.7

 
$
324.6

 
$
559.3

Accumulated impairment losses
(35.9
)
 
(17.3
)
 
(53.2
)
Goodwill, net
198.8

 
307.3

 
506.1

 
 
 
 
 
 
Divestiture
—

 
(1.4
)
 
(1.4
)
Currency fluctuations
(0.2
)
 
(4.5
)
 
(4.7
)
 
 
 
 
 
 
Balances as of June 30, 2018:
 
 
 
 
 
Goodwill
234.5

 
318.7

 
553.2

Accumulated impairment losses
(35.9
)
 
(17.3
)
 
(53.2
)
Goodwill, net
$
198.6

 
$
301.4

 
$
500.0



In March 2018, we wrote off $1.4 million of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line.
Schedule of identifiable purchased intangible assets with definite lives Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
 
June 30, 2018
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-7
 
$
89.6

 
$
(65.7
)
 
$
23.9

Know how
1-8
 
192.3

 
(158.6
)
 
33.7

Developed product technology
3-11
 
131.8

 
(74.2
)
 
57.6

Licenses
1-11
 
76.4

 
(38.5
)
 
37.9

Tradenames
3-6
 
3.9

 
(3.2
)
 
0.7

Covenants not to compete
1-8
 
7.9

 
(3.7
)
 
4.2

     Total definite-lived intangible assets
 
 
$
501.9

 
$
(343.9
)
 
$
158.0


 
December 31, 2017
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-7
 
$
92.3

 
$
(64.4
)
 
$
27.9

Know how
1-8
 
194.9

 
(157.9
)
 
37.0

Developed product technology
1-12
 
133.3

 
(70.3
)
 
63.0

Licenses
1-12
 
76.7

 
(36.0
)
 
40.7

Tradenames
1-6
 
3.9

 
(3.0
)
 
0.9

Covenants not to compete
1-8
 
7.9

 
(3.3
)
 
4.6

     Total definite-lived intangible assets
 
 
$
509.0

 
$
(334.9
)
 
$
174.1
Finite-lived Intangible Assets Amortization Expense [Table Text Block] Amortization expense related to purchased intangible assets is as follows (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
Amortization expense
$
7.4

 
$
8.7

 
$
14.8

 
$
15.6
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure (Tables)
 6 Months Ended
Jun. 30, 2018
Supplemental Cash Flow Elements [Abstract]  
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
Six Months Ended
 
June 30, 2018
 
June 30, 2017
Net income
$
924.8

 
$
17.4

Adjustments to reconcile net income to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
68.7

 
70.7

Share-based compensation
12.1

 
10.6

Losses on dispositions of securities
0.6

 
0.3

Changes in fair market value of equity securities
(1,102.3
)
 
—

Gain on divestiture of a product line
(5.1
)
 
—

Losses on dispositions of fixed assets
0.8

 
—

Gain on sale of land
(4.1
)
 
—

Changes in fair value of contingent consideration
(2.4
)
 
(8.7
)
Decrease (increase) in accounts receivable
52.5

 
(1.8
)
Increase in inventories
(11.7
)
 
(37.9
)
Increase in other current assets
(5.9
)
 
(14.8
)
Decrease in accounts payable and other current liabilities
(43.7
)
 
(24.2
)
Decrease in income taxes payable
(20.9
)
 
(13.2
)
Increase (decrease) in deferred income taxes
246.2

 
(3.1
)
Net increase in other long-term assets/liabilities
8.6

 
11.0

Net cash provided by operating activities
$
118.2

 
$
6.3
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
5. Long-Term Debt (Tables)
 6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments [Table Text Block] The principal components of long-term debt are as follows (in millions):

 
June 30,
2018
 
December 31,
2017
4.875% Senior Notes due 2020 principal amount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(1.6
)
 
(1.9
)
4.875% Senior Notes less unamortized discount and debt issuance costs
423.4

 
423.1

Capital leases and other debt
17.1

 
11.9

 
440.5

 
435.0

Less current maturities
(1.7
)
 
(0.4
)
Long-term debt
$
438.8

 
$
434.6
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables)
 6 Months Ended
Jun. 30, 2018
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total accumulated other comprehensive income
Balances as of January 1, 2018*:
$
77.4

$
(22.3
)
$
4.5

$
59.6

Other comprehensive (loss) income, before reclassifications
(77.6
)
0.5

(2.1
)
(79.2
)
Amounts reclassified from Accumulated other comprehensive income
—

0.8

0.2

1.0

Income tax effects
—

(0.1
)
—

(0.1
)
Other comprehensive (loss) income, net of income taxes
(77.6
)
1.2

(1.9
)
(78.3
)
Balances as of June 30, 2018:
$
(0.2
)
$
(21.1
)
$
2.6

$
(18.7
)

 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total accumulated other comprehensive income
Balances as of January 1, 2017:
$
1.3

$
(18.6
)
$
435.0

$
417.7

Other comprehensive income (loss), before reclassifications
60.5

(2.5
)
213.2

271.2

Amounts reclassified from Accumulated other comprehensive income
—

—

—

—

Income tax effects
—

0.5

(78.5
)
(78.0
)
Other comprehensive income (loss), net of income taxes
60.5

(2.0
)
134.7

193.2

Balances as of June 30, 2017:
$
61.8

$
(20.6
)
$
569.7

$
610.9
Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block] The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows:

 
Income before taxes impact (in millions):
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
 
June 30,
 
June 30,
 
 
Components of Comprehensive income
 
2018
 
2017
 
2018
 
2017
 
Location
Amortization of foreign other post-employment benefit items
 
$
(0.5
)
 
$
0.2

 
$
(0.8
)
 
$
—

 
Other (income) expense, net
Net holding (losses) gains on equity securities and available-for-sale investments
 
$
(0.1
)
 
$
(0.2
)
 
$
(0.2
)
 
$
—

 
Other (income) expense, net

Reclassification adjustments are calculated using the specific identification method.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
7. Earnings Per Share (Tables)
 6 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
Basic weighted average shares outstanding
29,814

 
29,613

 
29,801

 
29,597

Effect of potentially dilutive stock options and restricted stock awards
405

 
393

 
396

 
365

Diluted weighted average common shares
30,219

 
30,006

 
30,197

 
29,962

Anti-dilutive shares
13

 
—

 
13

 
15
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
8. Other Income and Expenses (Tables)
 6 Months Ended
Jun. 30, 2018
Other Income and Expenses [Abstract]  
Schedule of other income (expense), net Other (income) expense, net includes the following components (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
Interest and investment income
$
(16.2
)
 
$
(12.0
)
 
$
(18.3
)
 
$
(13.1
)
Net realized loss (gain) on investments
0.1

 
0.2

 
0.2

 
(0.1
)
Gain on sale of land
—

 
—

 
(4.1
)
 
—

Gain on divestiture of product line
—

 
—

 
(5.1
)
 
—

Other expense
0.2

 
0.4

 
0.3

 
0.8

Other (income) expense, net
$
(15.9
)
 
$
(11.4
)
 
$
(27.0
)
 
$
(12.4
)
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
10. Segment Information (Tables)
 6 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
Net sales Information regarding industry segments for the three months ended June 30, 2018 and 2017 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2018
$
217.8

 
$
354.0

 
$
4.1

 
2017
$
179.4

 
$
322.1

 
$
3.2

 
 
 
 
 
 
 
Segment net profit (loss)
2018
$
12.2

 
$
27.8

 
$
—

 
2017
$
(22.9
)
 
$
18.5

 
$
0.2


Information regarding industry segments for the six months ended June 30, 2018 and 2017 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2018
$
415.6

 
$
704.8

 
$
7.0

 
2017
$
353.6

 
$
644.4

 
$
6.7

 
 
 
 
 
 
 
Segment net profit (loss)
2018
$
15.5

 
$
64.4

 
$
—

 
2017
$
(41.7
)
 
$
60.1

 
$
0.4



Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits).
Reconciliation of segment profit to consolidated income before taxes The following reconciles total segment profit to consolidated income before taxes (in millions):
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
Total segment profit (loss)
$
40.0

 
$
(4.2
)
 
$
79.9

 
$
18.8

Foreign currency exchange losses, net
—

 
(2.5
)
 
(1.2
)
 
(4.3
)
Net corporate operating, interest and other expense not allocated to segments
(2.2
)
 
(3.6
)
 
(4.2
)
 
(5.6
)
Change in fair market value of equity securities
286.4

 
—

 
1,102.3

 
—

Other income (expense), net
15.9

 
11.4

 
27.0

 
12.4

Consolidated income before income taxes
$
340.1

 
$
1.1

 
$
1,203.8

 
$
21.3


Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits).
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
12. Restructuring Costs (Tables)
 6 Months Ended
Jun. 30, 2018
Restructuring Cost and Reserve [Line Items]  
Restructuring and Related Costs [Table Text Block] The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closure restructuring reserves for severance and exit costs (in millions):

 
 
2018
Balance as of January 1
 
$
14.1

Charged to expense
 
1.3

Adjustment to expense
 
(0.7
)
Cash payments
 
(2.7
)
Foreign currency translation gains
 
(0.3
)
Balance as of June 30
 
$
11.7

The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):
 
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1, 2018
 
$
2.2

 
$
4.1

 
$
6.3

Charged to expense
 
—

 
—

 
—

Adjustment to expense
 
—

 
(0.1
)
 
(0.1
)
Cash payments
 
(0.6
)
 
(1.3
)
 
(1.9
)
Foreign currency translation gains
 
—

 
(0.1
)
 
(0.1
)
Balance as of June 30, 2018
 
$
1.6

 
$
2.6

 
$
4.2
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Jan. 01, 2018
Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Net sales $ 575,911 $ 504,666 $ 1,127,430 $ 1,004,717    
Cost of goods sold 274,244 231,291 523,560 461,279    
Deferred Revenue 41,400   41,400     $ 36,700
Revenue, Net 22,400          
Retained earnings 4,281,275   4,281,275     1,830,439
Accumulated other comprehensive income (18,710)   (18,710)     738,794
Total stockholders' equity 4,638,946   $ 4,638,946     2,930,250
Revenue Allocation Percent To Lease Elements     5.00%      
Additional paid-in-capital 376,595   $ 376,595     $ 361,231
Unrealized Gain on Securities 286,398 0 1,102,332 0    
Selling, general and administrative expense 210,425 212,489 419,555 406,891    
Research and Development Expense 47,450 62,587 96,877 112,039    
Interest expense 5,977 6,045 11,759 11,361    
Prepaid Taxes         $ (22,800)  
Deferred Tax Assets, Net, Noncurrent         5,200  
Accounting Standards Update 2014-09 [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Retained earnings         100  
Accounting Standards Update 2016-01 [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Other Investments 600   600      
Accumulated other comprehensive income         679,200  
Adjustments for New Accounting Pronouncement [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Investments         1,097,400  
Deferred Income Tax Expense (Benefit) 62,600   243,800      
Cost of goods sold   (76)   (152)    
Retained earnings         1,543,700  
Deferred Income Tax Assets, Net         232,900  
Total stockholders' equity         864,500  
Unrealized Gain on Securities 286,400   1,102,300      
Selling, general and administrative expense   (538)   (1,076)    
Research and Development Expense   (36)   (72)    
Interest expense   275   550    
Other Nonoperating Income (Expense)   375   750    
Restricted Cash 1,100 1,000 1,100 1,000    
Accounting Standards Update 2016-16 [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Retained earnings         $ (17,600)  
Europe [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Net sales 197,200 163,900 396,800 348,900    
Asia Pacific [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Net sales 122,000 107,500 231,400 202,300    
UNITED STATES            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Net sales 221,600 202,500 431,500 389,800    
Americas [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Net sales $ 35,100 $ 30,800 $ 67,700 $ 63,700    
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details)
$ in Millions
 6 Months Ended
Jun. 30, 2018
USD ($)
Accounting Policies [Abstract]  
Warranty accrual, beginning of period $ 18.7
Provision for warranty 14.9
Actual warranty costs (17.5)
Warranty accrual, end of period $ 16.1
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
2. Fair Value Measurements Fair Value Level Table (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Unrealized Gain on Securities $ 1,102.3  
Debt Securities, Available-for-sale 370.7  
Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 5.6 $ 5.6
Available-for-sale Securities [1]   1,301.4
Equity Securities [1] 3,196.6  
Debt Securities, Available-for-sale [1] 370.7  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [2] 0.6 0.5
Assets, Fair Value Disclosure 3,715.6 1,411.8
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [3] 1.0 1.6
Business Combination, Contingent Consideration, Liability [4] 13.0 16.7
Liabilities, Fair Value Disclosure 14.0 18.3
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 5.6 5.6
Available-for-sale Securities [1]   973.4
Equity Securities [1] 3,196.6  
Debt Securities, Available-for-sale [1] 0.0  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [2] 0.0 0.0
Assets, Fair Value Disclosure 3,258.1 1,026.1
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [3] 0.0 0.0
Business Combination, Contingent Consideration, Liability [4] 0.0 0.0
Liabilities, Fair Value Disclosure 0.0 0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 0.0 0.0
Available-for-sale Securities [1]   328.0
Equity Securities [1] 0.0  
Debt Securities, Available-for-sale [1] 370.7  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [2] 0.6 0.5
Assets, Fair Value Disclosure 457.5 385.7
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [3] 1.0 1.6
Business Combination, Contingent Consideration, Liability [4] 0.0 0.0
Liabilities, Fair Value Disclosure 1.0 1.6
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 0.0 0.0
Available-for-sale Securities [1]   0.0
Equity Securities [1] 0.0  
Debt Securities, Available-for-sale [1] 0.0  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [2] 0.0 0.0
Assets, Fair Value Disclosure 0.0 0.0
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [3] 0.0 0.0
Business Combination, Contingent Consideration, Liability [4] 13.0 16.7
Liabilities, Fair Value Disclosure 13.0 16.7
US Treasury Securities [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 6.0  
US Treasury Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0  
US Treasury Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 6.0  
US Treasury Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0  
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5]   11.2
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5]   0.0
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5]   11.2
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5]   0.0
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 68.4 36.0
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0 0.0
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 68.4 36.0
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0 0.0
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 1.8  
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0  
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 1.8  
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0  
Time Deposits [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 35.7 53.7
Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 25.7 43.7
Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 10.0 10.0
Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0 0.0
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 30.2 3.4
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 30.2 3.4
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0 0.0
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0 0.0
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 142.1 104.3
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 55.9 47.1
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 86.2 57.2
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0 0.0
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.7
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.7
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   973.4
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   973.4
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   15.0
Debt Securities, Available-for-sale [1] 15.6  
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale [1] 0.0  
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   15.0
Debt Securities, Available-for-sale [1] 15.6  
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale [1] 0.0  
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   3.4
Debt Securities, Available-for-sale [1] 2.6  
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale [1] 0.0  
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   3.4
Debt Securities, Available-for-sale [1] 2.6  
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale [1] 0.0  
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   185.7
Debt Securities, Available-for-sale [1] 223.6  
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale [1] 0.0  
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   185.7
Debt Securities, Available-for-sale [1] 223.6  
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale [1] 0.0  
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   67.6
Debt Securities, Available-for-sale [1] 66.0  
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale [1] 0.0  
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   67.6
Debt Securities, Available-for-sale [1] 66.0  
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale [1] 0.0  
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   55.6
Debt Securities, Available-for-sale [1] 62.9  
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale [1] 0.0  
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   55.6
Debt Securities, Available-for-sale [1] 62.9  
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale [1] 0.0  
Other Current Liabilities [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability 2.6 2.7
Other Noncurrent Liabilities [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability 10.4 14.0
Short-term Investments [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   371.2
Equity Securities 44.7  
Debt Securities, Available-for-sale 370.5  
Short-term Investments [Member] | Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   0.7
Short-term Investments [Member] | Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   43.4
Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   15.0
Debt Securities, Available-for-sale 15.6  
Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   3.4
Debt Securities, Available-for-sale 2.6  
Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   185.7
Debt Securities, Available-for-sale 223.6  
Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   67.6
Debt Securities, Available-for-sale 66.0  
Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   55.4
Debt Securities, Available-for-sale 62.7  
Other Investments [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   $ 930.2
Equity Securities 3,151.9  
Debt Securities, Available-for-sale 0.2  
Analytical Flow Cytometer Platform [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability 13.0  
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low $ 0.0  
[1] Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):
 
June 30, 2018
 
December 31, 2017
Short-term investments
$
370.5

 
$
371.2

Other investments
0.2

 
930.2

Total
$
370.7

 
$
1,301.4
[2] Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.
[3] Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.
[4] Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):

 
June 30, 2018
 
December 31, 2017
Other current liabilities
$
2.6

 
$
2.7

Other long-term liabilities
10.4

 
14.0

   Total
$
13.0

 
$
16.7
[5] Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
2. Fair Value Measurements 2. Contingent Consideration (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 19 Months Ended
Jun. 30, 2018
Jun. 30, 2018
Jun. 30, 2018
Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 13.0 $ 13.0 $ 13.0 $ 16.7
Analytical Flow Cytometer Platform [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent consideration milestone payments (1.3) (1.3)    
Business Combination, Contingent Consideration, Liability $ 13.0 13.0 13.0  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances   $ (2.4) $ (8.5)  
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Acquisition, Contingent Consideration, Potential Percentage Payout 39.00% 39.00% 39.00%  
Market Price of Risk [Member] | Analytical Flow Cytometer Platform [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Discount Rate   11.10%    
Projected Volatility of Growth Rate [Member] | Analytical Flow Cytometer Platform [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Discount Rate   4.80%    
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Acquisition, Contingent Consideration, Potential Percentage Payout 20.00% 20.00% 20.00%  
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low $ 0.0 $ 0.0 $ 0.0  
Fair Value, Measurements, Recurring [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Combination, Contingent Consideration, Liability [1] 13.0 13.0 13.0 16.7
Other Noncurrent Liabilities [Member] | Fair Value, Measurements, Recurring [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Combination, Contingent Consideration, Liability 10.4 10.4 10.4 14.0
Other Current Liabilities [Member] | Fair Value, Measurements, Recurring [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Combination, Contingent Consideration, Liability $ 2.6 $ 2.6 $ 2.6 $ 2.7
[1] Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):

 
June 30, 2018
 
December 31, 2017
Other current liabilities
$
2.6

 
$
2.7

Other long-term liabilities
10.4

 
14.0

   Total
$
13.0

 
$
16.7
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
2. Foreign Exchange Forward Contracts (Details)
$ in Millions
 6 Months Ended
Jun. 30, 2018
USD ($)
Forward foreign exchange contract to sell foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Notional value $ 37.8
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments (0.1)
Forward foreign exchange contract to purchase foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Notional value 327.6
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments $ (0.5)
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
2. Available-for-Sale Investments (Details) - USD ($)
$ in Millions
Jun. 30, 2018
Dec. 31, 2017
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 373.7  
Estimated Fair Value 370.7  
Fair Value, Measurements, Recurring [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities [1]   $ 1,301.4
Amortized Cost 373.7  
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.1  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (3.1)  
Estimated Fair Value [1] 370.7  
Available-for-sale Securities, Amortized Cost Basis   418.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   884.8
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   1.5
Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities [1]   185.7
Estimated Fair Value [1] 223.6  
Fair Value, Measurements, Recurring [Member] | Brokered certificates of deposit [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities [1]   0.7
Fair Value, Measurements, Recurring [Member] | Municipal obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities [1]   15.0
Estimated Fair Value [1] 15.6  
Fair Value, Measurements, Recurring [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities [1]   55.6
Estimated Fair Value [1] 62.9  
Fair Value, Measurements, Recurring [Member] | Marketable Equity Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities [1]   973.4
Fair Value, Measurements, Recurring [Member] | US Government Sponsored Agencies [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities [1]   67.6
Estimated Fair Value [1] 66.0  
Fair Value, Measurements, Recurring [Member] | Foreign Government Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities [1]   3.4
Estimated Fair Value [1] 2.6  
Fair Value, Measurements, Recurring [Member] | Other Long-term Investments [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   0.2
Amortized Cost 0.2  
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0  
Estimated Fair Value 0.2  
Available-for-sale Securities, Amortized Cost Basis   0.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.0
Fair Value, Measurements, Recurring [Member] | Other Long-term Investments [Member] | Marketable Equity Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   930.0
Available-for-sale Securities, Amortized Cost Basis   54.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   875.5
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.0
Fair Value, Measurements, Recurring [Member] | Other Long-term Investments [Member] | Available-for-sale Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   930.2
Available-for-sale Securities, Amortized Cost Basis   54.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   875.5
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.0
Fair Value, Measurements, Recurring [Member] | Other Long-term Investments [Member] | Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 0.2  
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0  
Estimated Fair Value 0.2  
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   371.2
Estimated Fair Value 370.5  
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Corporate Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   185.7
Amortized Cost 224.9  
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.1  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (1.4)  
Estimated Fair Value 223.6  
Available-for-sale Securities, Amortized Cost Basis   185.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.3
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.5
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Brokered certificates of deposit [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   0.7
Available-for-sale Securities, Amortized Cost Basis   0.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.0
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Municipal obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   15.0
Amortized Cost 15.7  
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.1)  
Estimated Fair Value 15.6  
Available-for-sale Securities, Amortized Cost Basis   15.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.1
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   55.4
Amortized Cost 63.1  
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.4)  
Estimated Fair Value 62.7  
Available-for-sale Securities, Amortized Cost Basis   55.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.2
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Marketable Equity Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   43.4
Available-for-sale Securities, Amortized Cost Basis   34.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   9.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.0
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Available-for-sale Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   371.2
Available-for-sale Securities, Amortized Cost Basis   363.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   9.3
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   1.5
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | US Government Sponsored Agencies [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   67.6
Amortized Cost 67.2  
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (1.2)  
Estimated Fair Value 66.0  
Available-for-sale Securities, Amortized Cost Basis   68.3
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.7
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Foreign Government Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   3.4
Amortized Cost 2.6  
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0  
Estimated Fair Value 2.6  
Available-for-sale Securities, Amortized Cost Basis   3.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.0
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 373.5  
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.1  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (3.1)  
Estimated Fair Value 370.5  
Fair Value, Measurements, Recurring [Member] | Other Investments [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   $ 930.2
Estimated Fair Value $ 0.2  
[1] Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):
 
June 30, 2018
 
December 31, 2017
Short-term investments
$
370.5

 
$
371.2

Other investments
0.2

 
930.2

Total
$
370.7

 
$
1,301.4
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
2. Amortized Cost and Fair Value of Debt Securities (Details)
$ in Millions
Jun. 30, 2018
USD ($)
Fair Value Disclosures [Abstract]  
Mature in less than one year $ 156.7
Mature in one to five years 170.9
Mature in more than five years 46.1
Total Amortized Cost 373.7
Mature in less than one year 156.4
Mature in one to five years 169.3
Mature in more than five years 45.0
Estimated Fair Value $ 370.7
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Price Change Debt Security 5.00%  
Tolerable variance Level 2 debt security pricing 1.00%  
Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more $ 36.9 $ 43.9
Cost Method Investment, Percentage Owned 37.00%  
Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months $ 199.4 168.7
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss 0.9  
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss   0.7
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $ 2.2  
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss   $ 0.8
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
2. Fair Value Financial Instruments (Details) - USD ($)
$ in Millions
Jun. 30, 2018
Dec. 31, 2017
Carrying (Reported) Amount, Fair Value Disclosure [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Other Investments   $ 91.8
Total long-term debt, excluding capital leases and current maturities $ 423.4 423.1
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Other Investments   1,249.4
Total long-term debt, excluding capital leases and current maturities $ 439.4 $ 449.8
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
3. Intangible Assets, Goodwill and Other (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Mar. 31, 2018
Jun. 30, 2018
Dec. 31, 2017
Goodwill [Line Items]      
Goodwill   $ 553,200 $ 559,300
Accumulated impairment loss   (53,200) (53,200)
Goodwill, net   500,022 506,069
Goodwill, Written off Related to Sale of Business Unit   (1,400)  
Currency fluctuations   (4,700)  
Life Science [Member]      
Goodwill [Line Items]      
Goodwill   234,500 234,700
Accumulated impairment loss   (35,900) (35,900)
Goodwill, net   198,600 198,800
Goodwill, Written off Related to Sale of Business Unit   0  
Currency fluctuations   (200)  
Clinical Diagnostics [Member]      
Goodwill [Line Items]      
Goodwill   318,700 324,600
Accumulated impairment loss   (17,300) (17,300)
Goodwill, net   301,400 $ 307,300
Goodwill, Written off Related to Sale of Business Unit $ (1,400) (1,400)  
Currency fluctuations   $ (4,500)  
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
3. Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 501.9   $ 501.9   $ 509.0
Accumulated Amortization (343.9)   (343.9)   (334.9)
Net Carrying Amount 158.0   158.0   174.1
Amortization [Abstract]          
Amortization expense 7.4 $ 8.7 14.8 $ 15.6  
Customer Relationships [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price 89.6   89.6   92.3
Accumulated Amortization (65.7)   (65.7)   (64.4)
Net Carrying Amount 23.9   23.9   27.9
Know how [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price 192.3   192.3   194.9
Accumulated Amortization (158.6)   (158.6)   (157.9)
Net Carrying Amount 33.7   33.7   37.0
Developed Technology Rights [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price 131.8   131.8   133.3
Accumulated Amortization (74.2)   (74.2)   (70.3)
Net Carrying Amount 57.6   57.6   63.0
Licensing Agreements [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price 76.4   76.4   76.7
Accumulated Amortization (38.5)   (38.5)   (36.0)
Net Carrying Amount 37.9   37.9   40.7
Trade Names [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price 3.9   3.9   3.9
Accumulated Amortization (3.2)   (3.2)   (3.0)
Net Carrying Amount 0.7   0.7   0.9
Noncompete Agreements [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price 7.9   7.9   7.9
Accumulated Amortization (3.7)   (3.7)   (3.3)
Net Carrying Amount $ 4.2   $ 4.2   $ 4.6
Minimum [Member] | Customer Relationships [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     1 year 1 year  
Minimum [Member] | Know how [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     1 year 1 year  
Minimum [Member] | Developed Technology Rights [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     3 years 1 year  
Minimum [Member] | Licensing Agreements [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     1 year 1 year  
Minimum [Member] | Trade Names [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     3 years 1 year  
Minimum [Member] | Noncompete Agreements [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     1 year 1 year  
Minimum [Member] | Other Intangible Assets [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     0 years 0 years  
Maximum [Member] | Customer Relationships [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     7 years 7 years  
Maximum [Member] | Know how [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     8 years 8 years  
Maximum [Member] | Developed Technology Rights [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     11 years 12 years  
Maximum [Member] | Licensing Agreements [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     11 years 12 years  
Maximum [Member] | Trade Names [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     6 years 6 years  
Maximum [Member] | Noncompete Agreements [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     8 years 8 years  
Maximum [Member] | Other Intangible Assets [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     0 years 0 years  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
4. Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Supplemental Cash Flow Elements [Abstract]        
Net Income (Loss) Attributable to Parent $ 268,043 $ 5,035 $ 924,817 $ 17,448
Depreciation and Amortization     68,700 70,700
Share-based Compensation     12,100 10,600
Loss on Sale of Securities, Net     600 300
Changes in fair market value of equity securities     (1,102,300) 0
Gain on divestiture of a product line     (5,100) 0
Loss on Disposition of Property Plant Equipment     800 0
Gain on sale of land $ 0 $ 0 (4,100) 0
Changes in fair value of contingent consideration     (2,400) (8,700)
Decrease (increase) in accounts receivable     52,500 (1,800)
Increase in inventories     (11,700) (37,900)
Increase in other current assets     (5,900) (14,800)
Decrease in accounts payable and other current liabilities     (43,700) (24,200)
Decrease in Income Taxes Payable     (20,900) (13,200)
Increase (Decrease) in Deferred Income Taxes     246,200 (3,100)
Net increase in other long-term assets/liabilities     8,600 11,000
Net cash provided by operating activities     $ 118,208 $ 6,297
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
5. Long-Term Debt (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Dec. 31, 2010
Debt Instrument [Line Items]      
Debt and Capital Lease Obligations $ 440,500 $ 435,000  
Less Current Maturities (1,700) (400)  
Long-term debt, net of current maturities 438,776 434,581  
Unsecured Debt [Member] | Senior Notes 4.875% due 2020 [Member]      
Debt Instrument [Line Items]      
Unsecured Debt 425,000 425,000  
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $ 1,600 1,900  
Debt Instrument, Interest Rate, Stated Percentage     4.875%
Debt Instrument, Redemption Price, Percentage 100.00%    
Long-term debt $ 423,400 423,100 $ 422,600
Debt Instrument, Interest Rate, Effective Percentage     4.946%
Face amount of debt sold     $ 425,000
Capital Lease Obligations [Member] | Capital Leases and Other Debt [Member]      
Debt Instrument [Line Items]      
Long-term Debt and Capital Lease Obligations, Including Current Maturities 17,100 $ 11,900  
Line of Credit [Member]      
Debt Instrument [Line Items]      
Line of credit maximum borrowing capacity 200,000    
Outstanding borrowings $ 0    
Line of Credit Facility, Interest Rate at Period End 3.46%    
Standby Letters of Credit [Member]      
Debt Instrument [Line Items]      
Line of credit maximum borrowing capacity $ 500    
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     $ 738,794  
Total other comprehensive income (loss) net of tax $ (122,795) $ 94,305 (78,247) $ 193,182
Ending balance, Accumulated other comprehensive income (18,710)   (18,710)  
Accumulated Translation Adjustment [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     77,400 1,300
Other Comprehensive Income (Loss), before Reclassifications, before Tax     (77,600) 60,500
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     0 0
Other Comprehensive Income (Loss), Tax     0 0
Total other comprehensive income (loss) net of tax     (77,600) 60,500
Ending balance, Accumulated other comprehensive income (200) 61,800 (200) 61,800
Accumulated Defined Benefit Plans Adjustment [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     (22,300) (18,600)
Other Comprehensive Income (Loss), before Reclassifications, before Tax     500 (2,500)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     800 0
Other Comprehensive Income (Loss), Tax     (100) 500
Total other comprehensive income (loss) net of tax     1,200 (2,000)
Ending balance, Accumulated other comprehensive income (21,100) (20,600) (21,100) (20,600)
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Other (income) expense, net (500) 200 (800) 0
Accumulated Net Unrealized Investment Gain (Loss) [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     4,500 435,000
Other Comprehensive Income (Loss), before Reclassifications, before Tax     (2,100) 213,200
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     200 0
Other Comprehensive Income (Loss), Tax     0 (78,500)
Total other comprehensive income (loss) net of tax     (1,900) 134,700
Ending balance, Accumulated other comprehensive income 2,600 569,700 2,600 569,700
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Other (income) expense, net 100 200 200 0
Parent [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     59,600 417,700
Other Comprehensive Income (Loss), before Reclassifications, before Tax     (79,200) 271,200
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     1,000 0
Other Comprehensive Income (Loss), Tax     (100) (78,000)
Total other comprehensive income (loss) net of tax     (78,300) 193,200
Ending balance, Accumulated other comprehensive income $ (18,700) $ 610,900 $ (18,700) $ 610,900
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
7. Earnings Per Share (Details) - shares
shares in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Basic weighted average shares outstanding 29,814 29,613 29,801 29,597
Effect of potentially dilutive stock options and restricted stock awards 405 393 396 365
Diluted weighted average common shares 30,219 30,006 30,197 29,962
Anti-dilutive shares 13 0 13 15
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
8. Other Income and Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Interest and investment income $ (16,200) $ (12,000) $ (18,300) $ (13,100)
Net realized loss (gain) on investments 100 200 200 (100)
Gain on sale of land 0 0 (4,100) 0
Gain on divestiture of a product line 0 0 (5,100) 0
Other Nonoperating Expense 200 400 300 800
Nonoperating Income (Expense) $ (15,858) $ (11,382) $ (27,003) $ (12,425)
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
9. Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Jan. 01, 2018
Effective tax rate 21.00% (350.00%) 23.00% 18.00%    
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent     21.00%      
Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)         $ 55.0  
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit $ 3.0   $ 3.0      
U.S. Federal [Member]            
Statutory Rates       35.00%    
Adjustments for New Accounting Pronouncement [Member]            
Deferred Income Tax Assets, Net           $ 232.9
Deferred Income Tax Expense (Benefit) $ 62.6   $ 243.8      
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
10. Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Segment Reporting Information [Line Items]        
Net sales $ 575,911 $ 504,666 $ 1,127,430 $ 1,004,717
Income before income taxes 340,086 1,120 1,203,775 21,267
Life Science [Member]        
Segment Reporting Information [Line Items]        
Net sales 217,800 179,400 415,600 353,600
Income before income taxes 12,200 (22,900) 15,500 (41,700)
Clinical Diagnostics [Member]        
Segment Reporting Information [Line Items]        
Net sales 354,000 322,100 704,800 644,400
Income before income taxes 27,800 18,500 64,400 60,100
All Other Segments [Member]        
Segment Reporting Information [Line Items]        
Net sales 4,100 3,200 7,000 6,700
Income before income taxes $ 0 $ 200 $ 0 $ 400
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
10. Segment Profit Reconciliation (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Mar. 31, 2017
Jun. 30, 2018
Jun. 30, 2017
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Income before income taxes $ 340,086 $ 1,120   $ 1,203,775 $ 21,267
Unrealized Gain on Securities 286,398 0   1,102,332 0
Operating Segments [Member]          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Income before income taxes 40,000 (4,200)   79,900 18,800
Corporate, Non-Segment [Member]          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Income before income taxes (2,200) (3,600)   (4,200) (5,600)
Segment Reconciling Items [Member]          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Unrealized Gain on Securities 286,400 0   1,102,300 0
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Income before income taxes 0 (2,500)   (1,200) (4,300)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Income before income taxes 15,900 11,400   27,000 12,400
Life Science [Member]          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed     $ 10,000    
Income before income taxes 12,200 (22,900)   15,500 (41,700)
Clinical Diagnostics [Member]          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Research and Development Asset Acquired Other than Through Business Combination, Written-off   7,500      
Income before income taxes $ 27,800 $ 18,500   $ 64,400 $ 60,100
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1
11. Legal Proceedings 11. Contingent Liability (Details)
 12 Months Ended
Dec. 31, 2017
USD ($)
Legal Proceedings [Abstract]  
Loss Contingency, Damages Awarded, Value $ 10,920,000
Litigation Settlement Interest $ 141,608
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
12. Restructuring Costs (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 7 Months Ended 26 Months Ended
Jun. 30, 2018
Jun. 30, 2018
Jun. 30, 2018
Jun. 30, 2018
Dec. 31, 2017
European Reorganization [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve $ 4.2 $ 4.2 $ 4.2 $ 4.2 $ 6.3
Restructuring Charges   0.0   12.9  
Restructuring Reserve, Current 4.1 4.1 4.1 4.1  
Restructuring Reserve, Noncurrent 0.1 0.1 0.1 0.1  
Restructuring Reserve, Accrual Adjustment   (0.1)      
Payments for Restructuring   (1.9)      
Restructuring Reserve, Foreign Currency Translation (Gain) Loss   (0.1)      
European Reorganization [Member] | Cost of Goods, Total [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve, Accrual Adjustment   (0.1)      
European Reorganization [Member] | Selling, General and Administrative Expenses [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve, Accrual Adjustment   (0.1)      
European Reorganization [Member] | Life Science [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve 1.6 1.6 1.6 1.6 2.2
Restructuring Charges   0.0      
Restructuring Reserve, Accrual Adjustment   0.0      
Payments for Restructuring   (0.6)      
Restructuring Reserve, Foreign Currency Translation (Gain) Loss   0.0      
European Reorganization [Member] | Clinical Diagnostics [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve 2.6 2.6 2.6 2.6 4.1
Restructuring Charges   0.0      
Restructuring Reserve, Accrual Adjustment   (0.1)      
Payments for Restructuring   (1.3)      
Restructuring Reserve, Foreign Currency Translation (Gain) Loss   (0.1)      
Termination of a Diagnostics Research and Development Project [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Charges     20.4    
Restructuring Reserve, Accrual Adjustment (0.6) (0.7)      
Facility Closing [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Charges   1.3      
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve 11.7 11.7 11.7 11.7 $ 14.1
Restructuring Charges   1.3      
Restructuring Reserve, Accrual Adjustment   (0.7)      
Payments for Restructuring   (2.7)      
Restructuring Reserve, Foreign Currency Translation (Gain) Loss   (0.3)      
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Cost of Goods, Total [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Charges 1.3 1.3      
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Selling, General and Administrative Expenses [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve, Accrual Adjustment (0.3) (0.1)      
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Research and Development Expense [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve, Accrual Adjustment (0.3) (0.6)      
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Accounts Payable and Accrued Liabilities [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve, Current 7.2 7.2 7.2 7.2  
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Other Current Liabilities [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve, Current 3.2 3.2 3.2 3.2  
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Other Noncurrent Liabilities [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve, Noncurrent $ 1.3 $ 1.3 $ 1.3 $ 1.3  
EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

0?DZ)K MH$/6]"F[TO7U734'V\O9_J^^ &5]]/U:2KZ8O3>!>LUMI^$G&L.&DGM?\J68 MU0D:?:M1,8OF3CV"5&FG,@/5'">L8,(*)*R#WZ<&H&P3$;.R1_\N$Q%&D]Q#J:1.E?%_S$F16/F/*)F!/E\PWB R7O1T)5:1<:= M19@NQ3H9R?CDAW 0PW1F(L#SO6AP7NZS*DR60IFA2,7PHL# JJ!B(@3&-%,C M^AH#DR%B>GV-4#=HN+Y\8;H4ZTC4,\Q.9D(:V("&JUD>:3?W0&%*".G+C\'- M$+F]M@6,%<)W7Y L[66GJYH@%AN&4

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

  •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end XML 63 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 338 252 1 true 84 0 false 4 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.bio-rad.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets Parenthetical Sheet http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets Parenthetical Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 2101100 - Disclosure - 1. Organization, Consolidation and Presentation of Financial Statements Sheet http://www.bio-rad.com/role/A1OrganizationConsolidationAndPresentationOfFinancialStatements 1. Organization, Consolidation and Presentation of Financial Statements Notes 7 false false R8.htm 2103100 - Disclosure - 2. Fair Value Measurements Sheet http://www.bio-rad.com/role/A2FairValueMeasurements 2. Fair Value Measurements Notes 8 false false R9.htm 2104100 - Disclosure - 3. Intangible Assets, Goodwill and Other Sheet http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOther 3. Intangible Assets, Goodwill and Other Notes 9 false false R10.htm 2107100 - Disclosure - 4. Supplemental Cash Flow Information (Notes) Notes http://www.bio-rad.com/role/A4SupplementalCashFlowInformationNotes 4. Supplemental Cash Flow Information (Notes) Notes 10 false false R11.htm 2109100 - Disclosure - 5. Long-Term Debt Sheet http://www.bio-rad.com/role/A5LongTermDebt 5. Long-Term Debt Notes 11 false false R12.htm 2110100 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Notes) Notes http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeNotes 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Notes) Notes 12 false false R13.htm 2112100 - Disclosure - 7. Earnings Per Share Sheet http://www.bio-rad.com/role/A7EarningsPerShare 7. Earnings Per Share Notes 13 false false R14.htm 2113100 - Disclosure - 8. Other Income and Expenses Sheet http://www.bio-rad.com/role/A8OtherIncomeAndExpenses 8. Other Income and Expenses Notes 14 false false R15.htm 2114100 - Disclosure - 9. Income Taxes Sheet http://www.bio-rad.com/role/A9IncomeTaxes 9. Income Taxes Notes 15 false false R16.htm 2115100 - Disclosure - 10. Segment Information Sheet http://www.bio-rad.com/role/A10SegmentInformation 10. Segment Information Notes 16 false false R17.htm 2116100 - Disclosure - 11. Legal Proceedings Sheet http://www.bio-rad.com/role/A11LegalProceedings 11. Legal Proceedings Notes 17 false false R18.htm 2118100 - Disclosure - 12. Restructuring Costs (Notes) Notes http://www.bio-rad.com/role/A12RestructuringCostsNotes 12. Restructuring Costs (Notes) Notes 18 false false R19.htm 2201201 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies) Sheet http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsPolicies 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies) Policies 19 false false R20.htm 2301302 - Disclosure - 1. Basis of Presentation and Use of Estimates Schedule of Revenue from External Customers Geographic (Tables) Sheet http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables 1. Basis of Presentation and Use of Estimates Schedule of Revenue from External Customers Geographic (Tables) Tables 20 false false R21.htm 2303301 - Disclosure - 2. Fair Value Measurements (Tables) Sheet http://www.bio-rad.com/role/A2FairValueMeasurementsTables 2. Fair Value Measurements (Tables) Tables http://www.bio-rad.com/role/A2FairValueMeasurements 21 false false R22.htm 2304301 - Disclosure - 3. Intangible Assets, Goodwill and Other (Tables) Sheet http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherTables 3. Intangible Assets, Goodwill and Other (Tables) Tables http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOther 22 false false R23.htm 2307301 - Disclosure - 4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure (Tables) Sheet http://www.bio-rad.com/role/A4SupplementalCashFlowInformationCashFlowSupplementalDisclosureTables 4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure (Tables) Tables 23 false false R24.htm 2309301 - Disclosure - 5. Long-Term Debt (Tables) Sheet http://www.bio-rad.com/role/A5LongTermDebtTables 5. Long-Term Debt (Tables) Tables http://www.bio-rad.com/role/A5LongTermDebt 24 false false R25.htm 2310301 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables) Sheet http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables) Tables http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeNotes 25 false false R26.htm 2312301 - Disclosure - 7. Earnings Per Share (Tables) Sheet http://www.bio-rad.com/role/A7EarningsPerShareTables 7. Earnings Per Share (Tables) Tables http://www.bio-rad.com/role/A7EarningsPerShare 26 false false R27.htm 2313301 - Disclosure - 8. Other Income and Expenses (Tables) Sheet http://www.bio-rad.com/role/A8OtherIncomeAndExpensesTables 8. Other Income and Expenses (Tables) Tables http://www.bio-rad.com/role/A8OtherIncomeAndExpenses 27 false false R28.htm 2315301 - Disclosure - 10. Segment Information (Tables) Sheet http://www.bio-rad.com/role/A10SegmentInformationTables 10. Segment Information (Tables) Tables http://www.bio-rad.com/role/A10SegmentInformation 28 false false R29.htm 2318301 - Disclosure - 12. Restructuring Costs (Tables) Sheet http://www.bio-rad.com/role/A12RestructuringCostsTables 12. Restructuring Costs (Tables) Tables http://www.bio-rad.com/role/A12RestructuringCostsNotes 29 false false R30.htm 2401403 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) Sheet http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) Details http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsPolicies 30 false false R31.htm 2401404 - Disclosure - 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) Sheet http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesWarrantyRollforwardDetails 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) Details 31 false false R32.htm 2403402 - Disclosure - 2. Fair Value Measurements Fair Value Level Table (Details) Sheet http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails 2. Fair Value Measurements Fair Value Level Table (Details) Details 32 false false R33.htm 2403403 - Disclosure - 2. Fair Value Measurements 2. Contingent Consideration (Details) Sheet http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails 2. Fair Value Measurements 2. Contingent Consideration (Details) Details 33 false false R34.htm 2403404 - Disclosure - 2. Foreign Exchange Forward Contracts (Details) Sheet http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails 2. Foreign Exchange Forward Contracts (Details) Details 34 false false R35.htm 2403405 - Disclosure - 2. Available-for-Sale Investments (Details) Sheet http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails 2. Available-for-Sale Investments (Details) Details 35 false false R36.htm 2403406 - Disclosure - 2. Amortized Cost and Fair Value of Debt Securities (Details) Sheet http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails 2. Amortized Cost and Fair Value of Debt Securities (Details) Details 36 false false R37.htm 2403407 - Disclosure - 2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Sheet http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails 2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Details 37 false false R38.htm 2403408 - Disclosure - 2. Fair Value Financial Instruments (Details) Sheet http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails 2. Fair Value Financial Instruments (Details) Details 38 false false R39.htm 2404402 - Disclosure - 3. Intangible Assets, Goodwill and Other (Details) Sheet http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails 3. Intangible Assets, Goodwill and Other (Details) Details http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherTables 39 false false R40.htm 2404403 - Disclosure - 3. Intangible Assets, Goodwill and Other Intangible Assets (Details) Sheet http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails 3. Intangible Assets, Goodwill and Other Intangible Assets (Details) Details 40 false false R41.htm 2407402 - Disclosure - 4. Supplemental Cash Flow Information (Details) Sheet http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails 4. Supplemental Cash Flow Information (Details) Details http://www.bio-rad.com/role/A4SupplementalCashFlowInformationCashFlowSupplementalDisclosureTables 41 false false R42.htm 2409402 - Disclosure - 5. Long-Term Debt (Details) Sheet http://www.bio-rad.com/role/A5LongTermDebtDetails 5. Long-Term Debt (Details) Details http://www.bio-rad.com/role/A5LongTermDebtTables 42 false false R43.htm 2410402 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details) Sheet http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details) Details http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables 43 false false R44.htm 2412402 - Disclosure - 7. Earnings Per Share (Details) Sheet http://www.bio-rad.com/role/A7EarningsPerShareDetails 7. Earnings Per Share (Details) Details http://www.bio-rad.com/role/A7EarningsPerShareTables 44 false false R45.htm 2413402 - Disclosure - 8. Other Income and Expenses (Details) Sheet http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails 8. Other Income and Expenses (Details) Details http://www.bio-rad.com/role/A8OtherIncomeAndExpensesTables 45 false false R46.htm 2414401 - Disclosure - 9. Income Taxes (Details) Sheet http://www.bio-rad.com/role/A9IncomeTaxesDetails 9. Income Taxes (Details) Details http://www.bio-rad.com/role/A9IncomeTaxes 46 false false R47.htm 2415402 - Disclosure - 10. Segment Information (Details) Sheet http://www.bio-rad.com/role/A10SegmentInformationDetails 10. Segment Information (Details) Details http://www.bio-rad.com/role/A10SegmentInformationTables 47 false false R48.htm 2415403 - Disclosure - 10. Segment Profit Reconciliation (Details) Sheet http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails 10. Segment Profit Reconciliation (Details) Details 48 false false R49.htm 2416401 - Disclosure - 11. Legal Proceedings 11. Contingent Liability (Details) Sheet http://www.bio-rad.com/role/A11LegalProceedings11ContingentLiabilityDetails 11. Legal Proceedings 11. Contingent Liability (Details) Details 49 false false R50.htm 2418402 - Disclosure - 12. Restructuring Costs (Details) Sheet http://www.bio-rad.com/role/A12RestructuringCostsDetails 12. Restructuring Costs (Details) Details http://www.bio-rad.com/role/A12RestructuringCostsTables 50 false false All Reports Book All Reports a10q63018.htm bio-20180630.xsd bio-20180630_cal.xml bio-20180630_def.xml bio-20180630_lab.xml bio-20180630_pre.xml ex31163018.htm ex31263018.htm ex32163018.htm ex32263018.htm http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true JSON 68 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a10q63018.htm": { "axisCustom": 1, "axisStandard": 22, "contextCount": 338, "dts": { "calculationLink": { "local": [ "bio-20180630_cal.xml" ] }, "definitionLink": { "local": [ "bio-20180630_def.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml" ] }, "inline": { "local": [ "a10q63018.htm" ] }, "labelLink": { "local": [ "bio-20180630_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "bio-20180630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml" ] }, "schema": { "local": [ "bio-20180630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" ] } }, "elementCount": 473, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 43, "http://xbrl.sec.gov/dei/2018-01-31": 7, "total": 50 }, "keyCustom": 9, "keyStandard": 243, "memberCustom": 19, "memberStandard": 63, "nsprefix": "bio", "nsuri": "http://www.bio-rad.com/20180630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://www.bio-rad.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - 4. Supplemental Cash Flow Information (Notes)", "role": "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationNotes", "shortName": "4. Supplemental Cash Flow Information (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - 5. Long-Term Debt", "role": "http://www.bio-rad.com/role/A5LongTermDebt", "shortName": "5. Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Notes)", "role": "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeNotes", "shortName": "6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - 7. Earnings Per Share", "role": "http://www.bio-rad.com/role/A7EarningsPerShare", "shortName": "7. Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - 8. Other Income and Expenses", "role": "http://www.bio-rad.com/role/A8OtherIncomeAndExpenses", "shortName": "8. Other Income and Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - 9. Income Taxes", "role": "http://www.bio-rad.com/role/A9IncomeTaxes", "shortName": "9. Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - 10. Segment Information", "role": "http://www.bio-rad.com/role/A10SegmentInformation", "shortName": "10. Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - 11. Legal Proceedings", "role": "http://www.bio-rad.com/role/A11LegalProceedings", "shortName": "11. Legal Proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - 12. Restructuring Costs (Notes)", "role": "http://www.bio-rad.com/role/A12RestructuringCostsNotes", "shortName": "12. Restructuring Costs (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies)", "role": "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsPolicies", "shortName": "1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2018Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - 1. Basis of Presentation and Use of Estimates Schedule of Revenue from External Customers Geographic (Tables)", "role": "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables", "shortName": "1. Basis of Presentation and Use of Estimates Schedule of Revenue from External Customers Geographic (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - 2. Fair Value Measurements (Tables)", "role": "http://www.bio-rad.com/role/A2FairValueMeasurementsTables", "shortName": "2. Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - 3. Intangible Assets, Goodwill and Other (Tables)", "role": "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherTables", "shortName": "3. Intangible Assets, Goodwill and Other (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - 4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure (Tables)", "role": "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationCashFlowSupplementalDisclosureTables", "shortName": "4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - 5. Long-Term Debt (Tables)", "role": "http://www.bio-rad.com/role/A5LongTermDebtTables", "shortName": "5. Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables)", "role": "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables", "shortName": "6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - 7. Earnings Per Share (Tables)", "role": "http://www.bio-rad.com/role/A7EarningsPerShareTables", "shortName": "7. Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - 8. Other Income and Expenses (Tables)", "role": "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesTables", "shortName": "8. Other Income and Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - 10. Segment Information (Tables)", "role": "http://www.bio-rad.com/role/A10SegmentInformationTables", "shortName": "10. Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318301 - Disclosure - 12. Restructuring Costs (Tables)", "role": "http://www.bio-rad.com/role/A12RestructuringCostsTables", "shortName": "12. Restructuring Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets Parenthetical", "role": "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets Parenthetical", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details)", "role": "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "shortName": "1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "lang": null, "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details)", "role": "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesWarrantyRollforwardDetails", "shortName": "1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - 2. Fair Value Measurements Fair Value Level Table (Details)", "role": "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "shortName": "2. Fair Value Measurements Fair Value Level Table (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - 2. Fair Value Measurements 2. Contingent Consideration (Details)", "role": "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "shortName": "2. Fair Value Measurements 2. Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_bio_ForwardforeignexchangecontracttosellforeigncurrencyMember", "decimals": "-5", "first": true, "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - 2. Foreign Exchange Forward Contracts (Details)", "role": "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails", "shortName": "2. Foreign Exchange Forward Contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_bio_ForwardforeignexchangecontracttosellforeigncurrencyMember", "decimals": "-5", "first": true, "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403405 - Disclosure - 2. Available-for-Sale Investments (Details)", "role": "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "shortName": "2. Available-for-Sale Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403406 - Disclosure - 2. Amortized Cost and Fair Value of Debt Securities (Details)", "role": "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails", "shortName": "2. Amortized Cost and Fair Value of Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": "2", "first": true, "lang": null, "name": "bio:PriceChangeDebtSecurity", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403407 - Disclosure - 2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "role": "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "shortName": "2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": "2", "first": true, "lang": null, "name": "bio:PriceChangeDebtSecurity", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403408 - Disclosure - 2. Fair Value Financial Instruments (Details)", "role": "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails", "shortName": "2. Fair Value Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - 3. Intangible Assets, Goodwill and Other (Details)", "role": "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails", "shortName": "3. Intangible Assets, Goodwill and Other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited)", "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "-3", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - 3. Intangible Assets, Goodwill and Other Intangible Assets (Details)", "role": "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "shortName": "3. Intangible Assets, Goodwill and Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - 4. Supplemental Cash Flow Information (Details)", "role": "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails", "shortName": "4. Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": "-5", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - 5. Long-Term Debt (Details)", "role": "http://www.bio-rad.com/role/A5LongTermDebtDetails", "shortName": "5. Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - 6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details)", "role": "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "shortName": "6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - 7. Earnings Per Share (Details)", "role": "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "shortName": "7. Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - 8. Other Income and Expenses (Details)", "role": "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails", "shortName": "8. Other Income and Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414401 - Disclosure - 9. Income Taxes (Details)", "role": "http://www.bio-rad.com/role/A9IncomeTaxesDetails", "shortName": "9. Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - 10. Segment Information (Details)", "role": "http://www.bio-rad.com/role/A10SegmentInformationDetails", "shortName": "10. Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2QTD_us-gaap_StatementBusinessSegmentsAxis_bio_LifeScienceMember", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - 10. Segment Profit Reconciliation (Details)", "role": "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails", "shortName": "10. Segment Profit Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-5", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416401 - Disclosure - 11. Legal Proceedings 11. Contingent Liability (Details)", "role": "http://www.bio-rad.com/role/A11LegalProceedings11ContingentLiabilityDetails", "shortName": "11. Legal Proceedings 11. Contingent Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q2QTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2_us-gaap_RestructuringPlanAxis_bio_EuropeanReorganizationMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418402 - Disclosure - 12. Restructuring Costs (Details)", "role": "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "shortName": "12. Restructuring Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_RestructuringPlanAxis_bio_EuropeanReorganizationMember", "decimals": "-5", "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - 1. Organization, Consolidation and Presentation of Financial Statements", "role": "http://www.bio-rad.com/role/A1OrganizationConsolidationAndPresentationOfFinancialStatements", "shortName": "1. Organization, Consolidation and Presentation of Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - 2. Fair Value Measurements", "role": "http://www.bio-rad.com/role/A2FairValueMeasurements", "shortName": "2. Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - 3. Intangible Assets, Goodwill and Other", "role": "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOther", "shortName": "3. Intangible Assets, Goodwill and Other", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 84, "tag": { "bio_AnalyticalFlowCytometerPlatformMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Analytical Flow Cytometer Platform", "label": "Analytical Flow Cytometer Platform [Member]", "terseLabel": "Analytical Flow Cytometer Platform [Member]" } } }, "localname": "AnalyticalFlowCytometerPlatformMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "bio_BusinessAcquisitionContingentConsiderationPotentialPercentagePayout": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "business acquisition contingent consideration percentage payout", "label": "Business Acquisition, Contingent Consideration, Potential Percentage Payout", "terseLabel": "Business Acquisition, Contingent Consideration, Potential Percentage Payout" } } }, "localname": "BusinessAcquisitionContingentConsiderationPotentialPercentagePayout", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "bio_CapitalLeasesandOtherDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capital Leases and Other Debt [Member]", "label": "Capital Leases and Other Debt [Member]", "terseLabel": "Capital Leases and Other Debt [Member]" } } }, "localname": "CapitalLeasesandOtherDebtMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_ClinicalDiagnosticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Clinical Diagnostics [Member]", "label": "Clinical Diagnostics [Member]", "terseLabel": "Clinical Diagnostics [Member]" } } }, "localname": "ClinicalDiagnosticsMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationDetails", "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_DiscountRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Discount Rate", "label": "Discount Rate", "terseLabel": "Discount Rate" } } }, "localname": "DiscountRate", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "bio_DocumentAndEntityInformationParentheticalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information (Parenthetical) [Abstract]", "label": "Document and Entity Information (Parenthetical) [Abstract]" } } }, "localname": "DocumentAndEntityInformationParentheticalAbstract", "nsuri": "http://www.bio-rad.com/20180630", "xbrltype": "stringItemType" }, "bio_EuropeanReorganizationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "European Reorganization [Member]", "label": "European Reorganization [Member]", "terseLabel": "European Reorganization [Member]" } } }, "localname": "EuropeanReorganizationMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward foreign exchange contract to purchase foreign currency [Member]", "label": "Forward foreign exchange contract to purchase foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to purchase foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_ForwardforeignexchangecontracttosellforeigncurrencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward foreign exchange contract to sell foreign currency [Member]", "label": "Forward foreign exchange contract to sell foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to sell foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttosellforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_Investmentownershippercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investment ownership percentage", "label": "Investment ownership percentage", "terseLabel": "Cost Method Investment, Percentage Owned" } } }, "localname": "Investmentownershippercentage", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_KnowHowMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Know how [Member]", "label": "Know How [Member]", "terseLabel": "Know how [Member]" } } }, "localname": "KnowHowMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_LegalProceedingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Legal Proceedings [Abstract]" } } }, "localname": "LegalProceedingsAbstract", "nsuri": "http://www.bio-rad.com/20180630", "xbrltype": "stringItemType" }, "bio_LifeScienceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Life Sciences [Member]", "label": "Life Science [Member]", "terseLabel": "Life Science [Member]" } } }, "localname": "LifeScienceMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationDetails", "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_MarketPriceOfRiskMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Market Price of Risk [Member]", "label": "Market Price of Risk [Member]", "terseLabel": "Market Price of Risk [Member]" } } }, "localname": "MarketPriceOfRiskMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_Paymentsforproceedsfromderivativeinstrumentsoperatingactivities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments for (proceeds from) derivative instruments, operating activities", "label": "Payments for (proceeds from) derivative instruments, operating activities", "negatedTerseLabel": "Proceeds from (payments for) forward foreign exchange contracts, net" } } }, "localname": "Paymentsforproceedsfromderivativeinstrumentsoperatingactivities", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bio_PriceChangeDebtSecurity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price Change Debt Security", "label": "Price Change Debt Security", "terseLabel": "Price Change Debt Security" } } }, "localname": "PriceChangeDebtSecurity", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_ProjectedVolatilityOfSalesMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Projected Volatility of Sales [Member]", "label": "Projected Volatility of Sales [Member] [Member]", "terseLabel": "Projected Volatility of Growth Rate [Member]" } } }, "localname": "ProjectedVolatilityOfSalesMemberMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_RevenueAllocationPercentToLeaseElements": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue Allocation Percent To Lease Elements", "label": "Revenue Allocation Percent To Lease Elements", "terseLabel": "Revenue Allocation Percent To Lease Elements" } } }, "localname": "RevenueAllocationPercentToLeaseElements", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "percentItemType" }, "bio_SalesmilestoneminimumamountMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone minimum amount [Member]", "label": "Sales milestone minimum amount [Member]", "terseLabel": "Sales milestone minimum amount [Member]" } } }, "localname": "SalesmilestoneminimumamountMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone percentage of annual invoices [Member]", "label": "Sales milestone percentage of annual invoices [Member]", "terseLabel": "Sales milestone percentage of annual invoices [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoicesMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoiceslowMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone percentage of annual invoices low [Member]", "label": "Sales milestone percentage of annual invoices low [Member]", "terseLabel": "Sales milestone percentage of annual invoices low [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoiceslowMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SartoriusAGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sartorius AG [Member]", "label": "Sartorius AG [Member]", "terseLabel": "Sartorius AG [Member]" } } }, "localname": "SartoriusAGMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_ScheduleofRevenuebyGeographicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Revenue by Geographic [Abstract]", "label": "Schedule of Revenue by Geographic [Abstract]" } } }, "localname": "ScheduleofRevenuebyGeographicAbstract", "nsuri": "http://www.bio-rad.com/20180630", "xbrltype": "stringItemType" }, "bio_SeniorNotes4.875due2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 4.875% [Member]", "label": "Senior Notes 4.875% due 2020 [Member]", "terseLabel": "Senior Notes 4.875% due 2020 [Member]" } } }, "localname": "SeniorNotes4.875due2020Member", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_StatutoryRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statutory Rate [Axis]", "label": "Statutory Rate [Axis]", "terseLabel": "Statutory Rate [Axis]" } } }, "localname": "StatutoryRateAxis", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "bio_StatutoryRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statutory Rate [Domain]", "label": "Statutory Rate [Domain]", "terseLabel": "Statutory Rate [Domain]" } } }, "localname": "StatutoryRateDomain", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_StatutoryRates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statutory Rates", "label": "Statutory Rates", "terseLabel": "Statutory Rates" } } }, "localname": "StatutoryRates", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "bio_TaxCutsandJobsActIncompleteAccountingProvisionalIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)", "terseLabel": "Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)" } } }, "localname": "TaxCutsandJobsActIncompleteAccountingProvisionalIncomeTaxExpenseBenefit", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_TerminationofaDiagnosticsResearchandDevelopmentProjectMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of a Diagnostics Research and Development Project [Member]", "label": "Termination of a Diagnostics Research and Development Project [Member]", "terseLabel": "Termination of a Diagnostics Research and Development Project [Member]" } } }, "localname": "TerminationofaDiagnosticsResearchandDevelopmentProjectMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "bio_TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]", "label": "Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]", "terseLabel": "Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]" } } }, "localname": "TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "bio_TolerablevarianceLevel2debtsecuritypricing": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tolerable variance Level 2 debt security pricing", "label": "Tolerable variance Level 2 debt security pricing", "terseLabel": "Tolerable variance Level 2 debt security pricing" } } }, "localname": "TolerablevarianceLevel2debtsecuritypricing", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_TreasuryClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Class A [Member]", "label": "Treasury Class-A [Member]", "terseLabel": "Treasury Class A [Member]" } } }, "localname": "TreasuryClassAMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "domainItemType" }, "bio_TreasuryClassBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Class B [Member]", "label": "Treasury Class B [Member]", "terseLabel": "Treasury Class B [Member]" } } }, "localname": "TreasuryClassBMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "domainItemType" }, "bio_USFederalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "U.S. Federal [Member]", "label": "U.S. Federal [Member]", "terseLabel": "U.S. Federal [Member]" } } }, "localname": "USFederalMember", "nsuri": "http://www.bio-rad.com/20180630", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r409" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r409" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r409" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "invest_DerivativeNotionalAmount": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.", "label": "Derivative, Notional Amount", "terseLabel": "Notional value" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "invest_InvestmentHoldingAxis": { "auth_ref": [ "r410" ], "lang": { "en-US": { "role": { "documentation": "For an investments table in which there is more than one holding of the same investment instrument, this axis contains the members of that categorization.", "label": "Investment Holding [Axis]", "terseLabel": "Investment Holding [Axis]" } } }, "localname": "InvestmentHoldingAxis", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "invest_InvestmentHoldingDomain": { "auth_ref": [ "r410" ], "lang": { "en-US": { "role": { "documentation": "For an investments table in which investments are categorized by issuer (company, investee) this axis contains the members of that categorization.", "label": "Investment Holding [Domain]", "terseLabel": "Investment Holding [Domain]" } } }, "localname": "InvestmentHoldingDomain", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Americas [Member]", "terseLabel": "Americas [Member]" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific [Member]" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r147", "r156" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables", "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables", "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r159", "r254", "r256", "r405", "r407" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09 [Member]" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201601Member": { "auth_ref": [ "r337" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.", "label": "Accounting Standards Update 2016-01 [Member]", "terseLabel": "Accounting Standards Update 2016-01 [Member]" } } }, "localname": "AccountingStandardsUpdate201601Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201616Member": { "auth_ref": [ "r275", "r276" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.", "label": "Accounting Standards Update 2016-16 [Member]", "terseLabel": "Accounting Standards Update 2016-16 [Member]" } } }, "localname": "AccountingStandardsUpdate201616Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable, accrued payroll and employee benefits" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities [Member]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r27", "r255" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r12", "r14", "r42" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r61", "r67", "r68", "r262", "r300" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Defined Benefit Plans Adjustment [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r36", "r209" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r58", "r59", "r60", "r67", "r68" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Accumulated Net Unrealized Investment Gain (Loss) [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r64", "r66", "r67" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Ending balance, Accumulated other comprehensive income", "periodStartLabel": "Beginning balance, Accumulated other comprehensive income", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r63", "r67", "r68", "r300" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r57", "r67", "r68", "r300" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Translation Adjustment [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentForAmortizationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Amortization [Abstract]" } } }, "localname": "AdjustmentForAmortizationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r125" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r140", "r141", "r142", "r143", "r144", "r145" ], "lang": { "en-US": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "All Other Segments [Member]" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r49", "r161" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.", "label": "Allowance for Doubtful Accounts Receivable, Current", "terseLabel": "Allowance for Doubtful Accounts Receivable, Current" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r109", "r196", "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r175", "r260" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed Securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r151", "r359", "r386" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r55" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r321" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets, Fair Value Disclosure" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r167" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r168" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r165" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Total Amortized Cost", "verboseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails", "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Available-for-sale Securities" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r167" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "terseLabel": "Available-for-sale Securities, Amortized Cost Basis" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for twelve months or longer.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value", "terseLabel": "Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value", "terseLabel": "Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r173" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth fiscal year through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r169", "r173", "r377" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r172" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r169", "r172", "r376" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r171" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r169", "r171", "r375" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r163", "r166" ], "calculation": { "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt Securities, Available-for-sale", "totalLabel": "Estimated Fair Value", "verboseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AmortizedCostAndFairValueOfDebtSecuritiesDetails", "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Schedule of available-for-sale investments" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AvailableforsaleSecuritiesMember": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities [Member]", "terseLabel": "Available-for-sale Securities [Member]" } } }, "localname": "AvailableforsaleSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r308", "r311" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Time Deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables", "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r284", "r285" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables", "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r108", "r295" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Changes in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": { "auth_ref": [ "r296" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r291", "r292", "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "terseLabel": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsMember": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.", "label": "Capital Lease Obligations [Member]" } } }, "localname": "CapitalLeaseObligationsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r335", "r336" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying (Reported) Amount, Fair Value Disclosure [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r33", "r111" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and Cash Equivalents, Fair Value Disclosure" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r102", "r111", "r116" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Ending Cash, Cash Equivalents, and Restricted Cash", "periodStartLabel": "Beginning Cash, Cash Equivalents, and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r102", "r341" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Cash Flow, Supplemental Disclosures [Text Block]" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]", "verboseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]", "verboseLabel": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r243" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r71", "r73", "r298", "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]", "verboseLabel": "Contingent Consideration by Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r260", "r263" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r81" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consolidated cost of goods (such as cost of goods sold, or purchases) for the period after providing for returns, allowances and discounts, when it serves as a benchmark in a concentration of risk calculation.", "label": "Cost of Goods, Total [Member]", "terseLabel": "Cost of Goods, Total [Member]" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r368", "r394" ], "calculation": { "http://www.bio-rad.com/role/A5LongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.", "label": "Debt and Capital Lease Obligations", "totalLabel": "Debt and Capital Lease Obligations" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndEquitySecuritiesGainLoss": { "auth_ref": [ "r78", "r79" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities.", "label": "Debt and Equity Securities, Gain (Loss)", "negatedTerseLabel": "Loss on Sale of Securities, Net" } } }, "localname": "DebtAndEquitySecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r20", "r22", "r23", "r360", "r361", "r381" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r345", "r347" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount of debt sold" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r44", "r241", "r345" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r379" ], "lang": { "en-US": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Debt Instrument, Redemption Price, Percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r45", "r120", "r244", "r245", "r246", "r247", "r344", "r345", "r347", "r380" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r239", "r346" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r177" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r177" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Debt Securities, Available-for-sale [Table Text Block]" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Debt Securities [Member]" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r273" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred Income Tax Assets, Net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r109", "r119", "r274", "r278" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred Income Tax Expense (Benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "terseLabel": "Revenue, Net" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r272" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Deferred Tax Assets, Gross" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": { "auth_ref": [ "r266", "r267", "r273" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Assets, Net, Noncurrent", "terseLabel": "Deferred Tax Assets, Net, Noncurrent" } } }, "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r266", "r267", "r268" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r109", "r149" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and Amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r309", "r310", "r314", "r316" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r123", "r303", "r304", "r305", "r306", "r307", "r312", "r314", "r317", "r318", "r319" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r77", "r126", "r131", "r133", "r134", "r135", "r138", "r371", "r396" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income per share basic attributable to Bio-Rad" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r77", "r126", "r131", "r133", "r134", "r135", "r138", "r371", "r396" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income per share diluted attributable to Bio-Rad" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted earnings per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r341" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of foreign exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r122", "r269", "r270" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r269", "r270", "r277" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and employee benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r332" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Equity Securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r182" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Unrealized Gain on Securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r16", "r21", "r181", "r367", "r382", "r404" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "verboseLabel": "Marketable Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r334" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of Fair Value, Fair Value Disclosure [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FacilityClosingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Facility Closing [Member]", "terseLabel": "Facility Closing [Member]" } } }, "localname": "FacilityClosingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r320", "r321", "r322", "r323", "r328", "r329" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r321", "r335", "r336" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r321", "r335" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Estimated fair value of financial instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r260", "r261", "r263", "r322", "r350" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r321", "r330" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r320" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Fair Value by Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r331" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r260", "r261", "r263", "r322", "r351" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r260", "r261", "r263", "r322", "r352" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r260", "r261", "r263", "r322", "r353" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r325", "r329" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r320", "r327" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r326" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "negatedTerseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Contingent consideration milestone payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r325" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r320", "r327" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r203" ], "calculation": { "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r197", "r200", "r203", "r206", "r355" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Acquired Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r203", "r355" ], "calculation": { "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Purchase Price" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r197", "r202" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r203" ], "calculation": { "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Average Remaining Life (years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Foreign Currency Gain (Loss) [Member]" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r338", "r339", "r340" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign exchange (gains) losses, net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "Debt security issued by government not domiciled in United States of America (US).", "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Foreign Government Obligations [Member]" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r109" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Gain on sale of land" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r309", "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "negatedLabel": "Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2ForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfOtherAssets": { "auth_ref": [ "r109" ], "calculation": { "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of other assets.", "label": "Gain (Loss) on Disposition of Other Assets", "negatedTerseLabel": "Gain on divestiture of a product line" } } }, "localname": "GainLossOnSaleOfOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r109" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Loss on Disposition of Property Plant Equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r187", "r188" ], "calculation": { "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill, net", "totalLabel": "Goodwill, net" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets Disclosure" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOther" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r191" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency fluctuations" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r189", "r192" ], "calculation": { "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails": { "order": 1.0, "parentTag": "us-gaap_Goodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "terseLabel": "Goodwill" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r189", "r192" ], "calculation": { "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails": { "order": 2.0, "parentTag": "us-gaap_Goodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "negatedTerseLabel": "Accumulated impairment loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r190" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedTerseLabel": "Goodwill, Written off Related to Sale of Business Unit" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r80" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r121" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationDetails", "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r119", "r150", "r280" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "(Provision) benefit for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r112" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "negatedTerseLabel": "Income tax payments, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "auth_ref": [ "r108" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "terseLabel": "Decrease in accounts payable and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r108" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Decrease (increase) in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r108" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Decrease in Income Taxes Payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r108" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedTerseLabel": "Increase (Decrease) in Deferred Income Taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r108" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Increase in inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r108" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedTerseLabel": "Increase in other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r108" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Net increase in other long-term assets/liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r132", "r137" ], "calculation": { "http://www.bio-rad.com/role/A7EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Effect of potentially dilutive stock options and restricted stock awards" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r198", "r205" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r198", "r205" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r195", "r201" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Purchased intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestBearingDepositsMember": { "auth_ref": [ "r356", "r362" ], "lang": { "en-US": { "role": { "documentation": "Cash on deposit with financial institutions that earns interest, either at a fixed or market rate.", "label": "Interest-bearing Deposits [Member]", "terseLabel": "Brokered certificates of deposit [Member]" } } }, "localname": "InterestBearingDepositsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r75", "r148", "r343", "r346", "r372" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r100", "r106", "r112" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "negatedTerseLabel": "Interest paid, net" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r50" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r53", "r184" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r52" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r51" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r83" ], "calculation": { "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "negatedTerseLabel": "Interest and investment income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r393" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Summary of amortized cost and estimated fair value of debt securities by contractual maturity date" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Proceedings." } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11LegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r41" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r32", "r363", "r390" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r321" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities, Fair Value Disclosure" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r23", "r361", "r381" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Outstanding borrowings" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r39" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Line of Credit Facility, Interest Rate at Period End" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation.", "label": "Litigation Settlement Interest", "terseLabel": "Litigation Settlement Interest" } } }, "localname": "LitigationSettlementInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11LegalProceedings11ContingentLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r23", "r240", "r361", "r387" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r23" ], "calculation": { "http://www.bio-rad.com/role/A5LongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt and Capital Lease Obligations", "terseLabel": "Long-term debt, net of current maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligations including current maturities.", "label": "Long-term Debt and Capital Lease Obligations, Including Current Maturities", "terseLabel": "Long-term Debt and Capital Lease Obligations, Including Current Maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A5LongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation maturing in the remainder of the fiscal year following the latest fiscal year ended.", "label": "Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year", "negatedTerseLabel": "Less Current Maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Total long-term debt, excluding capital leases and current maturities" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r34" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Other investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r45", "r238" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r226", "r227", "r228" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Loss Contingency, Damages Awarded, Value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11LegalProceedings11ContingentLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesPaidValue": { "auth_ref": [ "r226", "r227", "r228" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of damages paid to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Paid, Value", "terseLabel": "Loss Contingency, Damages Paid, Value" } } }, "localname": "LossContingencyDamagesPaidValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11LegalProceedings11ContingentLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Loss Contingency, Information about Litigation Matters [Abstract]" } } }, "localname": "LossContingencyInformationAboutLitigationMattersAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss", "negatedTerseLabel": "Changes in fair market value of equity securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r154", "r155" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items [Member]" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal Obligations (Member)", "verboseLabel": "Municipal obligations [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r102" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r102" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r102", "r107", "r110" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r69", "r72", "r76", "r110", "r137", "r370", "r395" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to Bio-Rad" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues \"Accounting Standards Updates\" to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Adjustments for New Accounting Pronouncement [Member]", "terseLabel": "Adjustments for New Accounting Pronouncement [Member]" } } }, "localname": "NewAccountingPronouncementMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r125", "r127", "r128" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": { "auth_ref": [ "r113", "r114", "r115" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received", "negatedTerseLabel": "Gain on divestiture of a product line" } } }, "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Noncompete Agreements [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Nonoperating Income (Expense)", "terseLabel": "Nonoperating Income (Expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansPayableCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "label": "Notes and Loans Payable, Current", "terseLabel": "Current maturities of long-term debt and notes payable" } } }, "localname": "NotesAndLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Segment profit (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesIncomeStatementLeaseRevenue": { "auth_ref": [ "r348" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of revenue recognized for the period from operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue.", "label": "Operating Leases, Income Statement, Lease Revenue", "terseLabel": "Operating Leases, Income Statement, Lease Revenue" } } }, "localname": "OperatingLeasesIncomeStatementLeaseRevenue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r147", "r156" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r302" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1OrganizationConsolidationAndPresentationOfFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r19", "r358", "r385" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r62", "r64", "r298", "r299" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedTerseLabel": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location [Axis]", "terseLabel": "Other Comprehensive Income Location [Axis]" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in other comprehensive income.", "label": "Other Comprehensive Income Location [Domain]", "terseLabel": "Other Comprehensive Income Location [Domain]" } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r67" ], "calculation": { "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r56", "r342" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r70", "r73", "r74", "r243" ], "calculation": { "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income (loss) net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r65", "r279", "r281" ], "calculation": { "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r58", "r64" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Net unrealized holding gains (losses) on available-for-sale investments net of tax expense" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r259", "r264" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Income and Other Expense Disclosure" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeAndExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInvestments": { "auth_ref": [ "r34", "r392" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments classified as other.", "label": "Other Investments", "terseLabel": "Other Investments" } } }, "localname": "OtherInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other Investments [Member]" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r42" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestmentsMember": { "auth_ref": [ "r383", "r400" ], "lang": { "en-US": { "role": { "documentation": "Long-term investments classified as other.", "label": "Other Long-term Investments [Member]", "terseLabel": "Other Long-term Investments [Member]" } } }, "localname": "OtherLongTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r85" ], "calculation": { "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "terseLabel": "Other Nonoperating Expense" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other (income) expense, net", "terseLabel": "Other Nonoperating Income (Expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r97" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Payments of contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r91", "r93", "r124" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedTerseLabel": "Proceeds from (payments for) acquisitions" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r95" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Payments for purchases of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r101", "r214" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Payments for Restructuring" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAssetsInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate cash payments for a combination of transactions that are classified as investing activities in which assets, which may include securities, other types of investments, or productive assets, are purchased from third-party sellers. This element can be used by entities to aggregate payments for all asset purchases that are classified as investing activities.", "label": "Payments to Acquire Assets, Investing Activities", "negatedTerseLabel": "Payments for acquisitions and long-term investments" } } }, "localname": "PaymentsToAcquireAssetsInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r93" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Payments for purchases of marketable securities and investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r92" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedTerseLabel": "Payments for purchases of intangible assets" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r92" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToSuppliersAndEmployees": { "auth_ref": [ "r98", "r99", "r105" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.", "label": "Payments to Suppliers and Employees", "negatedTerseLabel": "Cash paid to suppliers and employees" } } }, "localname": "PaymentsToSuppliersAndEmployees", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r7", "r186" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseOtherNoncurrent": { "auth_ref": [ "r10", "r37" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.", "label": "Prepaid Expense Other, Noncurrent", "terseLabel": "Prepaid taxes" } } }, "localname": "PrepaidExpenseOtherNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r5", "r7", "r185", "r186" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid Taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCustomers": { "auth_ref": [ "r103" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.", "label": "Proceeds from Customers", "terseLabel": "Cash received from customers" } } }, "localname": "ProceedsFromCustomers", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r94" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock for shared-based compensation" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r87", "r88", "r164" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from maturities of marketable securities and investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherOperatingActivities": { "auth_ref": [ "r104" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from operating activities classified as other.", "label": "Proceeds from Other Operating Activities", "terseLabel": "Investment proceeds and miscellaneous receipts, net" } } }, "localname": "ProceedsFromOtherOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r124" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net payments on line-of-credit arrangements and notes payable" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities": { "auth_ref": [ "r89", "r164" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.", "label": "Proceeds from Sale of Available-for-sale Securities", "terseLabel": "Proceeds from sales of marketable securities and investments" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r87", "r88", "r164" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from Sale of Debt Securities, Available-for-sale" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r90" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from divestiture of a product line" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r90" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from dispositions of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r233", "r234", "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual", "periodEndLabel": "Warranty accrual, end of period", "periodStartLabel": "Warranty accrual, beginning of period" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPayments": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "negatedLabel": "Actual warranty costs" } } }, "localname": "ProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r232" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "verboseLabel": "Provision for warranty" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r35", "r208" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r210", "r391" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r397" ], "calculation": { "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.", "label": "Realized Investment Gains (Losses)", "negatedTerseLabel": "Net realized loss (gain) on investments" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r67", "r68" ], "calculation": { "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "negatedTerseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification Out Of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r153", "r155" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r153", "r155" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of segment profit to consolidated income before taxes" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r96" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on long-term borrowings" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r199" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "terseLabel": "Research and Development Asset Acquired Other than Through Business Combination, Written-off" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r265", "r408" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r116", "r357", "r388" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r15", "r111", "r116" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted Cash and Cash Equivalents, Current" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r2", "r15", "r116" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted Cash, Current" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r9", "r19", "r116", "r406" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted Cash, Noncurrent" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r402", "r403" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments, at Fair Value", "terseLabel": "Restricted Investments, at Fair Value" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsCurrent": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.", "label": "Restricted Investments, Current", "terseLabel": "Restricted investments" } } }, "localname": "RestrictedInvestmentsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Related Activities Disclosure [Text Block]" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r109", "r213", "r218", "r223" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring Costs [Abstract]" } } }, "localname": "RestructuringCostsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r214", "r220" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Restructuring Reserve" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r213", "r219" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Restructuring Reserve, Accrual Adjustment" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r213", "r222" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "terseLabel": "Restructuring Reserve, Current" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveNoncurrent": { "auth_ref": [ "r213" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Noncurrent", "terseLabel": "Restructuring Reserve, Noncurrent" } } }, "localname": "RestructuringReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveTranslationAdjustment": { "auth_ref": [ "r214", "r222" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Restructuring Reserve, Foreign Currency Translation (Gain) Loss" } } }, "localname": "RestructuringReserveTranslationAdjustment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r248", "r389" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r252", "r253", "r254" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationDetails", "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r118", "r258" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue from Contract with Customer [Policy Text Block]" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reporting scenario used to indicate financial results forecast for a future period.", "label": "Scenario, Forecast [Member]", "terseLabel": "Scenario, Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "verboseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of identifiable purchased intangible assets with definite lives" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r170", "r174", "r176", "r177", "r178", "r180", "r374", "r378" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationCashFlowSupplementalDisclosureTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r45", "r120", "r244", "r245", "r246", "r247", "r344", "r345", "r347", "r380" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r123", "r303", "r304", "r305", "r306", "r307", "r312", "r314", "r317", "r318" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Discussion of current derivative risk management" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r320" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities carried at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r193", "r194" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r193", "r194" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Changes to goodwill by segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of other income (expense), net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Product Warranty Liability [Table Text Block]" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r216", "r217", "r221" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r216", "r217", "r221" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs [Table Text Block]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r146", "r151", "r152", "r154", "r193" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationDetails", "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r146", "r151", "r152", "r154", "r193" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Net sales" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of Unrealized Loss on Investments [Table Text Block]", "terseLabel": "Summary of fair value of gross unrealized losses for investments with unrealized losses" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]", "verboseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationDetails", "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables", "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationDetails", "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r82", "r183" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r86" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r108" ], "calculation": { "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Share-based Compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r21", "r364", "r365", "r367", "r384" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r364", "r365", "r384", "r399" ], "lang": { "en-US": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]", "terseLabel": "Short-term Investments [Member]" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "auth_ref": [ "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r230", "r236", "r297", "r401" ], "lang": { "en-US": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Standby Letters of Credit [Member]" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r151", "r193", "r212", "r215", "r224", "r398" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentInformationDetails", "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A12RestructuringCostsDetails", "http://www.bio-rad.com/role/A12RestructuringCostsTables", "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables", "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r24", "r25", "r26", "r243" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r48", "r243" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A9IncomeTaxesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Statement, Scenario [Axis]", "verboseLabel": "Statement, Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A2FairValueMeasurements2ContingentConsiderationDetails", "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "http://www.bio-rad.com/role/A8OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A9IncomeTaxesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r30", "r31", "r162" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "terseLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6AccumulatedOtherComprehensiveIncome6AccumulatedOtherComprehensiveIncomeNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsConsolidationItemsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Axis]", "terseLabel": "Subsegments Consolidation Items [Axis]" } } }, "localname": "SubsegmentsConsolidationItemsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Domain]", "terseLabel": "Subsegments Consolidation Items [Domain]" } } }, "localname": "SubsegmentsConsolidationItemsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables" ], "xbrltype": "domainItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesScheduleOfRevenueFromExternalCustomersGeographicTables" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Income and other taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r354" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r47", "r249" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r47", "r249", "r250" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury Stock, Value" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/A9IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r260", "r366" ], "lang": { "en-US": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "US Government Sponsored Agencies [Member]" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r260", "r263", "r366" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "US Treasury Securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainOnSecurities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease), resulting in a gain, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain on Securities", "negatedTerseLabel": "Unrealized Gain on Securities", "terseLabel": "Unrealized Gain on Securities" } } }, "localname": "UnrealizedGainOnSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebt": { "auth_ref": [ "r23", "r361", "r387" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Unsecured Debt", "terseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r130", "r135" ], "calculation": { "http://www.bio-rad.com/role/A7EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares - diluted", "totalLabel": "Diluted weighted average common shares" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r129", "r135" ], "calculation": { "http://www.bio-rad.com/role/A7EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares - basic", "verboseLabel": "Basic weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7EarningsPerShareDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8615-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8654-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8660-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8663-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8672-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "8B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=SL6284393-111563" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=84241550&loc=SL75117546-209714" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=82913499&loc=d3e12803-110250" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r258": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31958-109318" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928189&loc=SL96870463-158277" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928189&loc=SL96870463-158277" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=66022390&loc=d3e923-111674" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL6742756-110258" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13220-108610" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13467-108611" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13476-108611" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75032774&loc=SL75039408-165497" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39896-112707" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=73530178&loc=d3e59706-112781" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f,g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C.9(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "305", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r409": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Sentence": "Column A" }, "r411": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column B" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" } }, "version": "2.0" } ZIP 69 0001628280-18-010896-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-18-010896-xbrl.zip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�YI-/B63]//$_]/[+1V'O@[)UZ>CSMI"&_[( M\S^DL$Z,_V=_=H M0%E'$BTBB7MO*3RDR;C$A'^FT6WB1OSA_O!U--+E-W[^]_TO;BY2_Y(+[[?C@;AVWEU>VAIVTMO^L-\ MIG!^G:(;JM^ Z&L(! S[PZ_[P!K184W;L.;'O @L*6:=YZ^GP_NDWZO4E5 ; MD!8R*I!(#8IZ?N=+H?9Q.HY&E4/=7Z7GQ=[N:8JCCJ;:1E-Y'^WA:!+-'CXG MJW$R_"-*_WOJL3'.LF@ZS M:0AC](?A>'(0^^)?#-,L*\G0I.-)XJ]_[6%MF(0NW\G]_> A2-$TN;[-]; H M]9><4?..B;-3Q-M'G/VRF"H:]._ZDQE>C0K!6+1^]Q_^%/F/TV'VMO#C!2K, MBV9#?"V:>&+.BL?R7[A+QU_3L7_ASR$/JY67'.>_S5U]Q;SB6L'MG$ OH^@J M(.R,::)PS%Y1RIU'%16/TT$Q%#'0[6B2,U%%_6\KM X_&7NJ\,\]&?E'':?W MT_'U;2CT>NO_N"[BG_U_)[.'[_7#3*IAKWBV7C_<_,NT6("_5W;K'\LK$Q[, M\P65" MEA1HOPJ?]?LTYMU& .PR^C4M(3]ZR@@>QN:[4]?^GGXOASE_7L&F_38:? N8 M]B7)^@7^7/L'^N(%?9;F$CK8,L%]XF$Z"/SD^K^G_:P_0RZ_"]'WT?B/<(49 MK!7*@G^_P-BOZ=!C89CY,;X?Y6XXCX7W(P^%EU'NA.D%P!U-)]G$_S!_DM66 ML$WTYC'9OT#DCWOAU]O@;V ZCC?7A[Z@74CD-?XE%= MI?__VDH<,\$,L<# 61*EH0Z1Q82A/;'_YT!S7Q[>IYZTQUGC0/!"M7)'>. 6$!H7+^DN:;KSHU6PF :M0)HFQS!E[N(1 ;3MQ7< M=&A5>?>3JE:8,K?5D#J\R4X\"V'CU&M2 <-*E=XK6V$RVN"A<,12!V;N(& M,]EKKWGISMOHZS3Q9OPD36=_YU9-8=/4[?N99^KFQE_>8TAI[^?&\-S>#^9V M\6S!S'];**[]X3?_G'FI6K$/XS3 :>Y6J,4"OP?C/W=9^?WOY^TVZ\ZPR4@]=*LLW>8X"N? LCC!^:2M\B,8O0N?8&_OY$?O-GV8L]&[$CC#9"RH))QJ MZ1E Q*&#OE-&<8SCL&4KC=YMV6CM+5QRCT?OL@VGG ;OZ,RQZ;PPG#P$[W#H M"SX895Z]?WW8*8=AF('C%C!DA:)8\1*6G.:V-NQ4" M_=U]BLS'7W_[Y/[N/GQ^]_^YZ-T'_[>+?GC_\?/G'U\6:RN/=UV^SJVV"2]! M[1W4JJW)W;MX@BTG&*OKZ^G==! "9GF/.^-UK'%ZZQ6P_K?TW="K7.G[499= MA?JC5SF>$R1T++53!!G#XGB> X.1TK0^9SOV,&VDH1(:BK'%!H%YI ]SH5XE M@Z7W6>#XVA+GH:7:(H/*ZU=9JMYY!DAN^8]""DCPLYI*B^U%.AGD&NCGVS3$ MJX*&V\^*6C\46>JU+S.W6[6/SB*D^92592E3;J;?1R"X_KFYOK MZYWL5 /[,E/W2E?B?R1>.1L_1$6<5_S/GW;09[FA7A[%MAZVJ<'VO3P6'WHI M!>V^EZ1D#L%LRZ%8TYCY@? M;ZZ2/Y>T1L_3* -(%MX?,[=G'L7Z:O>\JD2\FLNIQN+UG#<[-6E3,FMGFY . M=#K0>0UT7NY/6:".K$KA&8>:(*)TK)0U$ H@:(DZL5DRC&DY)1>JUPZ,/B_=LS'8H7*'71V/'G<. M&OMXNLY']V!/HGP7X8T&=N+C,][$'P:>PG^<.17?1E]23T^A?/IZD&19_\;O M1IY?V.H!(#NURBBNU)N8>9['2A(&E954ZIC/6UT[RA=Z3+R&*CK?Z4]/-[IX M>Q%MJCR"@_J&5K'..&\4=G8[7*!A.^HD.&()0]!*XFJ+O/I/F;&4*X1X;+0J M)2[02+><(1IT6ZQ9Y+0Y.QQ23S\)ZEZ&]XS79JQQ'>IQ-7>04\(9M;PT9Z5V M<W2K(A:!2<!4MS+.:614JDL>CNVBUO-@M(:?1#6Z'$EJ?2]9+L M-F1'"@31STVZA%ZBK*/04D^1+V#EK6".8BLY--8HQ@'1FL&RIX3EBZ,7VLX7 M>PXR@V;'A'6YHJ4$X878Q'[+MO+(_2Q ^T_/LE)CD_ )J!:5$ MD^3/V2R54XZ3+8&(FML4"(R9L4#[_VBH48PDF,?A$5G+;7KV)M91R+PVT^T2 MIR83U6@: $31!A&@0T=+822LP02A)#7#P]/N/N*6'5^_&,F^244+RMMC@+C M)(R=1DQJPP4!5)44'QI1'I[B=Y:CV8%VBREX"6AS6'6R0!!H#JF-)?1DZRB+ MRZP_@"54"U,#]T_".T_T.U>\[D),Z^3VA>F>^82WTFA)MS57MLX]7BMGNPW) MR,MPJ>94)!S%4@A"+$=$"ZJQG'?8 ;%=2[2^D(+<$E/H $F!7]S6:AE&WHM^],A?TA]4;3T+IS MFWKG(ZAA=X$I/@%09Z$TH1"3!T%DE#2_3\Q4%"UE2!\:%??5*0CN,$SQ# M.D?2]J@A]C[V]D:;\?XQN%P$J30& S@37"F- 284PEB(JJL"@PL>T@,CPQXS MJ,4E;[VRT%(7RU_S 2#S]S>>(+3"_)*MQI\LFR!46_'!QFZNTOV]@9U\LA6/ M +^%DV#NDO'7_K!XO&0Z&95O%-R3O],-B]G^@MVPF&Y83#QB-RQF@V$QO/6S8H[ "&^VQW [''.25A-?%#"$Q@A+:9Q U%I,BB;F M7C%GE.^@B3EK[\07V(YDAR-QTW7@<)S@L,0Y)WGEMJ<$2DHT1Q8Y(6/GK- % M.CC"'6'+XI^!6Y8-Q&B572]Q/J'H%;5KP2&5B@ 76AM MIK2) 2S-?R8H;3EA[SN[MU%"/RJC_B0X8QECU"KI56B;*S47!@,J+$5*S,MZ MM08+$XM;QAA[2V^%N-%*F [\=TSBMI&ES0/*;4Q2F&*F-".&XXTAU(33<5\8#:3"_UG M=MU-NV6&4S>[Y*P8H]:8E AEI(*:6&<$4;'&&I1V%O'?/C;&V%$'IXY!SHE! M8*WMJ6):4AA;%_J?&DN=<-74*[ XB[CM#'*4?7X[%FD=BZ!J,%PL1:RH U)" M#ABB@L:TDB%L[Z-*VF? G1=OG%\3)_+ MM5RD5NM;U60$JV.%EH=Z82W3&X6FEYHSQ'!,I IM,$%9!Z)CL%;GRR.S MF19;7NZ3"TXSSGO2;%-+8&:QCC6V1&B**3+ "C>J69=N>,&$AOC^=@]&=N%^MD#,<_.;5 HFTTT/CZN.>')(@WT M,>H:AA\'M/&:7N"840Q"(KQ*#A0P6(NY]:H6\\^W+]OE!YXL\IH5"R]%URB\ M8^N6LO52$UM6*HN%,<M^F-MCO1("CLJD[ M9#@Z9%@"#!C4JNB= C$$%AAGM;1>XK,J@=&8M@G\?3D$*)/[G0-P7K+_V'O[ M'/&0D&78@"JE@3E)!(IC;92#L296L'F*(B9\P2]_8&S8N;^#0;## _4LF_71Q-UJRWMM1D>#ZUOQCIM.!?F?5[=I]"7]VA\./31$7PKO2W2;9/[= M=!A-[WMYK:O_.XG&:38=Y-'YI#>ZGX0?J,^_!]<,NP#P,HH^IVGT831)0^/I M-SK)^KD/YS?_.\\ELZ;ZPU[T>Y:&]UTV\50\2;/ ")ZJHC>?TM J/!39AOK; M<'W/,NYET>_YDV27;_:Z/_L_D1D:?IC>^<^O7YH9O:R*X^/4(]H*2'05 M>"9,:-&#T?4?;YX9V$*50U(ZP"&CWEY3F$M1#FR!G,075:)!["CFA AIM+?I MB&%8S+W0"(<>TJ_,R%EZ'V\1IAX4[P.TC*?IF[\%TDV>J]0>37,B7:U6V_]G M,HK\QY$9A627S'_;O\J1+?_I'/5S8BZV[6WTO3^YC>[KE.TW,'_A/TO':>"8 MF]%@,/J>_50"].Q,G]#3\IDYJVS--CN+WK2-CU89'E#[_2.%[[R'!,DW+P<" MBGL0]/+@&[S1*!VVT:]>>8SN7BO^ZK6/V)D/,8)\!PUZULBJ;&[JR:R@;=9\ M,4^)C/IW'I$FT0_]8>1_/ AM='[<)#YV["=^3J1]ZNN;L^XN.'(SG^+G_9W>*I[V^3FRCG@Y[.NKIL*?UU',\&[,#+?K]+,&@;>ZL'2Q5W8W\T_^[ M2(CP)D,(?/GKS](X[D?9Y"*]NQ^,'D)>1O2E2,J/^I/T[H5F(2=M9^YB?:U, M>=WFN?=("$FDBJR^(F)QQO0DW\5P>.ZZF) M3;9;V$A-/"QO'DZ'7&/='?QV\+N9:DHJ]$6*^!Q_(T;+*U4Y;W;.LV,'9%DVM?R@267Z,T@(!\D[61]L-O(%M^9!.HMO1 M(-RV:.Z=9C]&7Y/^,(L\$JCWUO^Z'AF_#7I1\2_J#4(1WX6'A(O,8 M$?7G+34V<>V?;3!L(SWD8-T,-^I_L>QH6^ :6VK^B:JWA3%,&,)L+*FD L5( MQ+KTC5' %H:_GG64H-&N.ZMYQ^ ^Q@2>3B2A0]X.>5N,O!+49EY!X*25T@D* MC8V-06 >E5!XL17A640^)O/4Y*Q+J6#!)+<98*:$L M&- A8 :8..4DY1[['5EM(,! MLCWPGE*T8V1FGN;W ;_[V%(.C9![WS:)DG$:> MNJ]G33>G68C]A-::V;U'0_\3?U/_Q>K'=^GD=M2[7&G;GS:/+(_O*>TLDLJ; MU\^L 4I"Z D9Y?_>CLN+W"=?TXLO7H3\<9'<^$?Z*1E\3QXR?ZN_WHYGJ]GQ M(SY'[,NVL_]2=^#ZZ+=[X7]_@R&O3\1?EF#81=,@X=H+/?TO'G6\_' MK_8$9AX6D*(QL\@KE=3O#-,E4' (;*TG,*!2/%?ISY]>/?AE\_1;^Y3]/GOZI/;MBOO*@^WS=K6Z,K;(";L ME(##>+?,TV0Z([;(6Q-1%L@MZF=Y=^9ID!M?'B+_&/T\WSV]N?$' M&V[6"[\M.IMDGBASR?@VRJ;7MZ$G=#;Q/!6%[NFC89'SX!_)K^LZW"[_\&W^ M[C3S=PD7+E=3W/W>?S.=/74Z>VA_(V]M>*ERUQ^6 K=:^_UH$D1N,GBR"_FJ M\P6-HB_^-EX+[D6S3MBO;.7B'I9[]ML+-PKW2/^\'DS##6[&H[O\%KV7=[C4 M('*VNWFRNYX6_)7",O,=K>6/?!]-![U\*?XI+LI3N(RZ?O'/P/WGZ]NT-QVD M'V_^.3MK51SUA_RD/][D0B!;WAZ>Y47B>&X5? MS45%\JV I,N/ZO*C3H(M&9!5$CQ0DFA.J.=.S(A"4,8%6Q*BK5%-LR5OEBT9 MQ!U;=FQY&FR)JJI @*&AS&%L$&0HYL+%JF!+BI&4"R'5!J3EOYJ4EF O!FX4^30U(RR;9DDI^TFS9*@?R MXWN0)WD'%U#X=QH@83?/3IHG6PT>JCRPY2E?4?(]&??VU;J^)3Q-*U$KA0 F MM (6!@%C8Q0+E:>3.$VIH L%^.^&U^.\@B<9F#R-I^!F54L0O!KE[WFN3GN_ M)?F< #4>)\.O^>^R'5NK!#397KRU,O;41>D1K)":R2&I,K84.2N<413&< MRJS$E%4O6<5?'70?DKEK( G)E8F_@H9@* WG,.14E=VD-]R:[FN,N=A*: MX=F$&\M*H(6 XZ/Z@:VGU>'[/Z/>:!JRVW0B.'2P M\)*5"8PU09@@ZH@C0,L5G3RSPUOP]>S8^L/@+8*R^=[5&]#*<7:]/E_?;0<* M3T !5;J 91!2QPB/%3$04<4,*$ !ZE@9T#PH-&JT@K< -*E9=Z#0@<*9@@*N MDB<$=H BQ)B@@#$,J'8S4$ 6$KW0-;L13:$Y:P"\AMPMQLS8,\7AT9_+& M,T5+R9NGC9#47>CQLF./0;,IE,OHH+72_.R%]A%S:&V2C:8*$:V(@ CQD2LFP^!S&+ MQ4+"U0YE:&-JJ%HJ =RM#F M.+3)T'=[.?2Y!M<+W8P;N=M:K:F;6'$#75'1?"E+.SSO="FO-_V%2#G@B$)* M.&JE7XNF@A&'*.(:2NPOT*:FOV*S+I!YX_;9H(5A,3YA-M'!]K/KP2B;+FD$ MS D6R,9(< 8A1P1!/#]MY/7]6O='BXRB&L5$&2MC@@F7MC *#/7_BU_M_KCT M/JLW OYX]7?W*7KWP7S\U47J@XW<__W-??CLWD8?W-6V/8%7>(/0]H;B]"56Z6NN_!'ZNL)MTK-^^9OWBKUY8]DXPU*NWL]_ZNS[/W( MC[.59]>2]33.L6O)NMEQGFB_SNZ(3_Z(VYKML-.SQF?4SN_<6S>>TUF?>TO6 M]OTY_.19W/;CF:<^*;+;^\X\>V"U3^\&*WF M@H06(U6T6M 8.B8!ISH6)#:6D_EH+VW 0FE6-42[\-67%*2&/1LF_Z7#WBH9 MERL/VGX:B&:7C>97+SO,BA>W.=ZFZ/7'KLZB@Z+3@J):/Q9 F(1(&XL)% !3 M!"PIH0AKL5 0MAD4+:26;@Q%Z!)T4-1!40=%IP%%'%10)"6DU%F$B#"Q5AHI M0NCK 4HF!>+JIS=[W*Z4N?C5]DV\WOAWWN5?T&C[-O5VNS!6W_"K$2KPC>M M.=8N5C*.@>>A6*I*#@K_OVU9:3V_P&JLU*2KLF.ECI6V827.:E7><7#W2P U MXTB#8.R6N?#:V065<@.IM(8RV;%2QTHM8Z5EYIFL>$D9X8"+A8HAI(S$$KK9 M Q+N%!;\U)CAEFSBMT)FE_''LL/=!1LL,P30YAH,TB&+V2*KSYZ]Z0&4N6\ M*R"OSXGCFCL*MƦ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

      KE 'J0*A M.JF*1& 5/-5W?! ]'B?:\>ZH3A@=&=JUNUO8.?3JUI?JD[F(J?CV'5&!=J/=^GK_L;>WM;E/#S>%[$2>W?I: MY'Q5*$Y+#2XP?"8F\K)CY#]S^+"#RFD[,H+6N;:S=/N7W=G: MVMRZFY?M_\!CW.F(4TX5")J&QF2]NDI(W04/#0"#5J#> '-B/?+4\&$PYM%V MBF+"K]3L'%/D[<[*T-D]Q> PH^2C^>\:V9GD>#K)*95.C%1"BO?FH;$7:Q7; MQZEBBQ0%=A6%= 1IP Y\TXJ M8^<\6[AFA1'5,54L7"^3%5TFT.#%D5YJODNZ&4"OS%P-QJ-/:53. %=Y@ 1H MT5]2EPDNH3G(X?5J6M'5A$HK2"L,E ):*A 8F^)S>RX"X2KJ'1;"WE0R>5I# M/I%"-PP34+8>W2E88.O%LYJ+QYLB=5#E0^PR5>D4]LRQ%,7MV%#-!+DND$@@ MZ@*?QI9_!UEEKG*R4R2'H:?D$.]H\ZJUMO+I+PCLO4!S([DBUAXX*IQP-8TI MQOF!QK@"T@%U&R.96"@#O-TP;]]'Y!J+ACHD&TESG)L,92>)9 8:"A500]*7 M"6L-=,D'2!^*^F2#BU(J6!_^&L?-.=E'SK!>V"X(!@]=2K[&#)4U.< M&>2=%_F5M[Z$;:R'2!2 "GO]UDTKZ7AZ=!Z:?=^V\Y;0.'3#MZ[W*")->7T\ MN-YJ1&%YJ3MW-B ."JKR\)S(BH;L)#&6#(!PR"[^'-2J"WI<7JR*-9TR ?"A M29[&Q.^W>!-TRA8'I3)NE5>-!A#WA7O"/L]W['\/P.J@Q@),X?0-N]$X(O3M M\L''7=0H#./J>\M80;YORZ7VI)Z0JK&ON,BHNX_FRBKH20,J%AMC8U$?62Y-VQ^ XT64 )6Q!V9= #I"M$.\#UU$H#+LJ/P?* MOU*!!%O!,&/.M'@NZ.[OH061YU#E9D4AX<'#"%JT,]SO?ESWE#1K2.HAMFTI MD1]+5KYL4XI3N7D$OQT741TSU@;FJAN"Y!J^4/H]2.)9(Y%24^RXK>I("D#: MN&#!'&[R!"NEUY\%/_@M#*BUOL.<&;2P"Y&1BHPS=&3G[N^EAU,)=-%_-$Q M@!6N&V@"UY>L'K=SD3!9"W*425/=NAJUCG9O]6"MU3T OJ=_):-OT&&$$,$: M)6]QZL.UXB6EPHS^/II8 :#G23[ M]\8+UB2\Y PSST8I,V+!ZK!+J(;D#">+T9<2F4Y2]L,4LB9^L-_NH]L+[;RH M9$2J?9HB6BIBCBH@EOI7Y#:.,MMV+9\5T=0U;J\.\?\OR M"_LQI/T$OA(R](!8C;A['<,-_B/@2/G^8\J/3!U-I.R2OMLB?8]I10S^AJ,U M=LEY=.SPM0!Y"1Y>G1*'9XLC9YXCAVFWLJ0.+JH:P!.J()NH5[5Y: +_4*9BRL2.(A+41ETOP,\PIF079H+=E?4L$I+Y&D7TM5E9FY5[&YCRDEXUD&%]3YZ,+$1$J)+Q@[T[R$BLS=[U[UGME MO5?"O?(/ZCUX[YKV/P/H5'7=,>V-_ HU$Y[]X_WGP>#9"V*/!J?5\SZ["WI& MZZ]F-,E@^UR&#&YP^4/[8KB#^'MJ;]))6#+9&NKJZT-LO3'O;F-BT@[=+D[969<8 M6_'M$2+">U(;:3F0E)X# 7)/VH%\V=_$U\-DX#R/&YW.&61L(7?1X5\FTV%= ME+3A\8QK.L"!4()G,T%>$*@9_LA>>I3)7\J@>DD033LC%-\QU"Q1%CG81(9!G<.5B *S8,-VAB 5R**?ZL]Q)RGWI?:!8CZMRV! M%B>N/'&RG0R[R%-"CA=4.ZY%%+[5U]^7H=&Z#YW=EE= 8!Z$?.,GE3&7AY+M MBUJ-JNN8B7[MZ(Y3:-4$B2![,);"[-N'Q(=HB'6D#0O2<17 MF6&[CZ/"\9'7!"9R(3"/5Q]3:*#XVVN-I7@+L 7A=Q[YT#LRTWP$"WYD'WE6 M#^WWX.J'P)'>>W[TY? %*R?^F2<9'5U,I!P0FB#;38R(1/^T41"?_R?*Q=AC MABPODJB-*0HI[6R.>(]3ES8_.$?M$%M[.2!^=CB(Y7-TCGQT>J@#&RVD2I2. M%%P M;_B,%)D-NA<38#DR!,7'SWPC$/^5?5H7@,/#'"S.,V4@,05S2<0MJF-2K#S< M(+9&^PQ_Z:EXN/L8 71X 7OG!,4V62QL+DM6#5UR"?$\6%LB2R\ODK,D\$[:-/HF(J7+TL9=8UX @@)>965"%,;0#! MXRHM?;3P1]8)M N+R?Q:]+%.F<_IBWDF&'H!5DFG=[6SP&;8;GB_UL?6DK$9 M#L65K@F.)Z\LSG$N[/_*G%;Y.$F9NY65[H5Z< 0!4QP5J)],0EUZ"8,O_=$. MT1YUC2^W=/C^UM,HR?[\&.]^W)>&LY*4WT*Q3&KIF.8906J7ZW$)/?D8O<)! M$'U-HS]SS/BQN3K/*U+9 :1S M14J4M=GHXF%_8L_:M'3Q%:J-1$PJF(MJS4 MG:@_UU^48[VZ0#*PDDMP^M7>]'J'\)?> /GH[1H[Q3>FE"O\X5WPA\W>'XA' M[8W-!4IZS3@@8J W>G!\P7G7@ IG$04 MV'<^?,)\M"EO()!VM;\@B##>':<,1!<[+M9X6"!T@&P"?(T.3N0=*KPH.,+E\8Z[\02(EY;QZ"%LU"8X$WPKKV=_5_DF$71 ?CA MR-\8SZW6E1MO1<_/?KU]@8A<;/?\CRK2O)O02M/X=>QR&T38(,>.Z229B9&X M:J7WI1_%>X,TA5'+WJB5PQ(+T(T5<3ZET2I*'Q;<)X/J/?T6N?QV.NNR*2D5 M*L7;>\]II4%_SB5IDLJWP'.#891=:@Q^8[#(G_P.&5T@/JQ*]Y"0)4+_;03% M3X97B'E4D(BF B;>_=308'.\>;[W>'IR\>G5T^/+E#CB@T4]YU YO MX#W@YW8V>__."M")AT44]TZCE([,8Z(W;DBY_)OR(9^);[=<@K&^3Y_]=WL* M+L,*=NMI9^=D?W?[^.7>T<'N_M;>]NO7@_V#UWO'6]L[K[YQV79ID_W#GU=;!NYU7^\>'Q^^. M3EYM[V^?[.V\VGFWO;WU\*MT;[/W$>!.I\0I>>2R=*N_.BNE>GZ[=?KS7=R[ MYA_F=;I__.K=P=;NP*[LVMXZ/W[U[M[MU>#PX?OAUNK_9^X1N MH,(,K?P*M?;S!KK1][A,EBB_N?WD\IOWM.?W#@?'@_WC=SL'!UO[UC%_M7>X MN[MM_[?WZFA_^_CDVGM^HS2C#;L40$;@35E/IU%Q^1AWW#S3<[#9._Y.S6/7 M?YI5&91G?W\>O>!8_RF/ N0YQGF:8KM(+\Y'K"2%,!HL+$6Z0)^47&2Z07OK MT@Z6^G2 J=QJH%3A9WVY#"O:+NM?Y3,P30C#O#/0:&7LWF'2PNM@ESE]>=^$%= M:-"%Z-O[&*Q[H!CHJI_=;-7\FW>V0PCZ;=V2N2_] ME-[U6G#WQ[*,=[,;$MNT9]5;:_/SX@U:V9.3 M\ PV9-O>/NM-"C/^VS/S?7=[^V 7,""3:GJ;D3J<)&9LO4DSJA&W\@G0009S M@EB2V-W:Z1T2/F84AKC1ZBZ?FQN$57BYE9I":P%VEF$"?X8%V+D#"^ U3=<6 M8&T!5N$M=W>>C ^PNO H5FB8AAEIMSX]#TUU)YK_[*SM;6SMBZK^G(K-876NCP5_V+G?OR+ MM7596Y>U=>E^R^VM[L;BJ(JPM@'M9-B]#%C.___NRX=>%9U1Z<-,AR:.68C"70/,'GU0[C>WGW_9 MDIQ;3RC)>=_ONG)&XO3P'RMJ)'"S?HV^ ^G.I0U.*I-A+_WI:&*F4>^(M_%Z M%Z]W\:->Y["+#P7HE5#WOZZ/CDB>WI M(S-.LF2]I==;>@DF^)YV]8?!NR>VJS]$0Y.6ZQV]WM$K>$A__G+\Q+;S9^*- MOZ'G+1R7+3!E,!I+B[Y]_7KS8.OU[LO]1X?!_8G68__I&,K[?M6./;-L8/NE MZJ!J5E)OT4$E+43[QR\/3PYW#DX.7N^_/-AY=W+P:GNP>W2P=?QJL/ONJ-E" M],1;K^;>L;T,?G@EXH]A,]/I^]]^'WS]]Y?CT^L_V<\?BP>]XVUW_6=5(6\Q M,DJ9W/-''']GMA"NE6^_WMWK\Q?/D. YJY![**Y35LB,=5,14_8"A14PVF58 MF!N:292.A:8*X0?\ >B;-2!*"E>+ZFJ2%_;9X\?2\_QDNY#VKO: MN=[0#LO MY_]M=_Z?]E]W.T[JJ1[.7[\KZ_CL[^_>?]KX,CCJ?1B\^_1E\/73E_?'I_W> M^]\/KZI4K]@X//_B+,Z+58]!GR949_URC_7EEF+SX4?NXC6/HJHI]GOU%#Y$ M5^P]3/&@/JO+BB;Z-=$(/[7%_!2F^=?RU][OX&YFCA-QY;?UTS3-ZY=;\I=K M;,-^[W 2)?@KS9[;GZNXO=Z?CV&6UR_W6%\.*F,HQD+\R=T]<>O-^9BG>/UR M*_=RJ[7[UA'I.B)=\6F&B/1P4B1EA9KFF[VO(*B1E\NZM]?F>?UR*_QR75NQ MK_S>_Y> N+JXQOWU+EV_W/KE'F"7=G(HW!!ZME28K]T.4-3_^J]?AWE\^??_ M_5^_3JII^O?_ 5!+ P04 " !$;@E-2AX!6T - !XB@ $ &)I;RTR M,#$X,#8S,"YX5IMFH(&'*O3D_1).G-;GJ22M(S\S8E M; ':-A(CR2297[]'\AV,L(%TF#4OE)%UOG.D[^CHR!?YP\\O$Q_-B)"4LXN& M<]!N(,)<[E$VNFA\?6SV'OLW-XV?/_[PX1_-YN^?'F[1)7>#"6$*]07!BGCH MF:HQ^LTC\AL:"CY!OW'QC0J9$XK+$9$_8(G1$ZQ2RX:8Z6FYZW6\_/SP8#R MIL#>@$JTU.N4M*!2$VH10=U$;K507D!7\%0BD[7JJ!6>S%:EEC90)A5F M;M*&EX4V/W=-;>?L[*QESB95I5=4$6"=UN]?;A\-TXV//R!DF*>3*1<*L07& MAE@.C*04RE#0;#O-KM- H:_<PS6I@9IA]R6009K'8-LCKS$G$41_:\9RS5U M4=/I;&9%&A*J61'+;<.*LQ86KJ8::'-5D[Q,?O8H;U)6:JMV5.B66&)C_<530ADSLI*_A();M&8]2]8W MHWCZ*CE^8@&M^*B:2DG<@Q&?M5P>,"5>=60Z*1/2BN3B/\T49$UC B$@^5K# MFJQ@\F]C>SQ"5\9ZN4Q('ZP3W7-@Y,4=5SI8P3%U9V3M2J?!P8[^0U-5P3A4C8AE]T$R%US1 345UMTBDS)'%+3!C M7!DD71073J>4#7E8 F5ZUCZ/I^X',D0F/SZ/)DY[%MV:"CXE0E%(IC(+"0,P M%F1XT= KDWA%\H>+_0-(N^,:"_CYG,+,42#B!KYIPVUJ8XR@H_9%0T)G^R1J M^/=NDT>&5=L$(I31W6V2CP=5FP0BQ-_-UDP%J=H:$)&P:E_+ZS3 $U1 %!:6 M/:?]2$;Z"L -##DQ,8@-I.M\?;A9NH0W1A3+QLIB=:DO?>PXSI'3;J,FNJ32 M];D,!($_3OL H0@)9: ^M.8!YJ #2;P[]M$4F;,00-E(.G:/#=JC'"/.?=:?G"0]@G;\).Q&"C9RN M<]1M.^7)"2'KR)4#TH4U71P=1Y@)2P"5P4">J3/I9)5B;1 V%D[+4HI.@:F8Z2U'L&=ZIT69WC)FZICH M?<*2RKOA?:89/>9]E>1N>"45A1R8R#LQPHS^94["7""Y3[VX9E;P;GA-&88$ M#/N/4&)N@E<.C]_-(&NP;3M%*2?,D,8\Q(?\-"8*9>'[CO#[EXQL)[B_G6HF;E M+'JXH4UGQ8WFE](.L9D6ZT*I[10ME, ?MC$EU#-JLY[YK+AZQ3V[,DQCKK*O*0*VD\JB0RABX"=&Y MJ:%1!KNFQ"7#!H;09\&E_,H$P;[V^%OX!U,J5>/YLJJ4;J1D)=DG161G!JD> MLT8K2E6@4$?X4/UB<D'A'KW*E>#WSE8%NXCFCA4I_+W&[+ M*=R/O[2?DL);,B.^N3RP%;(MN"MY7K@X8N,Y4VY4(:-K3W':1=4NBUDQ[->U MN@7WB&S4U?%J5 =6#82.V-6+.\80FZ[#"S$Z5 GLKI'&E(-;.>86KBX9XD)P M%*.C"!XE^/4<9]T;L)V-*'AO#_)Q)3]S[CU3WX?UPYT:$U&6OM5 ]@3GL"#! MZ0)Q*2P*<7]",;)9;ACL/6.9CJXX[DKCV0?>8<%D5YJ__=@K[/GY\]MF=AG^ M2J87TM?R3"_4VG-?R$VU5*BJ,X1KF0(>/P70:;NV _3Z6XVN? M/V>>%(^+LM72[JW&\59TV1W@I, !#O4SU1E(I/4@K2CW2'Q2^E.^=@9K[R"+ MI%4,Z67A[!'\I&"N+DES+8-UR5[O@[&=+3,98N[I_)YT5GH^N!R8?>US4K#V M*4M@_1X=/KKE;/1$]$9* U66IKR0G8ZS CJ.])L0 -'4&.9.=&V[O.*452AK M#VAG!0%MD8!Z!J]<=U9+((M$[?G@64$^6$1$#1.[XY[K!A-M!PE76'T^@2:- M"9-T1FX8=#LI4Z?B:-JV6NM =-H% _%8/]^1*H@6?SD5*-2AJY:L6[^BGG 4GG[A-XIF-"+R:CG ME+S0K=7"XS)Q>YSK%,2Y9:34,%*=1O>J=*CN,>_J90K1NSPGR\3M4:OH>;M3 M_59"=!/+S!OZWD>,MV>DZNW)%2CV0%;T;)65GWK&LR5]7"VJV4'LL:WH0:H5 M/-4PQ)W%6?%+>59R,O9@5O1LS9FYKVNZWT#4M;LK!JTB47ND.BS86&>^\VL9 MG/J<>7K(>^F[?<3[A'V]?_GCF! E[R'E81 H% 6#2S)4%=5"'HP:Y\B0E[Q1 M",>) I35@"(5*-2!@%(G*VUD(KXU9] M"B1E1,J>^V= I>G@):]7WG,%113[]T2XFOL1N<>O/%!QF[<#M5:/0'=,0RA; M?X3?9U)%W;&,]#Z>4H7]6X(ED3AY)V.@\G2OKO9N1"]M&0P6[9^7%(\8!V-< M.=?R7F V28V>*[L#1UIG?ZVA?+<>K47 23-6D-PG;:')0 ! M W;;C;\*],OWB W@W<-2NL\.?V9$R#&=3I,I+F[AJDJ[-0/^ MA_'G?_'G/$GSA3OGAO-[L\\'5H#.S 9I<0LWAUG?(2><$87%ZWQ7#,(KK!<-5X#[J[5[2-/6-_$YLQ7=:]+R MI:=W+#6#./!?XBKB_%NJ/=-BQ+>O,N6KOWN'AQMZ-KS_>A+=M%R MZXF;AG)T=>0#KM3GN.KA65=H\ZA4$] M%Z_Z,DKOA2;30]&)ZS=V10/4E>YICZQ3W*C!A,2)F+JP]$$JRO]C#O4F] QZ?1 M-_ITMID/*AMB[%S,6:\]4(BOL6LR\'[X=-_,7B[V=Y>!LW_%#[QQ_^!U!+ P04 " !$;@E-E$%^ M*:P? "84 $ % &)I;RTR,#$X,#8S,%]C86PN>&UL[7U; M[>B01:J 2GSXD,@$$HF___NGL_FC#ZE;SMK%3X_I7\GC1VD1VCA;O/_I\>]O MX>G;9R]?/O[W?_SE[_\'X#]_?O/JT?,V7)REQ>K1LRZY58J//LY6IX_^B&GY MYZ//_FB[/V+=.C3\O9WY;A-)VY5VUPJ_6[ M3U>K\[\]>?+QX\>_?O+=_*]M]_X)(X0_^5+JUB?*)[AZ#,I70!EP^M=/R_CX M$;9PL5R_N\=+KA[_]-WS'_GZ:6JM?;+^ZY='E[-M#V*U],E__OKJ[;J=,%LL M5VX1TN-__.71HPT<73M/;U)^5/[]_]/GE+R-KTO MP+]+V=GYW-L]9,Q MQ7J>5FXV7]Y'NF^*3BCD.^?GZ5XR?EUR;!%?=VV>K=ZDT"[";#Z[%Z ]ZAA+ M;/HJO7=S?&%(J6B-_4+>6F(RD2A]UBY6^!M"\VKF/$*R^MP7TWO5-E93V)NT M7'478771X0N?MX[^O27'$O%GMYPM3_+K M+BV15NL!^W01?U^FD_S+OWJ0/:7&17J#) M]\NG5>H6;O[L8KEJS]"8_&=JWW?N_'06>HZSZ5]=$Z0_7->YQ>KSFW8^1ZOA MH^OBF,-O?_5C-7803?>V=93:1VHJ>WK6=JO9OU(L2AX%>.%FW7^X^04"_SSY MU=L4< I8X:CKV9/WKG"T!GW 6LL0>-%V;]T\O5Q\P+GL+G/!':H82^@O("%@ M_^S:Y?+W!7J9\P+C*_R$W$=G\]OO^C9GC,I';^@7:K]<%$OC3OUSETI&%_S7 MY)877;^AOKO4I**Q:V.]Z)A93-U=7*I!E4[:L"]?OL+9<+Z>[ :U:7]]DS:G MGZ'0I^QH8K9=FKU?_/(IG#KLZA>;F;;T?.?"'0;IG:H927C^$N?.Q?L9XO(4 MM=AJ^<^VC1]G\SFJOI/5:>KVB=V[@EH"]X3[KO74$O_;OX_5G#WUUFI>O]%[ MQVI&$EZ\O3C'&HJF0#_!+4]?S-N/-Y;SKKZZ^=CSV3+,VZ)@^K5LS'=4:G9/ M!MZQFKK"/W/SP$9JP5=U56I&KV6R.U4RDN#R5;MX_RYU9\55V2?@UH>G$*0G M97>5F4*L?BIB1Y&1A%)/0[@XNYB77;FU.GW6GIUWZ32AA?H!G3=\,O5YIB?, M$[WNR,#H-40G>=F1 =&/Y=.\;20H]"^N6Y0MG->I>WOJNK2O-;<6F$J@GD-O M7[FIQ.O'@3W%1A+.7-J_A2UH/_[RZ1SYLU^X/<6F%:YG]_8K/:VH_;JZ5^&1 M!+57FN'3?KFV/3N!&#W[1<81ZUBYB 3Y>+Z.G^+.;EX"3MZ<)/:W7. P7 MV%>K67#S/?+>L[9:3?E]X2[B#+\=W(SO:IJP"=<[%R?YRH@?UI1^-=9JTO=3 M^'B-ZU%WI6:.W+))&W,5J%?T\F(U6WWN'SC6I^BM0J)*",6XPV=?X>?+QXM( M R+<-F]+GU8)(8W3O6^K>I[^M=LFS(G>VCLV;.3W[PG[FOIM_:.V1I:D;QS6 M]*_=XEU._](*S#Y,R-)#:\3VJ*$#M&*,.)X#B-TWZF9DT48,DAE7LH$!+E^$ M*:)<"3-OPU>&R:4 ZU#][)9^'5A_L83WSIT_*1;+DS1?+:^^6=LP0.AEY/^_ M77[=?!O&\K5T7S5C380K0;%,FO_T&(5J[EM5DXG/C D*5&0#*F4*R40-63,1 M)7/1!OHU,/-R(J+M+CNI+C(W^\RO?G6KRT\E,&:V.%FD_TJN^ZJ5=\#J[I4W MSFK-6! 0C$E F$0(HPE@L@Q"6F:5(GW0NT'RIUUXU'8Q=3\]1N _IMG[T]7Z MUTTMK@O?%CD99D#YK4,P[,()I2-)DRZGU1 [@,/N? MR^&IX#]*.I?673;T75I,1^=][VF2),X%%B!E)4!8P<"%G"%[+H.RWCH=[T]G M_C^?VJD\YS([(!:Z4#:D"&0F$!X&?'[8&,2#\RJ^F(] MCVU1?:FXXH1EZC&^_(TU2"]3ZZ-)4 MY](JO'&.YTDJB%0WV- -629?N7_ M7J=SQA7ACB=M*K_\T&OW5_+LF+6O'FE0W;M(O 6+9@IP:S76FA0D:QVUSC$3 M_>&\PBLQUVJX1W/6SS4Y>\$,-B+0),$X[G%6LP'GUDQ5E%ES"/6>?-5T6RO^E%@;QV-9L$X0A5DBJ97B%Z DK*L4S%A M".4Z"3V*BP0/A1]38%;!4!SGH%]%Q8QV&_;J*[3(X[>B_99V+4?O+MA$[F-@ M)( ,9>?)8_='+140%Y)R5F=&V>&4^ [A]^GU?44;[=#GSNC <),5MMPY,#I& M8,DZG7(TG/!C5_5C=FX[.7ZUYH0=HM]04Y<+_5^%/=Z-1[=4U@3+M/7*06:* MH=H3!+2R"F0*@FAMN. #5B,JS1*'H=9XD![#)#*]0S7^0>BZ\AUZ6D4J%ZE> M=^V'&;[QY\^_+PLI3\[7ZP*+]T_#:O9AWSY:_TH:ZM'@BB*!<"J#)Y(!86A( MDQ0\"9(1)@\8GX0-V83([S&8OWJN<92DY*B +*+'*IF$2 T'K;V70A*2K#SV MB72J+FS'!:[6#/H\G72HP9#<%Z&L>OCS_]_XO9ZO/UKM0_W6RQ9S+:4Q(M M54,4D>B84)KQS0I'2$"W14=-.+.$>I?NSQI1QQJOIFC&QK(6?WYUW9]H2_J; M6YK7&VU7#?CE4YA?E/-)&_/\U"W>I;/SMG/=Y^M5JUUD&_,UC:!$ND0M"$4R MF,0RR.RPX[1D7.&/A:-/ZM701$\Z1[[;K5Y8?GL[*'/5NA MPX83_L5B58[HWMB[?)-"*KXTW66Q#ZFW(8(13@,#GK'WF#$9,J>H!;PTG"=& MK1JPH*%^**+61KK:1LOE$#M9E+B*16GU_/W6)5)HSS,K9V[;+TJJ!) MF7JMN0%JF0;N<;8[6;5;3 M=NFSW06;:$UF$9UJ0YP"KAB^V6MLNTW%U,U.F@$*R_R@)!H)REKD^?EB.5ND MY1(]'#];7)W8W!;=\[0<)7V_"7)YM@X\>;FXH8BW%?ER9GT7"RM)T-CH0S8< M[17O*'8JCF)3CB*(8)RUAKH@>T5:;*>S_9$%=E9KN%<9!HY!QW0\=(Y,K#1&YT#RSP..-=&Z0_. MH&%0'HXZF_R3%UW)9[:Q,.[$H.^+-YQX23UA.%RH ^U,!,.3!!*]8%XES<* MY3U::;?]8$0:!='#3VVOW>>B1J\VWK_@=C5CWU55W:'>IE@"F40'E"D"/!K4 MW\E+2,RZS+*AD@[)FO!#[4O41OJ@S.PN"H1?4E%>MO"N/-Q>2Y.4=52&#,X+ M#\$G!S%H L1K936.7^.&1"J+'YYUH^%Z.(X]3SFAYHY;LJ_V8M>6\HV1S!$J M#/K[J4B1- B9$&QAC9+:)J'4 %[]6+L24T%Z8 /M"TS/W/ELY>:[(XS[5](X MJX0R!$6Q)<6-L H2U3C"LK*$2$G0 QI KA]K)V%27"N$1][_(I"Z,8B3YVG< M<6''A"\Z=&CE92S!)4M?%0:?^/GL_;I=/0(Z;BG8:)>EU5*B_4<2N.P51,(< MX+SM([?&27+ 9"0W>^#V1EP?M'Z3SMWGR_3$K[O9(LS.W?Q-.G,S[*:N9!E< M(AW*V>L=B$WWTD8F[SB-'I@,#&VB@'.7L8A[S-?&:.930E-<*RH@6(HPL,B 6:XEY=XZ,6#;HTZ$Z,&Y=P\4*]@&>V]G M&G=BG/3NI(ISZFURE?U;M -/,CH<.\9=G^+H )N0.!% 31)@52# U\LMBCOD MDE'\D,>Z=S7AYX0V77J3PMPME[,\"YL1L/GZ_LCLJ[;ASGLNT;^3043(.EE( MP91CKCI(EW44W!W['#D^-=J#(EQK+OQ6Z))3S^@NVE%FUBG=\,DI>VC,:W%X%Y#W5YNES.&T&+%+S'X1GXZ-8P8*;\ [&X[3]IK=2]UQ_ M./'+#FW;_K$>RBD^_9 Z]S[]=G'FBT?\?#:_*-KY2[3Z! MMKU,$R1'QX@04&A$0XI&@1-(=*HH48EH3K[='ZPY_5YGD-U(_7*Q2CB RHKK M\UG9_UW$G1IO;^E&,Z5#M@H$1=>!4FX@"R- ".>58DX9/613O$X@SSB]^YWR MF@*]>DM#F\.IUZTH1VV6FZ2_.Y=Z=I1KT!&,V6L)5E,*SB4'EFD-D7D?#=&& MJ0&!TY729DS"EK%Q^]]#<$>0+F,2ICS8(V_?'OA(C$^ >]^.L>G7)+BO![X%%UMMQ+T)LS?\E_ M97BRH'AV(%TY*$)"">WG3FE-I20#-\.@Z16]VX$O-R/WZN!+I]K MHK8Q!!K M6W_\%TV/QHB1(*JW-KM<=;.PNKE:V&.BV%6LT8QZ%HT'RHPHF>G+33F4@)6: M673]%,L#W.6:\\88A!@9JFHFPW>I6!-?+LSGD&MMXQ!@9JGJ!$9N,*Y_W'8:]?JQ1R@>$"E4?#1P"$Q&\ M\0(TVL>):Z[ID ,L\H%U_$!HJG?T&_?Q5[=*WU;'F^<2E8Q0G2M^29 M#=%D,(QJL,0G[8*440S)D%6EZ^_?8;?U_$"(JE/@C[;[\^7B==>&M#,'^?8" MC77IE@6M'JQ MX*L"C4@4N-8!#"$>=);%*U+H!.44J!LP"]2Q"\=GP5",:K'@=9?.W>QJ MSV2_);CU^<8KFQW+":+."@@3)9@O>V VN$B"E48."%M4#\P2& NC RP3[R? M]P\W.%:$ MN79BEWZ[(EN>;@SCEKN,E1/TYH+1!H+#!AJCD\C!4R8&[)W67/$:-+6- TT] M1_>[^WV_7*34(^ZE3_'&94(9T\AWDU*Y #Y =*X<9$*V6V,C.GX/PP$:1(R) ML*JF(*Z3\:)*>[MJPY^G[1R[8+FY,FZ7MMA3M%'<4!T%@:S1\<_.!A#223 > M_^,J11EZY:28O.7]&MD0I10I"1XR$>C../1I>71ECXM+X94@B0Y)T%N%\>-V MVK=*XR@Z]GP$[2C6.>6-HF3B(#F SB5#RF8,37D:;!.%N MP")@=2K-FPO#]E-CR=(.#)(L4T4WU3@ 3FH(R7(*3WCD1 M%??\Z,-(1Z;".#!571*^T]QP2XE&^!"]Y1H$9PFTTPG0#V1(H'@3L386[;Q)#'-:"J'FFD)DHH@G7/ M+*I"0QR5:<#$46?!>&2*3 %:[1BSWC/(]@)-8 %A0O< .>($\3WVQ9:1:3$:4@?B0EE$W%Q-; MAQT.&#*$-7568J9ES]-F6XDF1IYQH CTY7D$XS0#PJ4" M2740Z.99-N0.F#K[U>-39"2H:B_F_V^6]HH+'-.G9)_ZTH[-]45OTH>TN$CE M_OJ]6N36,@BE)M'A"./)>& IE8O'<>A%Y96)VGDW4OK7!T"-,5$ZE)/;BPZW M%VK0BR2]20948!)?BHZ]PLF32$JY#.'^?*CNQPSBPZ@PU58/[]RGN])B M7]%&>9JR1V\^&6G!9A\A2)Q.RR%"H84UW Z(BJKNS8RB+$8$J]K1RKML"F[; M4=)*9J0XF* L^.0#.$I1&TKK)'-H;^1"LU#2?3G0!/)2_YS"Q)M!4E)MIP-4'WF1^5F3< / M-K-N;('[N0+[*VFT<,'H@ U$^V//NF/">HQS M\$CS;^.\"2;Y!$*5<]O&4W!*%6M6<1,EUTH-6!TK2/Z8"FX"8*L=!-N.UHO9 MPBW"P'VH+94TT>! 2VAS$!4C_B 1'+-H_@JF@C96)CD@=6"=!=B'OP\U3L\< M0A6^^6) G.17LT4J>^U=BK.^/LBMY1O'#4O2!_#HCT$*J>0QX"4)E"4L4)J8 M&W!JK=)-A1-U]P[=-R:@M0CUE$$P= M4\+79X1S%(5V ,-L;-Z,"&)E.Q^G]&?MHI@/^*$$_2!,W67_X>3 0H[4F)RD'G!FCO]0I*N-]"%FQ9?+Y46Y%@MU M[^8>[!)&UW-&W%JV42D8CS8K^! M<.4B1.,2MIOA6(TYVN-/XW> V7 L, ^P MK8G*^:)#XW/9GT5["S=1.,N4U1 ),6"M0BN6<0<^6H?CB C/!VR/'W:C:2)% M-2ZE[E)-DQ $:XP!H\I=QP@N.D9) 2$Y*4XR M&W1$N$[LQ0/R)2?NFP.O>)Q<778Z9,5C2R4-]9'X*!!CIS+XDEN-,!M*7F%/ M@F2$R0$;6G5FT@?$TDE[YA"VW;.+Y:H]2UW?5=XOSY?=$QN2X^!]#."L%I!T M-"53!+=6X,1Q_"F9INK.'3;<$ #K;S^]O3@_G\]0VA*0>9DWI-^>T]:2#0E> ME6LML9%H9U!M/23I"$BF%+,N9SGD>/QAUS-&9\WH6-;BS\O%*G6HL%^[6=QW MY]-73S:$9>"-$L T41 9-X!?,BM]LF1(P1-9AM'>S MD_L4+U?NY!!$!EONQ;,Z.G#2"0C4<9<2\XD."*NIM!T.N,4F*57X_*YSBV6AX?I6BO6GRT$:_]_%)K9Z(&;W?V'CB='!>+3S M258@@LY@RIXW83I+%CG3XNB/68]/IVW988X!^ZJIAK8T^'G*LP4J][3 7U;E M6.7R^W:]+M>N8(-7JV[F+U8EP.Q=^]KU250TP2N;+***0GK$-C) @T* <3F M1JP9$S'H>/SK P>C^ '@/S3)?U]TR9V?I M8!P_ /I'8%@>BRV)*%[W\^X=K.OG&D=)2HX*0/WBL4HF(5+#06OOI9"$)-O+ M;IER=6IM'I3U^748SP7RYM(;PA[Y.:$7DVZLK/PZ6[3(M,]72W!H/7Q=RR:[ MU*]I=5KVIOJ^>"]QO>6IQL9C"52$]2DJ/*UU>7L:<0?TEL50Q9RR&7==5AU MM%SX=G8_S%;G5YM>W\)S"BGYO#_N-L&OT=M#0V* MB% N0W?4@J06@69>@34^$PR^?SHM;M8,=_2IHE.5!Z!@A MJ>P04R-!.25!>^>8REIY.6 3L=:ZU,@3TF38U9NKE@G?5>(+GZ.BG+?K?'/[ M2;.S7$-IL%$G"4&J!$D;!RYI7R)TC'6&:D8&:)5*,2QC-)7^Z)>;'PH/I^V76AR]7F,O M4M]<6-]!R=L+-67+E!+I@$B%+_-)@2$^@6?1ATBL4'K Q01U#BD\% :.V@W5 M3LVTB_9K@V/_?'MKF29(;HTA!!3Z0I"B4> $S@ 46Z\2T>C"#J!;G8B_AT*W M,7NA>CCRI:B7^^5]8I*_+M%8[;U+4J-Q802(Z"RX@ 8'-C%)A4:K9?;H;;RQ M=U+&@&GZ+=?G;5@''Y8C%3BXRK#!\;0![);MU2+0I3CEAW?+](^__#=02P,$ M% @ 1&X)3=%"CLE=;@ "&T% !0 !B:6\M,C Q.# V,S!?9&5F+GAM M;.R]6Y?;1K(F^CZ_PL?S;#OOE[UVSZR\NC5'MK0D>?><)RR(1%5QFT54@Z2D MZE]_$BP"=5&1!'%)H,K=;5LE%C*9\<6'S(C(R,C__-_?KI<_?,F*]2)?_>U' M^#/X\8=L-W/]A\MKW. M5IL?3)&EFVS^P]?%YNJ'?\RS]9\_7!3Y]0__R(L_%U_2GWZZ:_3#[H?E8O7G M?Y3_^9RNLQ^^K1?_L9Y=9=?IVWR6;G;??;79W/S'+[]\_?KUYV^?B^7/>7'Y M"P( _U*W.OA$^;>?JL=^*C_Z":*?,/SYVWK^XP]!PM5Z]]T-OJ1ZO/SM?%,W M>/@P_>7NE_6CWW7]%>^>A5+*7W:_K1]=+YY[,'0*?_F_O[W]N(/DI\5JO4E7 ML^S'__4_?OCA#KDB7V8?LHL?RC__^/#F42>?%_E/13K_>99?_U+^_A<%P9'_[<;VXOED& M@'[I;#'8D" T^6H3?@K0O%VDGP,DF]NFF+;J MK2]1T(=LO2FVL\VV"%]H\O5FW73 M?-CPW85?K,):LTB7'\,G63DC-*9-[(&\& #?AZ=GBP:;V0[YQ>TIO:;56EI MG*6?"_9>EZ6S1[U8^W&G1HZ-Y8+^>8Q3PKSG&I.G4ZJ&#UAV_#:KC< M+7:=9#K=WZ#B-#,4FK3M;9AYD2TN5^[;["H-JO9W*VVI^2*=G?&2GM5-3X/' M;\+:N;I_=YBHK3@V[<0>Q!MP0[G/[B37\I[_O M2YP3_<82K]G;>V8W/0V>?-S>A![*F2+X">GZRB_SKP_">=5'#Q^SB_5LF9<3 M3#/)^OR.2&(W9."9W40:?*/XTEF=]#1P^C9?77[*BNO2QC\UP&)46V2EI#C88:D -7[U3 M[88:7C,.G&C6T^#$WG LV1(,+_?M)O#G].!.-!MV< W5VZSUL$-MINI&C7L: MJ*QFAF^GQ_76*\+7N+);59;&Z;9UPU:7IPD&DQJ\:Y__'A4.MLM<5J M\\M\>E /ER5XE;FTM'=:!^T['M0X>>2=OGJIWEVD6Z7FY9# M/-C/@ /.K]/%JOMX'W73^W!WO?]TG5U_?AK,;3[6Y_KH>Z!7H;]BMOV<_51# MTW*X1WHZ..A FL5J4;Y];\-?]T^7X^J0;'GW9=FW318FJ?E@7_>LO5-_:_F= MU;0;M<_7:;IS2_E=/5+MMRLJT]V$]A/ .Y3:__G_N-D M/Z(/V4VYC[VZ?#"T(%SV)LS%]>"6Z>=L^;$.(N4EN$/ M8K&2B%O A96/A5^6:<5YL4=\8.GK9),C@NC;_2]W9OLQ,,[O+9'22\((EU0R MH:B"4.RQ,L72(L11PR[K&P @GN*!450(XY'9%91^;T9Y@V)!F>$J]'!'<4B\&6 MNR':1X;'X:GY[KE$&4(=ATIIIQ%&BD'.[A$R*'G6\!J4%0>-OFGFJ_ M!X1>MM;'T?8C&::I['.5_)V+&#Y(WBXNLH^S1;::9;\]LKX?Z.W9YQ*(.79> M,^LA0I)PZ"S=#R\,&+B8>GO.?3AH'YP+;]X?"BV59,(#99C.+M++5;[>+&;K MH\HZ^'PBJ6(DC--C1\(ZQ#DC%3,UH;"1F?NLTM!TE=87&K&F4;5<[D+RU91R M4-7'&R36<=5JUUC:>IZU[AB*7L!P<(JD2\,O>W.D3@ MOLV6V_*L5YFE%/Z9?TJ_'6%"B]X2Y840T#J%! 2.28J!WSM$D D#)CN/#^/G M#0]A+&K=1:;+W/%*F,5J&T;^[F:?([S660 N>["S]=MBE1>[6/$F*[+=88'' MO;A_;L.O?\LV5_G\00[^$4I&'$7",1.0 :N,](82JQE3E1Z\9>UGO*%7MV&H M/%WH[U^!__SEF7#E,&',YW:TAXF=-C[T/&(0M1Y=(%U@F<^+/2U6EW?#KS1> M!3'RASM@;>*N/7UC8K5A'@+F';*>\6!S2PD5I]0+S;5KM& -M9@_U/B[B^/R MK1\+>"IRV[WSQ#E@"-" *ZR4<(9;Q2ODO/0Q7;:S KG1F?.=31 9^DF'@JN0 MAYJ%M6!]1X7C0> #+1*N(-:*LYWWQ1 0'J@*%&TDC,C'L\*_,?F0#P%E+!/T MN=&6/Q99=C)*>+)MHA7PX87F*#B(W!C#PHM=R4PH8=..%W?69 -F]('77X,K MDXPR3X\B(VTL#++Y")GV 'E& .=8$.F,>3 %@_8;#^=[BR]E]>D3T&GO2CE- MA/'6 :L%=,@Q;^M7C ?TIKVV]*2GH]M3[1!ZV5J?Y"HQ!66/O!?I.8; <"T$ MA6'YTE [ 96P#GMM,9W\7F1C>(_N19Z'PNA[D9Q 3K!@AJ(@.(<0 EH+S67[ MM+)(>Y%ME-87&G'W$.H9IBJG>L+N.M(J<<0"9:T5RB#,#35!ZMK"A!U2OL[? ME7PI5E=_<(Y,FY.K\=%V"9?*RB >Q\ M7C=')FG!38\:XU!B7Z#(;(LBF#6WOX:1EO/JR028H^T2 H0/-J^P$ C,)07< M@QI! *,F&#:S,WK273X<2K$8L4OD^3U?Y=5J>P?-_I#R26(T:9Y8$%XP18C4 M@@3XD! >59(S0=I/&8/9H4"3\[2D]PD?)HSJ=N_V] U;I MX8<3C+4A#%$-8;"_@OL4WH)*&D5-^W1(./9X(+0D$ MECC@H:0*8>/KC6)F/9VFI=F'BHYJNQ,ZKT'OD[(>IZ+ND2R#:LIKG"9]H$5" M-="4 >T-<@9XC8S0]7KIW82"A_VHZ>FRWPLLL=1N\N(F#^/-@J&R'_!)Q1]L MDR#C+/'!5%*,6P2=Y*YVKB1B?CJFWR"J[PN86,K_+0RU6*3+)_E@IU_]XPT3 MR2TQTN R:=N*8#5[7L=>A=3M:=#[28E!:- K.K'314Q^_7FQVF'Q,;M)2S8O M;TM)+E=EZ?1/1;I:I[-=MK.:SW<*>ECP]&$N1%D>?^_MS(^0:>!O3B!0D@O& ML34*,\(M123@S0 !0!)MI[,>335?4:)V%[[I2J[DM"Z?G-[OZ/V5Y MXWV6S[ZT\56Z^G15Y-O+JV> ^D>QV&RRX%->''D%^OZJ!($P0>F )M6>X%3H;S(ZODWX>:ACI9(R@W4(;9QC/!A1#(F#HE#T#3_M48^ACG M9%Z-Z6HKUEMS?Y5,&?5_M[J_\N<(R0\W2I##D@A(,9!6@E+*^P14H)V(&#=] MH9SL#=SAC]*=N"6SWR-T'>ZX['<@32^MC'B$[[L1A5FI7/:++]G;!N?QFC1/ M**$P.(\646N5DDZ:L.XS+AG6'DC6:+-TH(S.!Y?N/1!D)\2N#OG]G9C'\CV; M]Y)8A*RBA)<[7,13@VPP\^^P !:9F,>3CAZ7ZU>Q!^N>]0W8I ^Y/1+V_3(] ME?+V[/.)TE8'S] 'FP 1Z3&3CE6 ,,!BGCII6=^L1Z5_[[!T1BRB:_UXK">S ME ZT2&00$ FL*%8<&VPT1*B2SW&$I[FSV)/.3C&@$T:OCPN3VFV<%@7.5?VS MJ>QN6^0W6;KZD.4/[G\]FLU^K$EBN% 6$F\@X2"LM]0S50V: C3!1+/.\.># M0--2G^7-3/LX5GZ1/DBQKV)CZ:/86' R_CN;'=X^[-IE @ /AA:VR!LE"7;< M<%P)33R88#F:/OD0$;IH^:GI;.=^FF"M!H!.YZ4^]WP"A*/*!C[;'\#M[ FU,6IRNAW&P4>(]]M;Y !LRP)H@KJ[B0$!HK:?M@'977@,V M=$+JM?)BDL[HE.@P#@W4;)9O5^5U;K?EK!AFRO!)L2VWJ.[V2A99@P+"C3M) M/%162B"X-M0 S1A#M:/OC9Y@M=@^5/JTPO!0>$4]5G5W$&QS#E&.MDN =,[0 MX.7[X*)9(!C!E0$?C"T^P>+B W"C3XABG[*;M63$D::)4-H(RYVWE&/,I0W> M724Q1;C]A#&8MSL4*?I#*18OAJF[I9C12F@*/492FK)"=OT. -2A[L? %2!B M."=](A>-)>VN?4'2:NZ#8684]HIRYFK&*X/!M/V0GO1T_/Z75@B];*U/TLN8 M@K)["7ZV+[ %,& .<\P)@4(H0[FJS%CO&6Y_0B;693]-X3U:8.L\%%HJJ;\" M6X))#U&P4+"@&'(%M-75<*51[5WZ6)?]M%!:7VC$S6?OL\"6 H9)[0DCTG)& MJ>*Z1DUBW#[G:.":!C',J_YP&YD?':LD::D-$ 921J5D3!O,5>V&2BBF;7SU MHL6SRB6UP^MU7P<- MA$4U0/&E*NAT.K9W5C\),L8*2X&G"#), %?UFNRM8>V/+8]41JLM589$;=RC MQ$VKKC5HG3#EF44:2XL9$ 0I9>KC"([:"29!#<.6_K&*NX>47]\4V56Y.G_) MJA.2C5R8)LT3[PWQ##B!@:/;0* MPG./)YA#@J#A B!NK/'":%[SFH/V$T*^HSM5KG1&+19GWJ>WN^P0GQ>/Y#C"DD--$HD0P90H MJ:"7RG,)#*H!M+A];6+V(GG1$TYCSAZ[HI/+.P^LIO*9$\BS?21E?3&O-;, M("2P%)K7&%#1X39M_B*Y,A1P]^09JN#6,Z6G?L\W6>QR5[OPY.NN=N6P=,!9 MH9" RAG&;;!!+%46>T]XL[*C ^WA1:]VY03VG&JC,<;EC8/2D!H+CF3,6D7= MJUTU5FR':E?G 99&K'85[?X<)L**BPS%EB#*@LCCAFI"=?8*LT)D=97LF+IVP>W)E1AXMR9?PCDIGV];3T7,][1!ZV5J?U.0_)66/H^1*X >WF9RJ M*_1\BT1KS"10BCDBA Y+&G6RGA -Y:T5/Z&3NVTG_7XP&Y,3=[>$9*>+R)QJ MFQ"+D+*:(F@Q]<1S8GDE,U1FXGE7G379@!E]X/77X,HD%Y/I460"&QR/8W'G MU$O_OF5"#! "<\68-&4<#S!?(PFT;I_Y.Z%3C&V7FGZQB\653^';GJ!RE-@_FP>+U.;DQR29D>)2:PI+2_>$.& M!5,X;S64@EL8G"];R4:!;+\Q,:&#([TL'RT1&XT-K2];L-(2@"!G@>\6 J"5 MQG6DUX.7M&"$*1D1(!%ZPJ3E@ J([6"C7!F-TL=%\&NWJ]G=T-X5)OBSET%1#Y]8! %NEHU.$W7N.Q&*&(.$<5): MXQ' WG@ F5%AY?-:-3K).2W<3AT^ZM1O0CU1@"/AN79& ,8Y97N\A.]25J'G MXT@1F9&/A^_D3B_5T\ZO67Y9I#=79='O(P>8#CZ?>,TQAY25<"L%&#( 5$ $ M9R-F)9^S[.Q(ZL_[QW#( R[[A-R'(SQZPN7@\PDSW$BKN#-,*BF@-A+N99)& MV8E>4-*3GO+A$'H=VI^4V3LEI<=3]MV^U\$MHZ>/))@RJ*2%!(310BV50+0: M.0W&^71V"7O20-X+$$.J4*T7Z?MTMKA8S([J\;OG$@(Y@A9HBYAE3D+(L*ED MP++#&93>-^_Z5V97-,[3Z#J;_7R9?_EE9T@4MZ52>?674J?\@4[W'R=_?'Q& MD?>_3+AQ8: >,R4UD,P1<"\U4QT2,'JOF=:O]EI#,.A+>)T50:;#]>"_?RA! MFDNIO#00!8)Q3SG1^]$K0T'[UZ_WVF8#O'Y=H(@5'KPO;U,62SKB*YS8JCBK MG\0J*CQ$RE&-,'$**(PJ+ C![:]V'/A4<%Q?*@:V<3.WU3R_.9K"=>SQ)/1L M''>4B/#240P=T]5+J!B?>IGN@;3X;!IW+\"])FI,R@U[ 8P8:3&JY?^XRR K MYNL_;N;!7PW/![NGZ?WTQ]LG#B+OG3&&:DL"#LA16%@6:#=5/C\ MI?2]@C0%@H2EM!-!ZO:)I]0"HI$$K-SI25\ZPYLQ-R1@>A1<_X3&+*@*S;E%&U3Z@Q3FC! M&*)(0F6]XJB6G;CV]7<'J^$=;\IH"5*\XT)?LM4V\P$ADZ\V13K;_&.QN3+! M-,N#!^^^S9;;>9F8MEYGX9_YI_3;$;JTZ"T)RZSFUG!@/+=:*,]=A;K6$K4O MES*803+>9O;P^$9-S'JS^I+M78!3*5@/'DT@Y

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end